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ABSTRACT 
Warfarin is a challenging drug to dose accurately, especially during the initiation 
phase because of its narrow therapeutic range and large inter-individual variability.  
Therefore, the aim of this thesis was to investigate the use of pharmacogenetics and 
clinical data to improve warfarin therapy. 
Genetic variants in cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide 
reductase (VKORC1) are known to influence warfarin dose.  Therefore we developed a 
pharmacogenetic dosing algorithm to predict warfarin stable dose prospectively in a 
British population based on 456 patients who started warfarin in a hospital setting and 
validated it in 262 retrospectively recruited patients from a primary care setting.  The 
pharmacogenetic algorithm which included CYP2C9*2, CYP2C9*3 and VKORC1-1693 
together with body surface area, age and concomitant amiodarone use, explained 43% of 
warfarin dose variability.  The mean absolute error of the dose predicted by the algorithm 
was 1.08 mg/day (95% CI 0.95-1.20).  49.6% of patients were predicted accurately 
(predicted dose fell within 20% of the actual dose).  
The HAS-BLED score, a bleeding risk score has recently been suggested for use 
in the management of patients with atrial fibrillation.  We validated HAS-BLED 
performance in predicting major bleeding using a prospective cohort with 6 months 
follow-up (n=482) (c-statistic 0.80 95% CI (0.71-0.90).  Factors significantly associated 
with major bleeding in our cohort (p≤0.1) were concurrent amiodarone use, labile INR, 
concurrent clopidogrel use, bleeding predisposition, concurrent aspirin use and 
CYP2C9*3.  Adding a genetic covariate (CYP2C9*3) to the HAS-BLED score did not 
significantly improve its performance in predicting major bleeding.  Considering 
CYP2C9*3 is a rare allele, our study was underpowered and requires further investigation 
in a larger cohort. 
A retrospective study of 97 Caucasian children was conducted to gain greater 
understanding of the factors that affect warfarin anticoagulant control and response in 
children.  Results from multiple regression analysis of genetic and non-genetic factors 
showed that indication for treatment (Fontan or non-Fontan group), VKORC1 -1693, and 
INR group explained 20.8% of variability in proportion time in which INR measurements 
fell within the target range (PTTR); CYP2C9*2 explained 6.8% of the variability in INR 
exceeding target range within the first week of treatment; CYP2C9*2, VKORC1 -1693, 
age and INR group explained 41.4% of warfarin dose variability and VKORC1 -1693 
explained 8.7% of haemorrhagic events.  The contributions of CYP2C9 and VKORC1 
polymorphism were small in the above outcomes. We therefore went onto explore other 
genetic markers using genome-wide scanning.  Two SNPs on chromosome 5, rs13167496 
and rs6882472 were found to be significantly associated at a genome-wide significance 
level with PTIR. However, none of SNPs were significantly associated with warfarin 
stable dose, INR values exceeding the target range within the first week of treatment and 
bleeding complications.  Because of our small sample size, these findings will need to be 
validated in a replication cohort. 
Finally, we have validated and evaluated the performance of Genie HyBeacon®, 
a point of care therapy (POCT) instrument to genotype 135 samples for CYP2C9*2, 
CYP2C9*3 and VKORC1 -1693.  We showed that the instrument accuracy was >98% 
(agreement with ABI Taqman® genotyping), it was relatively simple to use and had a 
good turn-around time (1.6 hours) making it suitable for clinical use. 
In conclusion, the results presented in this thesis demonstrate how knowledge of 
pharmacogenetics may help in assessing improvement in the quality of care of patients 
on warfarin.  However, for personalized medicine to be widely adopted in clinical 
practice, payers need evidence of clinical- and cost-effectiveness.  How such evidence is 
produced and evaluated varies in different healthcare settings, which further increases the 
challenge of implementing personalised medicine into the clinic. 
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1.1 The genetic basis of inter-individual differences in drug response 
One of the major challenges in prescribing medicines is to give the right 
medicine to the right patients at the right dose.  There are often large differences among 
individuals in the way they respond to medications, in term of toxicity, treatment 
efficacy or both.  Potential causes for variability in drug response include age, weight, 
organ function and drug interaction.  In addition, inheritance differences in the 
metabolism and drug disposition, and genetic polymorphisms in the target of drug 
therapy (e.g. receptor, target protein) also have an influence on the efficacy and 
toxicity of medications. 
An adverse drug reaction is one example of a toxic response, contributing 
significantly to morbidity and mortality, which imposes a considerable financial 
burden on the healthcare system.  For example, a meta-analysis of 39 prospective 
studies in the US revealed that adverse drug reactions (toxicity effects) accounted for 
more than 2.2 million serious cases and over 100,000 deaths, and are one of the leading 
causes of hospitalisation and death (Lazarou et al. 1998).   
1.1.1 Genetic variants 
The human genome consists of approximately 3 billion base pairs (bp) which 
reside in the 23 pairs of chromosomes within the nucleus of all our cells (Venter 2001). 
Variation within the human genome occurs approximately once every 300-3,000 bp if 
the genome of two unrelated individuals are compared, which is less than 1% of the 
entire human genome (Sachidanandam et al. 2001, Belmont et al. 2005).  Variants that 
are present in at least 5% of the population are called common variants, the variant 
which frequency lower than these (1-4%) are called low frequency variant and variants 
with frequency ≤1% are called very rare variants (Abecasis et al. 2012). 
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Genetic variations include insertions or deletions, copy number variations, 
variable numbers of tandem repeats and single nucleotide polymorphisms. Of these, 
the most common variations  are single nucleotide polymorphism (SNPs).  The SNP 
can occur in coding or non-coding regions of the genome.  Nonsynonymous SNPs that 
occur in a coding region may alter the amino acid sequence and therefore, change 
protein structure and/or function.  Some DNA sequences do not encode proteins but 
may have a regulatory role in influencing the gene expression level, timing, or tissue 
specificity.  The function of the remainder, and the vast majority, of the DNA sequence 
is not yet known and is the subject of many investigations. 
1.1.2 Pharmacogenetics and pharmacogenomics 
The first example of a pharmacogenetic trait was described by Pythagoras and 
dates back to 510 BC, when he noted that certain individuals who ate fava beans (broad 
beans) developed red blood cell haemolysis (Rowan 1859).  This condition, now 
known as favism, and it it is known to be affected in people of Mediterranean origins.  
Susceptibility to favism is inherited as a sex-linked trait and appears to be closely 
related to deficiency of the enzyme glucose-6-phosphate dehydrogenase (G6PD). 
(Meletis and Konstantopoulos 2004).  Genetic variation in human was recognised as 
important predictors of drugs response variability in 1950’s when researchers found 
that variability of drug concentration in plasma or urine correspond to a specific 
inherited phenotype of drug response (Kalow and Genest 1957, Kalow and Gunn 1957, 
Kalow and Staron 1957). 
The term ‘pharmacogenetics’ was first coined in 1959 (Vogel 1959) and can 
be defined as the study of the variability in drug response due to heredity.  
Pharmacogenetics focusing on genome, particularly the variation in nucleotide 
sequence of candidate genes with respect to drug action.  In 1977, the newer term of 
‘pharmacogenomics’ was introduced (Marshall 1997).  Both terms are used 
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interchangeably; however, pharmacogenomic signifies the availability of the 
knowledge and technology advances in high-throughput DNA and mRNA analysis to 
elucidate genetic determinants of drug effect and toxicity, and to study the effect of 
therapeutic agents on the pattern of gene expression in the tissue.  Therefore 
pharmacogenomics focuses on gene, RNA transcripts, and their encoded protein 
(example: the genome, transcriptome and proteome) and seek to define the effect of 
drugs on gene expression patterns and protein synthesis in cells, tissue and organ 
systems (Winkelmann et al. 2003).     
Advances in pharmacogenetics truly began in the last decade following the 
completion of the Human Genome Project (Craig Venter et al. 2001) and the 
International HapMap Project (Thorisson et al. 2005), along with the rapid 
development of genotyping and sequencing technologies which have facilitated the 
assessment of the whole genome and have greatly affected pharmacogenetic 
discoveries (Pirmohamed 2011).  Recently, the genomes of 1,092 individuals 
representing 14 populations across Europe, Africa, Asia and Americas were published 
and 38 million validated SNPs, 1.4 million short insertions and deletions, and more 
than 14,000 larger deletions have been identified in the human genome (Abecasis et 
al. 2012).  This has enabled a deep characterisation of human genome sequence 
variations and, therefore, serves as a foundation for investigating the relationship 
between genotype and phenotype.   
Results from a systematic review suggest that adverse drug reactions could be 
reduced through the use of pharmacogenomics knowledge (Phillips et al. 2001).  To 
date, few tests (genotype of phenotype) have made it to clinical trials (Roden and 
Tyndale 2011).  However, it is possible that a patient’s genetic make-up can be used 
to predict patient’s response to a specific drug, enabling the best possible treatment to 
be delivered.  But, it is also important to note that many of these variants will interact 
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with environmental factors.  Hence, a holistic approach that takes into account both 
environmental and genetic factors is needed to ensure that patients receive the right 
drug, at the right dosage, at the right time to maximise efficacy and minimise toxicity. 
1.2 Warfarin 
The discovery of warfarin began 90 years ago when a new cattle disease 
characterised by fatal bleeding following the consumption of spoiled sweet clover was 
reported in North America.  Later, Link identified dicoumarin as a haemorrhagic agent 
that is produced by spoiled sweet clover. In 1948 warfarin was patented and promoted 
as a rodenticide (Link 1959).  Three years later, it was reported that a patient who took 
a high dose of warfarin in a suicide attempt was treated without any complication by 
blood transfusion and an injection of vitamin K.  This incident acted as a catalyst for 
studying the effect of this drug in humans.   
Today, warfarin is the most commonly used oral anticoagulant (OAC) world-
wide for the prevention of thromboembolic events in high-risk patients (Fuster et al. 
2006, NICE 2006, Singer et al. 2008, Wallentin et al. 2010). The drug is now 
prescribed annually to 0.5-1.5% of the world-wide population (Johnson et al. 2011). 
The effectiveness of this drug has been demonstrated in a recent pooled analysis of 
studies, showing that warfarin reduces the risk of stroke by 64% compared with a 
placebo (Hart et al. 2007).  Although it is highly efficacious, warfarin’s narrow 
therapeutic index and wide inter-individual variability makes its dosing notoriously 
challenging (Jacobs 2006, Kimmel 2008).  Inappropriate warfarin dosing has been 
reported to the US Food and Drug Administration (FDA) as one of most frequent 
reasons for emergency room visits (Shehab et al. 2010).  Perhaps the most serious 
complication is a major haemorrhage and the rate of major haemorrhages in patients 
treated with warfarin has been reported as 2.5–3.4% in a recent study (Sportif 
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Executive Steering Committee for the SPORTIF V Investigators 2005, Wallentin et 
al. 2010).   
1.2.1 Warfarin chemistry 
Warfarin is a coumarin derivative.  The structures of coumarin and its 
derivatives are as shown in Figure 1-1.  The enolic benzopyrene structure is essential 
to their common pharmacological action as vitamin K antagonists (VKA).   
 
Figure 1-1. The structure of coumarin and derivatives adapted from Au and Rettie (2008). 
The enolic benzopyrene structure (shown in red) which is important for the molecule’s 
property as a vitamin K antagonist anticoagulant. 
 
The empirical formula for warfarin is C19H15NaO4.  Coumarin is insoluble in 
water but a 4-hydroxy substitution confers weak acidic properties on the molecule 
making it slightly soluble under weak alkaline conditions.  Warfarin contains a single 
chiral centre at the C9 carbon which gives two enantiomers, ‘R’ and ‘S’ warfarin (West 
et al. 1961).  In stable anticoagulated patients, free concentrations of S-warfarin range 
from 0.29-0.82% with the concentration of R-warfarin ranging from 0.26 to 0.96% 
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(Chan et al. 1994).  Despite its free concentration being almost the same as that of R-
warfarin, S-warfarin is three to five times more potent than its R-enantiomer in 
inhibiting vitamin K epoxide reductase complex (VKORC) activity. Thus the 
anticoagulation effects of warfarin are mainly attributed to S-warfarin.   
1.2.2 Pharmacokinetics of warfarin and the genes involved 
1.2.2.1 Absorptions and distribution 
Warfarin is completely absorbed after oral administration and reaches peak 
concentration in the blood within four hours (Pyörälä et al. 1971).  In the blood, it 
binds extensively to plasma proteins, primarily albumin (O'Reilly 1969).  The genes 
involved are presented in Table 1-1 with their known function. 
Table 1-1:  Genes involved in the transport of warfarin. 
Protein Name Gene Function 
Alpha-1-acid glycoprotein 1, 
Orosomucoid 1 
ORM1 A plasma glycoprotein that functions as a 
carrier in the blood (Otagiri et al. 1987, 
Nakagawa et al. 2003) 
Alpha-1-acid glycoprotein 2, 
Orosomucoid 2 
ORM2 A plasma glycoprotein that functions as a 
carrier in the blood (Otagiri et al. 1987, 
Nakagawa et al. 2003) 
P-glycoprotein, Multidrug 
resistance protein 1 
ABCB1 
(MDR1) 
A cellular efflux for xenobiotics (Kroetz et al. 
2003).  Warfarin is a weak inhibitor and may 
be a substrate (Sussman et al. 2002) 
Table adapted from Wadelius and Pirmohamed, 2007. 
 
1.2.2.2 Metabolism and excretion 
Warfarin is predominantly oxidised by cytochrome P450 in the liver to 
inactivated hydroxylated metabolites.  S-warfarin is oxidised  by CYP2C9 (primarily, 
~90%), CYP2C8, CYP2C19 and CYP2C18, whereas R-warfarin is oxidised by 
CYP1A2 (primarily, ~60%), CYP3A4, CYP2C8, CYP2C18, CYP2C19 and CYP3A5 
(Wittkowsky 2003).  Genes associated with these enzymes are listed in Table 1-2. 
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Table 1-2:  Genes associated with the warfarin metabolising enzymes, cytochrome P450. 
Protein Name Gene Function of Protein 
Cytochrome P450 
1A1 
CYP1A1 Metabolism of R-warfarin (Grossman et al. 1993, 
Zhang et al. 1995, Kaminsky and Zhang 1997) 
Cytochrome P450 
1A2 
CYP1A2 Metabolism of R-warfarin (Zhang et al. 1995, 
Kaminsky and Zhang 1997) 
Cytochrome P450 
2A6 
CYP2A6 Metabolism of S-warfarin (Freeman et al. 2000) 
Cytochrome P450 
2C8 
CYP2C8 Metabolism of R- and S-warfarin (Rettie et al. 1992, 
Kaminsky and Zhang 1997) 
Cytochrome P450 
2C18 
CYP2C18 Metabolism of R- and S-warfarin (Kaminsky et al. 
1993, Kaminsky and Zhang 1997) 
Cytochrome P450 
2C19 
CYP2C19 Metabolism of R- and S-warfarin  (Kaminsky et al. 
1993, Kaminsky and Zhang 1997) 
Cytochrome P450 
3A4 
CYP3A4 Metabolism of R-warfarin (Kaminsky and Zhang 
1997) 
Cytochrome P450 
3A5 
CYP3A5 Polymorphic hepatic and extrahepatic oxidation 
metabolism of R-warfarin? (Huang et al. 2004) 
Pregnane X receptor 
(PXR) 
NR1/2 Mediates induction of CYP2C9, CYP3A4, other CYP 
enzymes and ABCB1(Lehmann et al. 1998, Geick et 
al. 2001, Chen et al. 2004, Yuping et al. 2004) 
Constitutive 
androstane receptor 
(CAR) 
NR1/3 Transcriptional regulation of a number of genes 
including CYP2C9 and CYP3A4 (Assenat et al. 2004) 
Table adapted from Wadelius and Pirmohamed, 2007. 
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1.2.3 Pharmacodynamics of warfarin and the genes involved 
Warfarin exerts its anticoagulant effect by inhibiting the recycling of vitamin K which 
is important in the blood clotting cascade.  The recycling of vitamin K process is 
particularly important because the amount of vitamin K in the diet and its levels in the 
body are limited (Stafford 2005).   
1.2.3.1 Effect of warfarin on the blood clotting cascade 
The classic theory of blood coagulation was described using the Cascade and 
Waterfall model in the 1960s (Davie and Ratnoff 1964, Macfarlane 1964), as portrayed 
by Figure 1-2. 
 
  CHAPTER 1 
11 
 
 
Figure 1-2.  .  Blood clotting cascade (adapted from Rang and Dale (2012)).).  Extrinsic 
pathway: Any trauma to the tissue-activated endothelial cell leads to exposure of the Tissue 
Factor.  This is a cellular receptor for factor VII, which, in the presence of Ca2+, undergoes an 
active site transition.  This results in rapid autocatalytic activation of factor VII to VIIa.  The 
tissue factor, VIIa and Ca2+ formed an extrinsic tenase complex.  This compex convert Factor 
X (X) to Factor Xa (Xa). In the process acidic phospholipids (PL) function as surface catalyst.   
Intrinsic pathway:  This pathway is initiated when Factor XII (XII) (from the blood) makes 
contact with a negatively charged surface.  Once a small amount of Factor XIIa accumulates, 
it will convert prekallikrein (PK) to kallikrein (K) which in turn, accelerates the production of 
Factor XIIa.  Factor XIIa cleaves Factor XI (XI) to form Factor XIa (XIa).  Next, Factor X1a cleaves 
Factor IX (IX) to Factor IXa (IXa).  Finally, Factor IXa and Factor VIIa, together with Ca2+ and 
negatively charged phospholipids formed an intrinsic tenase complex.  Tenase complex 
subsequently converts Factor X to Factor Xa.  Common pathway:  Factor Xa (from the extrinsic 
and intrinsic pathways) activates prothrombin (II) to thrombin (IIa).  Thrombin then activates 
factor V and VIII (as indicated  by blue arrow and, furthering the cascade (+).  Ultimately, 
thrombin cleaves fibrinogen to form soluble fibrin monomers.  It also activates factor XIII, 
which strengthens fibrin-to-fibrin links, thereby stabilising the fibrin.  Coagulation pathways 
regulators indicated (-) by red arrow:  Thrombin binds to thrombomodulin leading to 
activation of protein C (APC) and protein S serves as cofactor in the process.  APC inactivates 
Va and VIIIa which limit thrombin generation. Warfarin interferes with post- translational 
gamma carboxylation of factors II, VII, IX and X, protein S and protein C (shown in blue box).  
Legends: HMWK: high molecular weight kininogen.       
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This model proposed that the process of coagulation can be divided into three 
distinct parts: extrinsic (so called because some components come from outside 
circulating blood), intrinsic (so called because all the components were present in 
circulating blood) and common pathway (process that initiate factor Xa by either 
pathway and eventually leads to generation of a fibrin clot).  When a blood vessel is 
injured a cascade of reactions aimed at forming fibrin is initiated.  The components 
(called factors) are present in the blood as inactive precursors (zymogen) of proteolytic 
enzymes and co-factors.  They are activated by proteolysis, the active forms being 
designated by the suffix ‘a’. This including vitamin K-dependent coagulation factors:- 
Factor II, VII, IX, X, protein C and protein S.  However, they require vitamin K in 
reduced form for their biological activity.  Factor II, VII, IX, X plays a role to activate 
blood clotting process whole protein C and S plays roles as regulators in the blood 
clotting process. The anticoagulant effect of warfarin is due to the sequential 
depression of Factor VII (t½ = 4-6 hours), Protein C (t½ = 8 hours), Factor IX (t½ = 24 
hours), Protein S (t½ =30 hours), Factor X (t½ = 48-72 hours) and Factor II (t½ = 60 
hours). The genes that are associated with vitamin K-dependent clotting factors are 
described in Table 1-3. 
Table 1-3.  Genes associated with vitamin K-dependent clotting factors. 
Protein Name Gene Protein Function 
Coagulation Factor II, 
prothrombin 
F7 Converts fibrinogen to fibrin; activates FV, FVIII, FXI, FXIII, 
protein C (Berkner 2000, Dahlback 2005) 
Coagulation Factor 
VII 
F7 Is converted to FIX and then to FXa (Berkner 2000, 
Dahlback 2005) 
Coagulation Factor IX F9 Makes a complex with FVIIIa and then converts FX to its 
active form (Berkner 2000, Dahlback 2005) 
Coagulation Factor X F10 Converts FII to FIIa in the presence of factor Va (Berkner 
2000, Dahlback 2005) 
Protein C PROC Activated protein C counteracts coagulation together 
with protein S by inactivating FVa and VIIIa (Berkner 
2000, Dahlback 2005) 
Protein S PROS1 Participates in many processes, for example, potentiation 
of agonist-induced platelet aggregation (Berkner 2000, 
Dahlback 2005) 
Table adapted from Wadelius and Pirmohamed, 2007. 
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1.2.3.2 The Vitamin K Cycle and the mechanism of warfarin action 
Reduced vitamin K, or hydroquinone (KH2), plays an important role as a 
cofactor for -glutamyl carboxylase (GGCX), which catalyses the post-translational 
carboxylation of a specific glutamic acid residue to -carboxyglutamic acid (gla) in a 
variety of vitamin K-dependent proteins (Presnell and Stafford 2002).  The 
carboxylation process is essential for the biologic functions of vitamin K-dependent 
proteins involved in blood coagulation. 
During the carboxylation process, KH2 is oxidised to vitamin K 2,3 epoxide 
(KO).  KO then undergoes electron reduction to give the reduced forms K1 and KH2.  
The reduction and subsequent re-oxidation of vitamin K, coupled with carboxylation, 
is known as the vitamin K cycle Figure 1-3.   
 
 
Figure 1-3.  The vitamin K cycle.  Vitamin K1, which is obtained from dietary sources, is 
reduced to vitamin KH2 by vitamin K epoxide reductase (VKOR) in a reaction that is coupled 
to the carboxylation of glutamic acid residues on coagulation factors.  By inhibiting VKOR, 
warfarin blocks the formation of vitamin K1 and vitamin KH2, thus removing the substrate 
(vitamin KH2) for the carboxylation of glutamic acid. 
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Warfarin binds to the vitamin K epoxide reductase enzyme (VKOR) and 
prevents VKOR from recycling vitamins KO and K1 to vitamin KH2 (Silverman 
1981).  The binding is tight and seems irreversible because of the structural similarity 
between warfarin and vitamin K (Fasco and Principe 1982).  Due to depletion of KH2, 
vitamin K dependent clotting factor is not activated.  As a consequence, the 
coagulation is reduced due to a decrease in thrombin generation.  The genes that are 
involved in the vitamin K cycle are presented in Table 1-4. 
 
Table 1-4.  Genes involved in the vitamin K cycle. 
Protein Name Gene Protein Function 
Vitamin K epoxide 
reductase 
VKORC1 A hepatic epoxide hydrolase that catalyses the 
reduction of vitamin K. The target of warfarin (Bell 
et al. 1972, Li et al. 2004, Rost et al. 2004a) 
Apolipoprotein E APOE Serves as a ligand for a receptor that mediates the 
uptake of vitamin K (Saupe et al. 1993, Kohlmeier et 
al. 1996) 
Epoxide hydrolase, 
microsomal 
EPHX1 A hepatic hydrolase in the endoplasmic reticulum 
that may be complexed with VKOR (Cain et al. 1997, 
Loebstein et al. 2005, Morisseau and Hammock 
2005)  
NAD(P)H 
dehydrogenase, 
quinine 1 
NQO1 A detoxifying enzyme that has the potential to 
reduce the quinine form of vitamin K (Wallin and 
Hutson 1982, Berkner and Runge 2004, Ross and 
Siegel 2004) 
Calumenin CALU Binds to vitamin K epoxide reductase complex and 
inhibits the effect of warfarin (Wallin et al. 2001, 
Wajih et al. 2004) 
Gamma-glutamyl 
carboxylase 
GGCX Carboxylates vitamin K-dependent coagulation 
factors and protein in the vitamin K cycle (Wu et al. 
1997, Rost et al. 2004b) 
Vitamin K oxidase CYP4F2 Metabolising  vitamin K1  (McDonald et al. 2009) 
Table adapted from Wadelius and Pirmohamed, 2007 
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1.3 Indication and monitoring warfarin responses 
Warfarin is widely used for the treatment and prevention of thrombosis and 
thromboembolism, the formation of blood clots in blood vessels and their migration 
elsewhere in the body.  The aim of warfarin treatment is to maintain a patient’s 
international normalised ratio (INR) within the therapeutic range, as recommended by 
the British Committee for Standards in Haematology fourth edition and shown in Table 
1-5 (Keeling et al. 2011).  
Table 1-5.  Indications and recommended target INR (adults). 
Indication Target INR (range) 
1. Venous thromboembolism 
First episode 
Recurrent whilst anticoagulated and within the therapeutic 
range 
 
2.5 (2.0-3.0) 
3.5 (3.0-4.0) 
2. Antiphospholipid 2.5 (2.0-3.0) 
3. Atrial fibrillation 2.5 (2.0-3.0) 
4. Cardioversion 2.5 (2.0-3.0) 
5. Mitral stenosis or regurgitation 2.5 (2.0-3.0) 
6. Mechanical prosthetic heart valves  
a) Patient without risk 
*Prothesis thrombogenicity: Low 
                                                    Medium 
                                                    High 
b) Patient with risk 
*Prothesis thrombogenicity: Low 
                                                    Medium 
                                                    High 
 
 
2.5 (2.0-3.0) 
3.0 (2.5-3.5) 
3.5 (3.0-4.0) 
 
3.0 (2.5-3.5) 
3.5 (3.0-4.0) 
3.5 (3.0-4.0) 
7. Bioprosthetic heart valves 2.5 (2.0-3.0) 
8. Myocardial infarction and cardiomyopathy 2.5 (2.0-3.0) 
*Prosthesis thrombogenicity: Low: Carbomedics (aortic position), Medtronic Hall, St Jude 
Medical (without silzone); Medium: Bjork-Shiley, other bileaflet valves; High: Starr-Edwards, 
Omniscience, Lillehei-Kaster. 
Patient-related risk factors for thrombosis: Mitral, tricuspid or pulmonary position; Previous 
arterial thromboembolism; Atrial fibrillation; Left atrium diameter >50 mm; Mitral stenosis 
of any degree; Left ventricular ejection fraction <35%; Left atrial dense spontaneous echo 
contrast. 
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The INR is the ratio of patient’s prothrombin time to a normal (control) sample, 
raised to the power of International Sensitivity Index (ISI) value.  It measures the time 
it takes for the blood to clot compared to an international standard.  It has been 
established by the World Health Organization (World Health Organization) and the 
International Committee on Thrombosis and Hemostasis for monitoring the effect of 
VKA (International Committee on Thrombosis and Haemostasis 1985).  Values above 
the ‘therapeutic range’ will place the patient at an increased risk of haemorrhagic 
complication, while low values may lead to thrombosis; both scenarios have 
potentially dangerous consequences, including serious morbidity and death (Baglin et 
al. 2007).   
Although the majority of warfarin usage occurs in adults, it is also the mainstay 
of oral anticoagulation therapy in children and adolescents.  Warfarin is recommended 
as thrombo-prophylaxis for heart valve replacement, cardiac catheterization, post-
surgical correction of congenital cardiac defects (e.g. shunt insertion), and 
haemodialysis (Monagle et al. 2012).  The recommended INR for children with 
different condition are shown in Table 1-6 (Keeling et al. 2011). 
Table 1-6.  Indications and recommended target INR (children). 
Indication Target INR (Range) 
Dialysis 2.0 (1.5-2.5) 
Fontan’s Circulation, Cavopulmonary 
anastomosis, Central Venous line 
thrombosis, Pulmonary embolus, Proximal 
DVT, Calf Vein Thrombosis, Recurrence of 
Venous Thromboembolism, Non-rheumatic 
Atrial Fibrillation, Mural Thrombus, 
Cardiomyopathy, Cardioversion, 
Symptomatic Inherited Thrombophilia 
2.5 (2.0-3.0) 
Recurrence of venous thromboembolism 
whilst on Warfarin therapy, Mechanical 
Prosthetic Valve, Unfenestrated Fontan 
Circulation 
3.5 (3.0-4.0) 
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After treatment is started, the INR response is monitored frequently until a 
stable dose-response relationship is obtained; thereafter, the frequency of INR testing 
is reduced. It has been recommended that patients have their INR measured at least 
every 12 weeks (Baglin et al. 2006).  Studies have shown that more frequent testing 
leads to tighter anticoagulant control and reduces bleeding and antithrombotic 
complications in patients on OAC (Cannegieter et al. 1995, Palareti et al. 1996).  
However, it would be inconvenient and expensive to monitor patients this frequently 
in primary or secondary care.   
Today, many point of care (POC) devices such as CoaguChek® XS (Roche 
Diagnostics), INRatio® (Hemosense) and ProTime®/ProTime 3 (International 
Technidyne Corporation) are available commercially which enables patients to test 
their own INR at home using a finger prick sample of blood.  These devices are easy 
to use and can generate immediate results.  Because patients can test their INR at home, 
this leads to greater convenience, especially for those living in remote rural areas or 
depend on carers to get them to and from the hospital.  Research has shown that home-
testing of the INR leads to better anticoagulation control and improved quality-of-life 
(Newall et al. 2006, Smith et al. 2012, Ansell 2013, Bereznicki et al. 2013, Gaw et al. 
2013). 
1.4 Current warfarin dosing algorithm 
In current clinical practice, there is no standardised warfarin dosing algorithm 
(Ansell et al. 2008, Keeling et al. 2011).  Adult patients are typically initiated with 
5mg for 1-2 days but the dose can range from 3-10mg of warfarin depending on age 
and disease (Harrison et al. 1997, Crowther et al. 1999, Ansell et al. 2008).  Then, the 
subsequent dosing is based on the INR response (Table 1-5 and Table 1-6).  For 
example, the targeted INR for atrial fibrillation is 2-3 whereas for mechanical heart 
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valves it is 2.5-3.5 (depending on thrombosis prosthesis thrombogenicity).  Prosthesis 
thrombogenicity is related to the biomaterial and valve design features (Edmunds Jr 
1996).  If the INR result is higher than the targeted value the dose will be decreased, 
whereas if it is lower the dose will be increased.  In patients with a stable dose the INR 
will be monitored every two to six weeks, although practice varies widely. 
There is no generally accepted method designed for increasing, decreasing, or 
maintaining the weekly warfarin dose based on the current INR.  In the Randomized 
Evaluation of Long-term Anticoagulation Therapy (RE-LY) trials, the algorithm dose 
recommendations for atrial fibrillation were as follows (Van Spall et al. 2012): no 
change for INR 2.00 to 3.00; increase 15% change for INR ≤1.50, increase 10% for 
INR 1.51 to 1.99, decrease 10% for INR 3.01 to 4.00. For INR 4.00 to 4.99, the 
recommendation was to hold the dose for 1 day and then to reduce it by 10%.  For INR 
5.00 to 8.99, the dose was to be held until the INR was therapeutic and then decreased 
by 15% per week.  It was suggested that the dose be calculated on a weekly, rather 
than daily basis, because the recommended dose changes were small and difficult to 
achieve with a daily dosing regimen.  Subsequently, weekly INR monitoring was also 
recommended for out-of-range INR values. 
There is lack of specific evidence regarding the safety and efficacy of OAC 
drugs in children, especially new-borns, as they are physiologically different to adults 
(Andrew et al. 1988, Andrew et al. 1992, Andrew 1995).  Current guidelines for anti-
thrombotic therapy in children have recommended an initial warfarin dose of 0.2 
mg/kg, with more frequent monitoring of INR than with adults (Monagle et al. 2008).  
This dosing recommendation was proposed by Michelson et al. (1998), based on six 
publications (Carpentieri et al. 1976, Hathaway 1984, Bradley et al. 1985, Woods et 
al. 1986, Doyle et al. 1988, Andrew et al. 1994) and has been evaluated in a 
prospective cohort (n=115) (Andrew et al. 1994).  The largest cohort study (n =319) 
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found that infants required an average of 0.33 (±0.20) mg/kg and teenagers 0.09 
(±0.05) mg/kg of warfarin to maintain an INR of 2.0 –3.0 (Streif et al. 1999). 
1.5 Anticoagulation control in patients receiving warfarin 
The safety and efficacy of warfarin therapy are dependent on maintaining the 
INR within the target range.  To attain INR values within the target range, patients are 
routinely monitored and their therapeutic dosage adjusted when necessary.  Regardless 
of the INR within the therapeutic range (at a level at which the incidence of both 
thromboembolic and bleeding complications is lowest), adverse events are still 
reported, but in smaller percentages than for those with time out of range (Cannegieter 
et al. 1995).   
Percentage or proportion of time that the patient was within the targeted 
therapeutic range (PTTR) is used to summarise INR control over time.  It has been 
suggested that this is also an evaluation of the effectiveness of anticoagulant therapies, 
including warfarin (Rosendaal et al. 1993).  A high amount of time spent in the 
therapeutic range is associated with a lower risk of thromboembolic events and 
bleeding events (Jones et al. 2005, Rose et al. 2009b).   
The relationship between PTTR and the benefit of OAC was examined by 
Connolly et al. (2008), using the PTTRs of patients from 526 centres, within 15 
countries involved in the ACTIVE W trial (Atrial Fibrillation Clopidogrel Trial With 
Irbesartan for Prevention of Vascular Events) and who were randomised to OAC.  In 
patients with a PTTR above 65%, OAC had a marked benefit, reducing vascular events 
by >2-fold (relative risk, 2.14; 95% confidence interval, 1.61 to 2.85; P<0.0001).  A 
population-average model predicted that a PTTR of 58% would be needed to 
confidently predict that patients would benefit from being on OAC therapy.  Similar 
findings were observed in a randomised trial evaluating the oral thrombin inhibitor, 
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ximelagatran, among individuals with atrial fibrillation assigned to warfarin (White et 
al. 2007).  Those individuals with poor control (defined as PTTR less than 60%), had 
higher rates of mortality (4.20% vs. 1.69%) and major bleeding (3.85% vs. 1.58%) 
compared with the good control group (defined as PTTR greater than 75 %), (P<0.01).  
The poor control group also had higher rates of myocardial infarction (1.38 vs. .62 %, 
P = 0.04) and of stroke or systemic embolic event (2.10 vs. 1.07 %, P = 0.02).   
In practice, it is recognised that long-term INR stability is difficult to achieve 
because of unexpected INR fluctuations in patients.  For example, a study conducted 
with a British population (n=2223) reported that patients who were treated with 
warfarin were inside in the target range only for 67.9% of the time. (Jones et al. 2005).  
This finding is supported by a further meta-regression analysis which reported a mean 
PTTR in all studies of 64% (van Walraven et al. 2006), although PTTR has been 
reported as low as 29% in some studies (Samsa et al. 2000, Sarawate et al. 2006).   
The PTTR also increases as the duration of INR monitoring increases.  In the 
above British population, during the first three months of warfarin therapy, the PTTR 
was 48%; after two years, the PTTR increased to 70% (Jones et al. 2005).  Similarly, 
in a systematic review and meta-analysis of forty studies reporting the PTTR in 
patients with VKA for treatment of venous thromboembolism, the mean PTTR was 
54.0% in the first three months of treatment and increased to 72% in months four to 
twelve and over (Erkens et al. 2012). 
Rose et al. (2010) demonstrated that younger age, female sex, lower income, 
black race, frequent hospitalisations, poly-pharmacy, active cancer, substance abuse, 
psychiatric disorders, dementia, and chronic liver disease were all associated with 
lower PTTR.  Processes related to warfarin management have also been shown to 
affect PTTR e.g. INR triggers for dose change, timing of repeat testing following an 
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out of range INR, selection of INR target and loss to follow-up  (Rose et al. 2009a, 
Rose et al. 2011, Rose et al. 2012, Rose et al. 2013).   
1.6 Over-anticoagulation and bleeding risk in patients receiving 
warfarin 
Over-anticoagulation is a common problem in warfarin therapy and can lead 
to a major or life-threatening bleed.  It is a measurable parameter for the analysis of 
bleeding risk in a modestly-sized population.  There is strong evidence that higher INR 
values are associated with bleeding risk (Hull et al. 1982, Saour et al. 1990, Altman et 
al. 1991, Kearon et al. 2003, Finazzi et al. 2005) (Table 1-7).  An INR higher than 4 
places a patient at a greater risk of bleeding (Cannegieter et al. 1995, Palareti et al. 
1996, Hylek et al. 2000, Hirsh et al. 2003, Pagano and Chandler 2012) and the risk of 
intracranial hemorrhage increases approximately 2-fold for every 1 unit rise in INR 
(Hylek et al. 1994).  
Table 1-7.  Relationship between INR and bleeding risk. 
Authors, studied population, 
anticoagulant used 
Target INR Range 
(n) 
Duration of 
Therapy 
Incidence of bleeding 
(%): 
 
Hull et al. (1982), deep vein 
thrombosis, warfarin 
3.0–4.5 (96) 
vs. 
2.0–2.5 (96) 
3 months 22.4 vs 4.3 
P=0.015 
Saour et al. (1990), mechanical 
prosthetic heart valves, warfarin 
2.3–2.7 (125) 
vs. 
1.3-2.7 (122) 
3.4 years 42.4 vs 21.3 
P<0.002 
Altman et al. (1991), mechanical 
prosthetic heart valves, 
acenocoumarol 
3.0–4.5 (99) 
vs. 
2.0–2.9 (99) 
11.2 months 24.0 vs 6.0 
P<0.02 
Kearon et al. (2003), recurrent 
venous thrombosis, warfarin 
1.5-1.9 (369) 
vs. 
2.0-3.0 (36) 
2.4 years 8.4 vs 10.6 
P=0.26 
Finnazi et al. (2005), antiphospholipid 
syndrome, warfarin 
3.0–4.0 (54) 
vs. 
2.0–3.0 (55) 
12 months 27.8 vs 14.6 
P=0.07 
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1.7 Under-anticoagulation and thromboembolism risk in patients 
receiving warfarin 
In contrast to the bleeding risk associated with VKA, there has been much less 
research on the thromboembolism risk with under-anticoagulation in patients receiving 
warfarin.  It is known that that under-anticoagulation (INR ≤ 1.5) has been associated 
with a 16-fold increase in the rate of thromboembolism (Rose et al. 2009b).  
Hylek et al. (1996) demonstrated that atrial fibrillation patients with INRs of 
1.7 had nearly twice the risk of stroke compared those with INRs of 2. Those with 
INRs of 1.5 had nearly three times the risk and those with INRs of 1.3 had a seven- 
fold greater risk.  Similarly, Palareti et al. (2005), have shown that the relative risk  of 
recurrence  thromboembolism (VTE) was significantly higher  in those who spent 
more time at an INR<1.5 especially in first 90 days of oral anticoagulant therapy.   
Dentali et al. (2012) conducted a study evaluating the risk of thromboembolic 
events in patients with isolated subtherapeutic levels of anticoagulant therapy, who 
were receiving warfarin because of high-risk conditions such as the presence of 
prosthetic mechanical heart valves or moderate-to-high risk AF (Stroke score 
CHADS2=3).  The sub therapeutic INR value (defined as 0.5–1.0 INR units below the 
lower limit of the patient-specific target INR range) was associated with a risk of 
thromboembolic events occurring within 2 weeks of the targeted INR being reached.  
Based on their observations, patients were exposed to an increased risk of 
thromboembolism due to a prolong period of inadequate anticoagulation, rather than a 
single low INR.  In contrast, other studies did not replicate this association (Clark et 
al. 2008, Dentali et al. 2009), possibly due to the patient’s risk profile being unknown 
(Clark et al. 2008) or the inclusion of patients with a single sub-therapeutic INR 
(Dentali et al. 2009). 
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1.8 Factors influencing the warfarin response 
Many clinical factors influence the warfarin dose requirement and response.  
These include age, weight, height, ethnicity, disease, medications, diet, alcohol, 
smoking and adherence. 
Warfarin dose requirements fall with increasing age (Loebstein et al. 2001, 
Kamali et al. 2004, Sconce et al. 2005, Gage et al. 2008); it has been postulated that 
this is due to a reduction in liver size with increasing age (Wynne et al. 1995).  Hillman 
et al. (2004) showed that age, body surface area and the male gender account for 
14.6%, 7.5% and 4.7% of variability of warfarin, respectively.  Inter-ethnic differences 
in warfarin dose requirements have been reported between African American, 
European American and Asian populations.  As compared with Caucasians, African-
Americans require a higher dose (Gage et al. 2004) and Asians require lower doses on 
average (Dang et al. 2005, Lee et al. 2006).   
The presence of other diseases and medications can affect the 
pharmacokinetics of warfarin, for example renal failure. Although warfarin is 
completely metabolised through the liver, chronic renal impairment can alter the 
degree of protein binding and bioavailability, thereby increasing the risk of adverse 
events (Grand'Maison et al. 2005).  Many drugs can inhibit the activity of CYP2C9 
enzymes.  These include amiodarone, cimetidine, isoniazid and trimetoprim (Smith et 
al. 2004, Greenblatt and Von Moltke 2005, Holbrook et al. 2005, Plakogiannis and 
Ginzburg 2007).  Lower warfarin dosing is required to maintain the targeted INR when 
these drugs are administered together.  Conversely, higher warfarin doses are needed 
when an inducer of CYP2C9 such as rifampicin, phenobarbital or carbamazepine is 
co-administered with warfarin.  Common drugs interactions with warfarin are 
presented in Table 1-8. 
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Table 1-8.  Common drug interactions with warfarin and proposed mechanism. 
INCREASED Effect of warfarin DECREASED Effect of warfarin 
PHARMACOKINETICS  
 
Inhibition of S-warfarin clearance 
 By inhibition CYP2C9 enzyme: 
trimethoprim/sulfamethoxazole, 
amiodarone, fluvastatin, fluvoxamine, 
isoniazide, phenylbutazone, sertraline, 
gemfibrozil, amiodarone, metronidazole, 
fluconazole 
Inhibition of R-warfarin Clearance: 
 Inhibition of CYP3A4 enzyme: 
cimetidine, omeprazole), Clarithromycin, 
Erythromycin, variconazole, metronidazole, 
fluconazole 
 By inhibition CYP1A2 enzyme: Ethanol 
 By inhibition CYP1A2/CYP3A4 enzymes: 
Ciprofloxacin 
 Increase warfarin absorption: acarbose 
 
PHARMACOKINETICS 
 
Induction  of  S-warfarin Clearance 
 By induction CYP2C9 enzyme: 
Rifampicin, secobarbital, 
carbamazepine, phenytoin, 
phenobarbiturate, primidone, St 
john’s wart 
 
 
 
Induction  of  R-warfarin Clearance 
 By induction CYP1A2 enzyme: 
Cigarette smoking 
 
Alteration of warfarin absorption: 
cholestyramine 
PHARMACODYNAMIC 
 
Inhibition of  synthesis of vitamin K: 
Second and third generation 
cephalosporins 
Increase catabolism of clotting factors:  
Levothyroxine 
Inteference  with other pathways of 
hemostasis:  Acetylsalicylic acid (aspirin) and 
Nonsteriodal anti-inflammatory drugs 
(NSAIDs) 
PHARMACODYNAMIC 
 
Alteration in Dietary Vitamin K 
Content:  Vitamin K, Vitamin K 
containing foods 
 
 
Patient lifestyle also contributes to the warfarin response.  As warfarin is a 
vitamin K antagonist, patients taking warfarin are likely deficient in regenerated 
vitamin K.  Therefore, it is a common practice to administer a supra-physiological 
doses of vitamin K to reverse the over-anticoagulation effect of warfarin (Hanley et 
al. 2004).  Several studies have confirmed an inverse relationship between warfarin 
maintenance dose requirement and dietary vitamin K intake (Franco et al. 2004, Khan 
et al. 2004).   
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Chronic alcohol intake (long-term) may activate warfarin metabolising 
enzymes, and as a result, decrease the anticoagulation effect by increasing warfarin 
metabolism (Weathermon and Crabb 1999).  For this reason, chronic alcohol drinkers 
will need a higher dose of warfarin.  Active smokers also need a higher dose of 
warfarin due to components in tobacco smoke which can induce activation of CYP1A2 
enzymes (Ansell et al. 2008).   
Many studies have validated the contribution of genetic polymorphisms to the 
warfarin response.  CYP2C9*2, CYP2C9*3 and VKORC1-1639 polymorphisms have 
been validated in many studies to contribute to warfarin stable doses.  These SNPs 
explain up to 40% of dose variability (Sconce et al. 2005, Gage et al. 2008, Jonas and 
McLeod 2009).  In 2007, the US FDA updated the warfarin label to include that the 
CYP2C9 and VKORC1 genotypes may be useful in determining the optimal initial 
dose of warfarin based on findings regarding pharmacogenetic effects (Thompson 
2007).   
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1.9 Genetics and warfarin dose requirement 
As genetic associations with warfarin responses vary between ethnicities, this 
section will compare the response to warfarin doses in different populations/ 
ethnicities.   
1.9.1 CYP2C9 gene and SNPs that affect variability in warfarin dose 
The CYP2C9 gene maps to chromosome 10q24.2, contains nine exons, and 
codes for a 60kDa microsomal protein.  Patients expressing the wild-type gene 
encoding CYP2C9 have the CYP2C9*1 genotype (Arg144/Ile359).  The most 
commonly studied SNPs in this gene are CYP2C9*2 and CYP2C9*3.  In patients 
expressing the CYP2C9*2 variant, arginine is replace by cysteine (Arg144Cys).  
Arg144 is encoded by exon 3 and is located in helix C, which forms part of the putative 
P450 reductase binding site of the protein (Rettie and Jones 2005).  Any changes are 
expected to contribute to a change in enzymatic function.  In contrast, CYP2C9*3 is a 
genotype produced when isoleucine is replace by leucine (Ile359Leu).  Ile359 is 
located in exon 7 and maps close to the active site. Replacement of this amino acid 
leads to a change in the Vmax and Km of the CYP2C9 substrate (Rettie and Jones 
2005).  CYP2C9*2 and CYP2C9*3  produce enzyme variants with catalytic activities 
involving S-warfarin that are reduced by 30% and 95% respectively compared with 
the wild type (Rettie et al. 1999).   
The minor allele frequency for CYP2C9*2 (rs1799853) is 0.12 in Americans 
and Europeans and much lower in Africans (0.02) (Abecasis et al. 2012). CYP2C9*2 
has not been reported in Asian populations except  in Malays and Indians in Malaysia 
(South East Asians) (Gan et al. 2004, Ngow et al. 2009).  The minor allele frequency 
of CYP2C9*3 (rs1057910) is 0.06 in both Americans and Europeans, 0,04 in Asians 
and 0.01 in Africans. 
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Figure 1-4 shows the effect of CYP2C9 polymorphisms on warfarin dose 
variation in different populations.  One allele, *2, gives a 6-45% dose reduction 
compared with wild type.  This contributes to a 13-25% dose reduction in Caucasian 
Americans (Higashi et al. 2002, Kealey et al. 2007, Limdi et al. 2007), 5-14% in 
Caucasian Europeans (Scordo et al. 2002, Topic et al. 2004, Sconce et al. 2005, Mark 
et al. 2006, Markatos et al. 2008) and 26-45% in Asian populations (Gan et al. 2004, 
Tanira et al. 2007). Another allele, *3, gives a 15-48% dose reduction.  This 
contributes to a 28-41% dose reduction in the Caucasian American population 
(Higashi et al. 2002, Kealey et al. 2007, Limdi et al. 2007), 25-48% in the Caucasian 
European population (Scordo et al. 2002, Topic et al. 2004, Sconce et al. 2005, Mark 
et al. 2006, Markatos et al. 2008) and 12-38% in the Asian population (Gan et al. 2004, 
Tanira et al. 2007, Yildirim et al. 2008, Huang et al. 2009, Ohno et al. 2009).  
Supposedly, the *3 allele has a greater effect on variation in warfarin dosing; in 
contrast to this, studies by Tanira et al. (2007) and Gan et al. (2004) revealed that the 
*2 allele had a greater influence on warfarin dose in the Omani population and the 
Indian group of the Malaysian population.  However, these studies have a small sample 
sizes and so these findings need to be treated with caution. In addition, there are many 
other possible factors which can influence warfarin dose such as diet, drugs and 
lifestyle.  
If having one *3 allele gives a great influence on warfarin dosing, 
homozygosity for the *3 allele gives the greatest influence on warfarin dose (Figure 
1-5).  Homozygosity for the *3 allele gives a 20-80% dose reduction compared with 
wild type (Higashi et al. 2002, Scordo et al. 2002, Gan et al. 2004, Topic et al. 2004, 
Huang et al. 2009, Ohno et al. 2009). 
There is no clear association between an individual’s genotype and the warfarin 
maintenance dose for the African American population.  Kealy et al. (2007) showed 
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that CYP2C9 explained the 6% warfarin dose variation in the Caucasian population 
but had no effect on dose variation in the African American population. Similar 
findings were observed by Limdi et al. (2007).  The inconsistent findings might be the 
result of low prevalence of the variant CYP2C9 genotype in these populations, rather 
than the lack of effect. 
A recent meta-analysis study (Jorgensen et al. 2012), has shown that no 
significant associations were found between CYP2C9*2 and warfarin stable dose 
requirements for either Asian or white patients butsignificant associations were 
observed between CYP2C9*3 and stable dose for the White, Chinese, Japanese and a 
mixed Indian, Chinese and Malaysian populations. Dose reduction observed by 
comparing  the heterozygotes CYP2C9*3 to wild-type showed  that white population 
required  the largest dose reduction (approximately 1.80mg/day less), followed by  
mixed Indian, Chinese and Malaysian populations (1.50mg/day less) and  Chinese 
populations ( 1.20 mg/day less).   
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Figure 1-4.  Percentage dose reduction by CYP2C9 polymorphisms   
(one allele compared with wild-type). 
 
Abreviation: 
USA: United state  AA: African American  W: White  M’sia: Malaysia  I: India 
M: Malay  C: Chinese 
 
 
Figure 1-5.  Percentage dose reduction by CYP2C9*3 (homozygous and 
heterozygous compared with one allele). 
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1.9.2 VKORC1 gene and SNPs that affect variability of warfarin dose 
In 2004, two independent study groups discovered the VKORC1 gene (Li et al. 
2004, Rost et al. 2004a).  The gene for human VKORC1, which maps to the short arm 
of chromosome 16, contains three exons and two introns. The membrane topology of 
VKORC1 has been investigated by Tie et al. (2005), as illustrated in Figure 1-6.  The 
protein is 163 amino acids in length and is an integral membrane protein with three 
trans-membrane domains. 
Alignment of amino acid sequences has identified several conserved amino 
acids and functional motifs. Five conserved  polar amino acids have been  proposed to 
form the active centre of VKORC1 (Goodstadt and Ponting 2004).  These are two 
conserved cysteine residues located within the cytoplasmic loop (Cys43 and Cys51 in 
human VKORC1), one conserved serine or threonine (Ser57/Thr57) located within the 
cytoplasmic region and two conserved cysteine residues  (Cys 132 and Cys 135) 
predicted to be partially buried in the ER membrane form a possible CIVC redox motif.   
In photo-affinity labelling and site-directed mutagenesis experiments, a 
hydrophobic sequence motif, Thr-Tyr139-Ala (TYA) was identified as essential for the 
dicoumarol binding site (Ma et al. 1992).  This was supported by evidence that 
mutation at residue Y139 in the rat produces warfarin-resistant phenotypes.  Although 
tyrosine and phenylalanine differ by only one hydroxyl group, substitution led to 
nearly complete warfarin resistance (Rost et al. 2005).   
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Figure 1-6.  Proposed membrane topology of VKORC1. (adapted from Tie et al., 2005).The 
model predicts three transmembrane α-helices.  The amino-terminal part (10aa) of the 
enzyme is located within the ER-lumen. This is followed by α-helix 1 (aa 11-30), a large 
cytoplasmic loop of 69 aa, α-helix 2 (aa101-120), and a small ER luminal loop of 7 aa.  The 
third α-helix (aa 128-147) leads over to the the cytoplasmic carboxy terminal comprising 16 
aa.  Also indicated is the functional motif comprising the TYA warfarin binding site 
(aa138=aa140, red circles), the CIVC redox motif (aa 132-135, green circles), the ER retention 
signal (aa159-163) and five amino acids conserved throughout all species (aaCys43, Cys51, 
Ser/Thr57, Cys132, Cys135, marked by blue circles).  Mutations reported to date are 
indicated by yellow circles with the amino acid exchange given next to the marked circle. 
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The first identified SNPs in the VKORC1 gene were reported by D’Andrea et 
al. (2005).  Rieder et al. (2005) grouped 10 common SNPs to two main haplotypes, A 
and B, where A required a low dose and B required high-dose warfarin.  Similar 
findings were observed by Giesen et al. (2005), who further extended the number of 
main haplotypes to VKORC1*1, VKORC1*2, VKORC1*3, VKORC1*4.  VKORC1*1 
is identified as ancestral, VKORC1 *2 corresponds to the low-dose group A, as defined 
by Rieder et al., (2005), while VKORC1*3 and *4 correspond to the high-dose group 
B. 
The effect of VKORC1*2 (the lower dose phenotype), VKORC1 1173 
(rs9934438) and VKORC1 -1693 (rs9923231) has been extensively studied in Asian 
populations. Both SNPs are in near perfect linkage disequilibrium (LD).  The minor 
allele frequency is 0.44 in American, 0.40 in European, 0.07 in African and 0.92 in 
Asian population (Abecasis et al. 2012). The effects of polymorphisms are described 
in Figure 1 7(A-C).  In Japanese populations, heterozygosity for these allele gave a 
~49% dose reduction whilst homozygosity gave a ~67% dose reduction compared with 
the wild-type carrier (Kosaki et al. 2006, Kimura et al. 2007, Ohno et al. 2009).  In the 
Chinese population, the heterozygous variant gave ~8-51% dose reduction and the 
homozygous variant gave ~43-71% dose reduction (Wang et al. 2008, Huang et al. 
2009).  The Korean population was shown to be more sensitive to the variant allele; 
the heterozygous variant led to a 60% dose reduction and the homozygous variant also 
gave a very similar dose reduction (Cho et al. 2007). 
In white American Caucasians, both SNPs contributed to a 24-27% dose 
reduction in heterozygotes and 40-49% in the homozygotes (Li et al. 2006, Schelleman 
et al. 2007).  However, there were contradictory findings about the association of these 
SNPs in the African American population.  For example, Shellemann et al. (2007) 
studied VKORC1*2 1173 and found no significant relationship between genotype and 
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warfarin dose in African American people.  In contrast, a study by Limdi et al. (2008) 
found similar SNP genotypes were associated with a lower warfarin dose (p<0.005) 
among African Americans.   
Perini et al. (2008) examined the distribution of VKORC1 -1693 in the 
Brazilian population.  The heterozygous variant for VKORC1 -1693 contributed to a 
20-36% dose reduction while the homozygous variant contributed to 40-46%.   
In European populations, studies from Italy on VKORC1 1173 and Greece on  
VKORC1 -1693 demonstrated a 20-35% dose reduction for the heterozygous variant 
and 60-70% for the homozygous variant  (Borgiani et al. 2007, Markatos et al. 2008). 
Only VKORC1*3 (rs 7294), the higher dose phenotype has been studied for its 
association with warfarin dose.  The minor allele frequency is 0.35 in both Americans 
and Europeans,  0.48 in Africans and 0.07 in Asians (Abecasis et al. 2012).  In Japanese 
populations, the heterozygous condition contributed to a 30% dose increment (Kimura 
et al. 2007).  In American Caucasians, heterozygosity contributed up to a 19% dosage 
increment while homozygosity contributed up to 39% (Kimura et al. 2007).  In 
European populations, Borgiani, et al. (2007) found that the heterozygous variant 
contributed up to 60% and the homozygous variant contributed up to 90% of the dose 
increment.  
In the same meta-analysis as mentioned earliar (Jorgensen et al. 2012), a 
significant association was observed between the VKORC1 rs9923231 SNP and stable 
dose in both the white and Chinese ethnic groups, with heterozygotes requiring 1.45 
mg/day less than wild-types in both ethnic groups.  A significant difference was also 
observed between  VKORC1 rs7294 carriers (heterozygotes) and wild-types the white 
population.  Carriers of VKORC1 rs7294 required 1.80 mg/day more than the wild-
type  carriers.  
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(A) rs9934438 (VKORC1*2 1173C>T) 
 
 
 
(B) rs9923231 (VKORC1*2-1693G>A) 
 
(C) rs7294 (VKORC1*3) 
 
Legends: 
            Heterozygous 
             Homozygous 
Figure 1-7 (A-C).  The effect of polymorphism of VKORC1 on warfarin dose.  
Figure (A)and (B) show the warfarin dose reduction by VKORC1*2 1173- 
rs9934438 and VKORC1*2 -1693 rs9923231. Carriers of this variant have a 
lower dose requirement compared with wild-type.  Heterozygous carriers 
have a lower dose requirement (up to 60%) compared with wild-type. Figure 
(C) shows the percentage dose increment caused by VKORC1*3 (rs7294). 
Carriers of this variant have a higher dose requirement compared with wild-
type.  Heterozygous carriers have a higher dose requirement of up to 60% 
dose increment compared with wild-type. 
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In summary, variants of both CYP2C9 and VKORC1 have a significant 
influence on warfarin dose requirement.  Many researchers have evaluated the 
relationship between genotype and dose to build a statistical model that incorporates a 
variety of factors (i.e., clinical, demographic and genetic) to estimate the influence of 
each factor on dose requirement. Such analyses have demonstrated that 
polymorphisms in VKORC1 account for approximately 40% of the variance in 
warfarin dose while CYP2C9 explains less than 10% (Schalekamp and De Boer 2010).  
Together with clinical data, they can explain up to 60% of warfarin variation (Wadelius 
et al. 2009, Lenzini et al. 2010).  Still, another 40% remains unrecognised and this 
could result in over or under dosing.  Considering  the difference of minor allele 
frequencies in different populations which may contribute to the different effect of the 
polymorphism to warfarin dose, pharmacogenetics algorithm for a specific population 
is needed. 
1.9.3 Other genes and variability in warfarin dose 
A recent study identified a non-synonymous variant (rs2108622) in exon 2 of 
a cytochrome P450 family 4, subfamily F, polypeptide 2 gene (CYP4F2) which led to 
an increase in warfarin requirement in a European–American cohort of patients 
(Caldwell et al. 2008).  CYP4F2 is a vitamin K1 oxidase and that carriers of the 
CYP4F2 V433M allele (rs2108622) have a reduced capacity to metabolize vitamin K1 
(McDonald et al. 2009).  Therefore, patients with the rs2108622 polymorphism are 
likely to have elevated hepatic levels of vitamin K1, necessitating a higher warfarin 
dose.   
Caldwell et al., (2008) then repeated the study to validate the result in three 
different sites at Marshfield University, the University of Florida and Washington 
University in St Louis. The variant predicted an additional 4% (Washington 
University), 7% (University of Florida) and 12% (Marshfield University) in the 
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variability of warfarin dose per T allele (minor allele).  The effect of this SNP has been 
confirmed in a Swedish population, where it accounted for 1% of dose variability 
(Takeuchi et al. 2009), Italians where it explained 7.5% of dose variability (Borgiani 
et al. 2009) and North Americans where each copy of the minor allele elevated the 
dose by ~0.5mg/day (Cooper et al. 2008).  The effect was not present in African-
American populations since the minor allele frequency is low in this population 
(Cavallari et al. 2010). 
Contradictory findings were shown in an association study of warfarin dose 
and polymorphisms of GGCX, Factor II, Factor VII, Factor X, EPHX1, CALU, 
ABCB1, and CYP3A4 (D'Ambrosio et al. 2004, Wadelius et al. 2004, Aquilante et al. 
2006, Vecsler et al. 2006, Rieder et al. 2007, Saraeva et al. 2007).  It was also 
discovered that the CYP3A5*3, CYP1A1*1F, CYP2C19 and PROC gene variants did 
not correlate with warfarin dosage variation (Wadelius et al. 2004, Saraeva et al. 
2007).   
1.10 Genetics and other warfarin-related outcomes 
Warfarin-related bleeding is the most problematic side effect of this drug.  As 
such, the relationship between genetic variation and bleeding risk has become an area 
of research interest.   
1.10.1 Genetics and over-anticoagulation during warfarin treatment 
Carriers of CYP2C9*2 and CYP2C9*3 are more frequently over-
anticoagulated (INR ≥4) than wild-type carriers (Higashi et al. 2002, Wadelius et al. 
2009, Molden et al. 2010, Ma et al. 2012).  A systematic review and recent meta-
analysis have demonstrated that both CYP2C9*2 and CYP2C9*3 carriers were 
susceptible to over anticoagulation (INR ≥4) when compared to the CYP2C9 wild-
type. The hazard ratio was also much higher in carriers of CYP2C9*3 as the hazard 
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ratio was 2.37(95%CI 1.46-3.83) for CYP2C9*3 compared to 1.52 (95%CI 1.11-2.09) 
for CYP2C9*2 and 1.90 (95%CI 1.58-2.29) for CYP2C9*2/*3 (Yang et al. 2013).  The 
studies also observed a significantly higher risk for over-anticoagulation (INR ≥4) in 
both homozygous and heterozygous mutant for VKORC1 rs 992323231 (compared to 
wild-type) within 30 days of treatment, but not after 30 days of treatment (Yang et al. 
2013).   
1.10.2 Genetics and major bleeding risk during warfarin treatment 
Even though polymorphisms in VKORC1 and CYP2C9 have been associated 
with lower dose and increased risk of over-anticoagulation, only for CYP2C9 has 
strong evidence been presented to show that it contributes to major bleeding. For 
example, the CYP2C9 polymorphism (CYP2C9*2 and CYP2C9*3 combined) 
influenced major bleeding risk in studies by Higashi et al. (2002) and Limdi et al. 
(2008b).  Only three studies have examined the effect of the VKORC1 genotype on 
major bleeding risk. Limdi et al. (2008b) and Huang et al., (2009) found no effect of 
the VKORC1 (rs9934438) polymorphism on warfarin-related major bleeding in 
Caucasian, African-American and Chinese populations.  A similar conclusion was 
drawn by Giansante et al. (2012) who studied the VKORC1 rs9923231 polymorphism 
in an Italian population.  In a recent meta-analysis, CYP2C9*2 and CYP2C9*3 were 
significantly associated with bleeding with *3/*3 carriers showing the highest hazard 
ratio (Jorgensen et al. 2012, Yang et al. 2013). However, there was no association with 
VKORC1 rs9923231 and rs9934438.  Even though over-anticoagulation is a strong and 
independent risk factor for hemorrhage, it does not always precede a hemorrhagic 
complication (Hylek et al. 2003, Hylek et al. 2008).  Therefore, the risk of over-
anticoagulation does not associate to the risk of hemorrhagic event (Limdi and 
Veenstra 2008).  This possibly explains why the association between VKORC1 and 
over-anticoagulation was observed but not with major bleeding. 
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1.10.3 Genetics and time to stable INR in patients treated with warfarin 
This parameter is of interest because achieving a rapid time to stable INR can 
benefit both patients and care-givers and it also contributes to improving the 
pharmaco-economic profile and genomic testing.  There are contradictory findings 
regarding the association between CYP2C9 polymorphism and time to stable INR.  
CYP2C9*2 and CYP2C9 *3 have been reported to increase the time required to reach 
stable dose in some studies (Higashi et al. 2002, Huang et al. 2009, Kim et al. 2009) 
but the association was not observed in other studies (Kealey et al. 2007, Limdi et al. 
2008a, Jorgensen et al. 2009).  Similarly, there are no conclusive findings regarding 
the association between the VKORC1 polymorphism and this outcome, with one study 
observing an association (Huang et al. 2009), while three other studies show an 
association (Schelleman et al. 2007, Limdi et al. 2008a, Kim et al. 2009). In a recent 
meta-analysis, the association between CYP2C9*2, CYP2C9*3 and VKORC1 
polymorphism and this outcome was found not to be significant (Jorgensen et al. 
2012). 
1.11 Ontogeny which may contribute to changes in warfarin 
pharmacokinetics 
The bioavailability of orally administered drugs such as warfarin may be 
reduced in infants and young children because the gastric pH is higher in neonates, 
infants and young children (Van Der Giesen and Janssen 1982).  The gastric pH 
reaches adult values by two years of age (Anderson and Lynn 2009).  Unfortunately, 
there are no bioavailability studies of warfarin in neonates and children.   
In neonates and infants, total body water is higher compared with an adult.  At 
birth, the total body water is 80%, decreasing to 60% at two years of age, while in 
adults the total body water is 54-62% at age 20 (Anderson and Lynn 2009).  As a result, 
the time required to achieve a stable dose is longer in children, especially neonates, 
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compared with adults.  It is possible that these patients require higher loading doses to 
achieve the targeted concentration in a shorter time. 
Koukouritaki et al. (2004) undertook the largest study to date to characterise 
the developmental expression pattern for human hepatic CYP2C9 and determine the 
overall inter-individual variation in CYP2C9 in 240 foetal and paediatric liver samples.  
The developmental expression of CYP2C9 is shown in the in scatter plot analysis in 
Figure 1-8.  Relative to mature levels, low CYP2C9 protein levels were detected in 
many foetal samples between eight and 24 weeks of gestation and increasing values 
were seen during the remaining gestational period.  The levels were significantly 
greater after birth; however, variability was extensive over a constant range during the 
first five months. An examination of post-natal samples (day 1 to 18 years, n=166) 
revealed that most samples from individuals of one to two years age exhibited a mature 
protein level.   
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Figure 1-8.  A scatter plot analysis showing the development expression pattern of CYP2C9 
against age (adapted from Koukouritaki et al,.2004). (A) A scatter plot analysis of CYP2C9-
specific content as a function of gestational age (weeks) is depicted along with the transition 
at birth and the neonatal and early infancy periods. (B) A scatter plot analysis of CYP2C9-
specific content as a function of postnatal age (years) is depicted EGA: Early gestational age, 
PNA: postnatal age. 
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Results of analyses of variability in expression during different developmental 
stages have shown that 51% of the samples taken from an early infancy period (up to 
five months) had protein values that corresponded with adult values but were highly 
variable (35-fold) compared with the five months to 18 year age group (4-fold 
variability) (Figure 1-9).  It was also shown that CYP2C9 activity (diclofenac 4-
hydroxylase metabolic activity) in samples taken from the group aged 0-5 months 
(median specific activity = 899; n: 88) is not much different compared with samples 
from the group aged >5 months to 18 years (median-specific activity = 628; n: 71) 
(Koukouritaki et al. 2004).   
 
 
Figure 1-9:  Inter-individual variability of CYP2C9 developmental expression within 
different age groups (adapted from Koukouritaki et al. 2004). The boxes represent the 25th 
to 75th percentiles, and the horizontal bar represents the median of the data.  Significant 
differences between groups, as determined by Kruskal-Wallis nonparametric analysis and 
Dunn's multiple comparisons test, are shown (*, p< 0.05; **, p< 0.01). 
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Since warfarin is a drug with a low hepatic extraction ratio (0.004) (Takahashi 
and Echizen 2001), the unbound intrinsic hepatic clearance is the sole pharmacokinetic 
parameter determining its unbound plasma concentration at steady-state.  In a study by 
Takahashi et al. (2000), the unbound oral clearance value for S- warfarin in the 
prepubertal (age 1-11 years) was compared to that of the adult (age 37-76 years) with 
genotypes *1/*1 and *1/*3 genotypes.  The median unbound oral clearance value 
obtained from the adult patients with the wild-type (CYP2C9*1/*1) genotype (ie, 667 
ml/min) was significantly greater than that obtained from the prepubertal patients with 
the corresponding genotype (ie, 367 ml/min), indicating a substantial development 
would take place for the activity of CYP2C9 in these subjects. In contrast, there was 
no significant difference in the median unbound oral clearance value between 
prepubertal and adult patients with the CYP2C9*1/*3 genotype (ie, 213 and 212 
ml/min, respectively), indicating that the development of CYP2C9 activity may be 
substantially attenuated in carriers of the CYP2C9*3 allele. However, the author 
concluded that was not a valid findings because the numbers of prepubertal and adult 
patients with the CYP2C9*1/*3 allele were rather small (n=5 and 4, respectively) and 
no longitudinal follow-up was made for individual children with CYP2C9*1/*3 
genotype. 
1.12 Ontogeny which may contribute to changes in warfarin 
pharmacodynamics 
There is disagreement between findings regarding the concentration of vitamin 
K-dependent proteins in children and in adults.  In his review, Andrew (1995) reported 
that Factor II, Factor VII, Factor IX and Factor X are expressed at approximately 50% 
of the adult level at birth, and the concentration increases but remains approximately 
15-25% lower than the adult value during childhood.  With routine vitamin K 
supplementation, these factors are significantly reduced in the first six months 
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(Andrew et al. 1988).  Proteins C and S are also expressed at lower levels at birth and 
during childhood.  A study by Massicotte et al. (1998) in paediatric patients (median 
age, 13 years old) found that plasma concentrations of six vitamin K-dependent 
clotting factors (Factor II, Factor VII, Factor IX, Factor X, Protein C and free Protein 
S) were similar for children and adults.  The review by Andrew (1995) is likely to be 
more accurate because he referred to studies which analysed different age groups (1-5 
years; 6-10 years, 11-18 years and adult) whilst Massicotte et al. analysed children 
ranging in age from one to 18 years.  
In contrast with Vitamin K coagulation factors, expression levels of 
thrombomodulin (Andrew et al. 1994) and α2-microglobulin (Andrew 1995, 
Massicotte et al. 1998) are highest during infancy and early childhood.  α2-
microglobulin is expressed at approximately twice the adult value at six months of age.  
Taking everything into account, there is less active thrombin circulating in children’s 
plasma due to an increase in the direct inhibitor, α2-microglobulin, and an increase in 
thrombomodulin in the Protein S/ Protein C system.   
As discussed in 1.2.3.2 (page 13), the role of VKORC1 is to recycle oxidised 
vitamin K into its hydroquinone form, becoming an essential cofactor for the post 
translational carboxylation of vitamin K-dependent clotting to its functional form.  The 
action of warfarin is to inhibit the ability of VKORC1 to recycle oxidised vitamin K 
and, as a result, to reduce the functional vitamin K-dependent clotting factors.  A small 
study (n=46) showed that the activity of VKORC1 is high in the early prenatal period 
but significantly decreases after birth.  However, the study did not observe any 
significant changes in VKORC1 activity during childhood (Itoh and Onishi 2000). 
Dietary vitamin K may influence warfarin response and this has been seen in 
several studies.  Breast-fed infants are more sensitive to the anticoagulant effects of 
warfarin than formula-fed infants and this is likely to be due to the relatively low 
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concentration of vitamin K in breast milk compared to vitamin K-supplemented 
formula feeds (Haroon et al. 1982).  Children receiving enteral feeding by nasogastric 
or gastrostomy tube have also been shown to require higher warfarin doses; again this 
is likely to be due to vitamin K supplementation of the enteral feed (Streif et al. 1999).   
Recently, Hirai et al. (2013) investigated the relationship between warfarin 
sensitivity and plasma Vitamin K in Japanese children (n=37) who were being treated 
with warfarin.  No significant association was found between warfarin sensitivity and 
plasma vitamin K1 concentration, but a significant negative correlation was detected 
with plasma concentrations of MK-4.  MK-4 is vitamin K2 homologue and is obtained 
from dietary Vitamin K1 and vitamin K2 found in various animal tissues.  A specific 
human enzyme which plays a role in converting Vitamin K1 to MK4 has recently been 
discovered, offering a mechanism for this observation (Nakagawa et al. 2010). 
1.13 Aims of the thesis 
My interest in warfarin pharmacogenomics began when I worked as a 
pharmacist in a warfarin clinic in my home country (Malaysia).  I observed large inter-
individual dose variability in different patients.  Some patients were very sensitive to 
warfarin; even a small dose adjustment could result in an unexpected INR and these 
patients only required less than 0.5mg/day warfarin to achieve a therapeutic INR.  In 
contrast, some patients required >15mg/day of warfarin to achieve a similar target 
INR.  
The primary aim of this work is based on the following two questions: first, 
would knowledge of genetics be useful in improving warfarin treatment decision?  
This includes predicting efficacious warfarin doses and at the same time, avoiding 
intolerable or dangerous side effects.  Second, are we ready to use genotyping in a 
clinical environment?  In the clinical setting, the faster we can obtain a genotyping 
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result the better to help avoid adverse events. Ideally, the genotyping result is needed 
before warfarin therapy begins, and the result must be accurate. 
An outline of my thesis is as follows: 
(i) Literature Review (Chapter 1).  My thesis starts with brief review of the relevant 
literature on the key concepts of pharmacogenetics of warfarin.  This includes 
basic genetic terminology, the blood coagulation process, the pharmacological 
properties of warfarin and a review of warfarin pharmacogenetic studies. I have 
also discussed human ontogeny as it influences the warfarin response.   
(ii) Development and validation of pharmacogenetic algorithms in adult 
populations (Chapter 2).  It is advantageous in clinical practice if there is an 
available algorithm to accurately predict the appropriate warfarin dose in given 
patients. Chapter 2 describes the development and validation of a warfarin 
dosing algorithm using CYP2C9 and VKORC1 polymorphisms together with 
clinical factors.   
(iii) Assessment of HAS-BLED score and contribution of genetics in predicting 
bleeding risk (Chapter 3).  Bleeding is the major risk in warfarin treatment.  
Bleeding assessment will help to determine whether patients will suffer 
intolerable or dangerous side-effects which are helpful in counselling patients 
and informing treatment decision. In this chapter, the performance of the novel 
bleeding score, HAS-BLED, was assessed in our prospective cohort (six months 
follow-up) and the prediction performance was compared to that incorporating 
genotype. 
(iv) The role of genetics in predicting warfarin response in children (Chapters 4 & 
5).  The contribution of CYP2C9 and VKORC1 polymorphisms to the warfarin 
response in children is introduced in the fourth chapter and then extended to an 
exploration of the Genome Wide Association study (GWAS) in the fifth chapter. 
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(v) Validation of Genie – a point of care device to genotype VKORC1 and CYP2C9 
polymorphisms (Chapter 6).  Chapter 6 focuses on the application of 
pharmacogenetic testing in a clinical set-up.  The work described in Chapter 6 
involves the validation of the Genie, a genotyping instrument used for the 
European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) trial (Van 
Schie et al. 2009). The aim is to establish whether it is accurate and applicable 
for use in a clinical situation.   
(vi) Finally, Chapter 7 summarises my research in this area to date, and outlines the 
next phase of my research. 
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Chapter 2 
Development and 
validation of a warfarin 
dosing algorithm 
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2.1 Introduction 
Current warfarin therapy adopts a precarious trial-and error approach where 
patients are prescribed a standard loading dose during the first 2-3 days of warfarin 
initiation before a therapeutic dose is titrated according to the patient’s INR response 
(Fennerty et al. 1984, Gedge et al. 2000, Kovacs et al. 2003, Siguret et al. 2005).  
During this dose-titration period, patients are at highest risk of adverse events 
(Landefeld and Goldman 1989, Fihn et al. 1993, Douketis et al. 2000).  As such, 
strategies to individualise initial warfarin dose have been sought. 
The notion of dosing algorithms utilising clinical variables to improve 
anticoagulation management has existed for decades (Williams and Karl 1979, Ovesen 
et al. 1989).  Studies incorporating clinical variables into computer programs have 
demonstrated improvement in stable INR maintenance and reduction of complications 
(Ageno et al. 2000, Manotti et al. 2001).  After the discovery of the CYP2C9 and 
VKORC1 genes, numerous studies have developed pharmacogenetic dosing 
algorithms that incorporate both genotype and clinical characteristics to predict 
warfarin dosing requirements.  SNPs in CYP2C9 and VKORC1 have shown to 
contribute approximately 30-40% dose variance, and together with clinical variables, 
they account for nearly up to 60% of dose variability (Sconce et al. 2005, Gage et al. 
2008, Hatch et al. 2008, Perini et al. 2008).  More recently, the International Warfarin 
Pharmacogenetics Consortium (IWPC) published a study which is the largest to date, 
where they demonstrated the addition of genetic information (CYP2C9 and VKORC1 
SNPs) to clinical variables provided dosage prediction that was significantly closer to 
the actual dosage required than estimates derived from a clinical algorithm or a fixed-
dose approach (Klein et al. 2009).   
Although many research groups throughout the world have developed 
pharmacogenetic algorithms in different populations, only one study utilising a cohort 
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of British Caucasians has been reported (2005).  Incorporating age, height, CYP2C9 
and VKORC1 genotypes from a retrospective cohort of 297 British Caucasian patients, 
Sconce and colleagues (2005) derived a pharmacogenetic algorithm which explained 
54.2% of warfarin stable dose variance.  However, to the best of our knowledge, no 
pharmacogenetic algorithm has yet been developed using one large cohort of 
prospectively recruited British Caucasian patients. 
Furthermore, most studies developing warfarin dosing algorithms have 
assessed their accuracy by referring to the R-squared (R2) value, which estimates the 
proportion of variability in the data captured by the model.  However, a high R2 value 
does not necessarily imply that the model is capable of accurate dose prediction 
(Jorgensen and Pirmohamed 2011).  More recently, studies have referred to the mean 
or median absolute error (MAE) as a measurement of predictive accuracy (Gage et al. 
2008, Klein et al. 2009, Zambon et al. 2011).  An alternative measure is the proportion 
of patients whose predicted dose is within x units of actual dose, with x appropriately 
chosen (Klein et al. 2009, Finkelman et al. 2011, Jorgensen and Pirmohamed 2011). 
The goals of this chapter were therefore (1) to develop a pharmacogenetic 
dosing model utilising our prospective cohort of Caucasian patients being initiated 
onto warfarin therapy in a secondary care setting, and, (2) to externally validate the 
predictive capability of our algorithm in an independent cohort of patients recruited 
retrospectively in a primary care setting.   
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2.2 Methods 
2.2.1 Patient recruitment 
The study was approved by the West Midlands Multi-Centre Research Ethics 
Committee and written informed consent was obtained from each patient prior to study 
commencement.  
Derivation Cohort: 1000 patients were recruited from the Royal Liverpool and 
Broadgreen University Hospital Trust (RLBUHT) and University Hospital Aintree 
between November 2004 and March 2006.  Patients were followed up prospectively 
from the start of warfarin treatment for a period up to 26 weeks.  The study design 
was observational.  Patients received standard loading doses and dose changes were 
determined according to in-hospital guidelines.  Each patient had four scheduled 
visits: the first was at the time of warfarin therapy commencement (index visit), then 
three subsequent follow-up visits at one week, eight weeks and twenty-six weeks of 
warfarin therapy.  At the index visit, several clinical parameters were recorded 
including baseline INR, concurrent medications, medical history and patient 
demographics.  All INR measurements and dose changes during follow-up were also 
systematically recorded. This cohort of patients was originally recruited as part of a 
large prospective study on warfarin pharmacogenetics and the interim analysis has 
been published (Jorgensen et al. 2009).   The  interim analysis of this cohort has 
discovered that CYP2C19 (SNP rs3814637) was significantly associated with 
warfarin stable dose.  However, the authors hypothesized that the significant 
associations found with SNPs in both CYP2C19 could be due to linkage 
disequilibrium (LD) with CYP2C9. 
Validation Cohort: 373 patients undergoing warfarin treatment were recruited 
retrospectively from 40 primary care practices across the West Midlands between 
June 2006 and October 2007.  Patients’ medical records were reviewed and clinical 
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information including demographic characteristics, indications for warfarin, warfarin 
dose changes, INR measurements and concurrent medication were collected. 
2.2.2 Outcome measure 
To develop our dosing algorithm, warfarin stable dose was taken as the main 
outcome measure.  Stable dose was defined as a consistent mean daily dose leading to 
an individual’s INR being within therapeutic range at three or more consecutive clinic 
visits.  Given the anticoagulant effect of warfarin is due to sequential depression of 
Factor II, Factor VII, Factor IX, Factor X, Protein C and Protein S activities, with the 
S-warfarin elimination half-life at approximately 24-33 hours (Hirsh et al. 1998, 
Horton and Bushwick 1999), it was assumed that stable dose could only be observed 
after a period of at least 5 consecutive days of warfarin treatment.  If several periods 
of stable dose were observed, the stable dose at the latest date was taken. The earlier 
stable dose was not chosen because the early periods of stable dose often associated 
with a short period of stable dose (example, stable for only 2-3 days). 
2.2.3 DNA extraction 
DNA was extracted from ethylenediaminetetraacetic acid (EDTA) whole 
blood using the phenol-chloroform method or the Chemagen Whole Blood DNA 
Extraction Kit on the Chemagic Magnetic Separation Module 1 (Auto-Q Biosciences, 
Germany).   
Briefly, the phenol-chloroform method involved adding an equal volume of 
phenol-chloroform to an aqueous solution of lysed red and white blood cells, followed 
by vigorous mixing and phase separation via centrifugation.  Since DNA is polar 
(because of its negatively charged phosphate backbone), DNA will partition into the 
aqueous phase (top layer).  DNA recovery was subsequently achieved by ethanol 
precipitation as illustrated in Figure 2-1. 
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Figure 2-1.  DNA extraction by phenol chloroform method. 
Figure 2-2 outlines the semi-automated DNA extraction process on the 
Chemagic Magnetic Separation Module 1.  The isolation of DNA is achieved through 
its capture by magnetic polyvinyl alcohol beads (M-PVA Magnetic Beads).  The M-
PVA Magnetic Beads exhibit both, a hydrophilic surface and low non-specific protein 
binding which allows for efficient binding to DNA with high yield and purity.  When 
an electromagnetic field is applied, the beads together with DNA will be attracted to 
the magnetized metal rods, which then transfer the DNA from one washing buffer to 
another.  At the end of each transfer step, the electromagnet is deactivated and the 
rotation of the rod is switched on, leading to an efficient and homogenous resuspension 
of the particles.  In the final step, the elution buffer inactivates the interaction between 
the beads and the DNA.  The magnetic beads are then removed, leaving the isolated 
DNA in suspension.   
 
 
Figure 2-2.  DNA extraction via magnetic beads technology. The magnetisable and rotatable 
rods allow the particles to be homogenously resuspended. 
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2.2.4 Genotyping 
Genotyping of CYP2C9*2 (rs1799853, C>T), CYP2C9*3 (rs1057910, A>C) 
and VKORC1 -1639 (rs9923231, -1639A>G) were performed on the ABI 7900HT Fast 
Real-Time polymerase chain reaction (PCR) system (Applied Biosystems).  Details of 
the probes used are listed in Table 2-1. 
Table 2-1.  Sequences of Taqman probes for CYP2C9*2, CYP2C9*3 and VKORC1 -1639. 
SNPs Context Sequence Design Strand 
CYP2C9*2 GATGGGGAAGAGGAGCATTGAGGAC[C/T]GTGTTCAAGA
GGAAGCCCGCTGCCT 
Reverse 
CYP2C9*3 TGTGGTGCACGAGGTCCAGAGATAC[C/A]TTGACCTTCTCC
CCACCAGCCTGCC 
Reverse 
VKORC1 -1639 GATTATAGGCGTGAGCCACCGCACC[C/T]GGCCAATGGTT
GTTTTTCAGGTCTT 
Forward 
 
Figure 2-3 illustrates the Taqman genotyping procedure.  Approximately 10 ng 
of DNA was amplified in a 10 µl reaction mix in a 384–well optical plate containing 
1x Taqman drug metabolism genotyping assay mix and 1x Taqman master mix.  
Thermo-cycling was carried out with an initial activation of the AmpliTaq Gold DNA 
polymerase at 95°C for 10 min, followed by 40 cycles of denaturing at 95°C for 15 sec 
and extension at 60°C for 90 sec.  Allelic discrimination was determined using SDS 
version 2.2 software (Applied Biosystem).  Examples of the allelic discrimination plots 
and their interpretation are shown in Figure 2-4 to Figure 2-6. 
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Figure 2-3.  Taqman genotyping procedure. The reaction mix was freshly prepared and 
pipetted to the dried DNA.  Two document plates, allelic discrimination and absolute 
quantification, were set up.  Pre- and post-read were performed to ensure accuracy of the 
results, where any background noise was taken into account when the end point flourescene 
was determined.  On the allelic discrimination plot, the red dot indicates XX homozygote, the 
green dot indicates XY homozygote, and the blue dot indicates YY heterozygote. 
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Figure 2-4.  Allelic discrimination plot for CYP2C9*2 genotype using ABI Taqman® 
Real-Time Polymerase Chain Reaction platform.  NTC: No template control. 
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Figure 2-5.  Allelic discrimination plot for CYP2C9*3 genotype using ABI Taqman® 
Real-Time Polymerase Chain Reaction platform. NTC: No template control. 
AA 
AC 
CC 
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Figure 2-6.  Allelic discrimination plot for VKORC1-1693 genotype using ABI Taqman® 
Real-Time Polymerase Chain Reaction platform.  NTC: No template control. 
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The Taqman SNP drug metabolism genotyping assay is also called the 5’-
nuclease allelic discrimination assay.  It requires a pair of forward and reverse PCR 
primers to amplify the polymorphism of interest, and two Taqman probes for detecting 
specific alleles.  Each Taqman probe has a fluorescent reporter dye (VIC of FAM) and 
a non-flourescent quencher attached to its 5’ and 3’ end, respectively.  In addition, 
each probe has a minor groove binder (MGB) at its 3’ end which increases the melting 
temperature (Tm) of a given probe length, allowing the design of shorter probes 
(Afonina et al. 1997, Kutyavin et al. 1997).  A greater difference in Tm value between 
the matched and mismatched probes will result in more robust allelic discrimination.  
Figure 2-7 illustrates the Taqman Probe-based genotyping assay chemistry.  
 
 
 
Figure 2-7.  Taqman probe-based genotyping assay chemistry. During PCR, each Taqman 
MGB probe anneals specifically to its complementary sequence between the forward and 
reverse primer sites.  Taq DNA polymerase cleaves the reporter dye from the probe and once 
the probe is cleaved, the reporter dye is free of the quencher dye and emits a fluorescent 
signal.  Therefore, an increase in either FAM or VIC dye fluorescence indicates homozygosity 
for FAM and VIC specific alleles and an increase in the fluorescence of both dyes indicates 
heterozygosity. 
Adapted from TaqMan® Drug Metabolism Genotyping Assays Protocol, Applied Biosystems 
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To ensure quality control, the PCR plate was designed to contain 10% 
duplicates, two negative controls (using DNase-free water) and two positive controls 
for each SNP.   
2.2.5 Statistical analysis 
The assessment of conformity with Hardy Weinberg Equilibrium (HWE) for 
each SNP was performed using Haploview software (version 4.2). A p value of <0.001 
was assumed to indicate deviation from HWE.  SPSS (version 17) was used to analyse 
associations between variables and outcomes.  As the distribution of warfarin stable 
dose was skewed, a square-root data transformation was performed to achieve 
normality (Figure 2-8). 
 
 
Figure 2-8.  Square-root transformation of stable warfarin dose. Normal distribution was 
achieved by square-root transformation. Normal distribution was achieved by square-root 
transformation. 
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2.2.5.1 Univariate analysis 
As discussed in section 1.8 (page 23), it is widely known that age, height and 
weight are significantly correlated with warfarin dose.  The following baseline clinical 
factors were therefore pre-identified as potential predictors of warfarin stable dose in 
our study: age (Anderson et al. 2007), weight (Carlquist et al. 2006, Anderson et al. 
2007), height (Sconce et al. 2005), body mass index (BMI) (Wells et al. 2010), body 
surface area (BSA) (Gage and Lesko 2008), gender (Hillman et al. 2004) and 
amiodarone use (Heimark et al. 1992).  BMI was calculated by dividing weight (kg) 
over squared height (m) (World Health Organization).  To determine BSA, the 
Mostereller equation was used due to its accuracy and ease of use (Vu 2002) and the 
equation are:  BSA = √((Height (cm) x Weight (kg)/3600).   
Each genetic and non-genetic factor was univariately assessed for association 
with warfarin stable dose in the derivation cohort.  Continuous variables were 
examined using univariate linear regression while binary variables were analysed 
using the Student’s T-test.  Associations with genotypes were assessed using univariate 
analysis of variance (ANOVA).  The correlations between BMI, weight, height and 
BSA were tested using Pearson Correlation.  Bonferroni correction was used to correct 
for multiple testing.  Bonferroni-corrected p values are denoted as Pc-values. All 
variables giving a p value <0.05 in the univariate analysis were subsequently included 
in the multiple regression model.   
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2.2.5.2 Multiple regression analysis 
Using both genetic and clinical factors, a multiple linear regression model was 
developed to build an algorithm for predicting the stable therapeutic dose of warfarin.  
A stepwise variable selection method was used, with variables retained in the model if 
they achieved statistical significance (p<0.05).  CYP2C9*2, CYP2C9*3 and VKORC1 
-1639 polymorphisms were coded to reflect an additive mode of inheritance (0, 
wildtype; 1, heterozygous; 2, homozygous). 
To assess the predictability and accuracy of our algorithm, the following 
parameters were investigated:   
i)  R2derived from the multiple linear regression model.  R2 describes the 
proportion of variance explained by the model.  The R2 value ranges from 0 to 100 
where 100 means the model fits the observed dependent variable values perfectly.   
ii) Mean or Median absolute error is calculated as the average absolute values 
for the difference between algorithm-predicted and observed warfarin stable dose.  
Lower mean or median absolute error value indicates better accuracy.  
iii) The proportion of patients whose predicted doses fell within 20% of their 
actual daily dose.  As described in previous studies, the ideal dose was defined as a 
predicted dose that differed by no more than 20% from the actual stable therapeutic 
dose of warfarin (Klein et al. 2009, Finkelman et al. 2011).  These values reflect a 
difference of 1 mg/day relative to the traditional starting dose of 5 mg/day, which 
clinicians would likely regard as clinically relevant (Klein et al. 2009). 
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2.3 Results 
2.3.1 Clinical and genetic characteristics of participants 
Derivation cohort:  Out of the 1000 patients recruited, 911 patient were 
successfully genotyped for CYP2C9*2, CYP2C9*3 and VKORC1 -1639.  Of these, 
468 achieved stable dose in accordance with our definition.  Seven non-Caucasians 
were excluded from the analysis.  A further 5 patients with missing data were also 
excluded.  Overall, 456 patients were included in the derivation of our 
pharmacogenetic algorithm.  
Validation cohort:  Of the 373 recruited patients, 371 were genotyped 
successfully. 266 achieved stable dose but 4 patients were excluded due to missing 
data.  As such, only 262 patients were included in the analysis.  
The baseline characteristics of both cohorts including demographics, 
indications for warfarin treatment and warfarin dose requirements are presented in 
Table 2-2.  The majority of patients were prescribed warfarin for the treatment of atrial 
fibrillation with target INR 2-3, with cardiovascular disease being the most common 
underlying co-morbidity.  No significant differences in clinical characteristics such as 
age, body weight, sex and indications of warfarin were observed between the two 
cohorts. 
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Table 2-2.  Baseline characteristics of patients in our derivation and validation cohorts 
who have achieved warfarin stable dose. 
Characteristic Derivation cohort 
n= 456 
Validation cohort 
n=262 
Gender – Male [n, %] 254 (55.7) 150 (57.3) 
Age (years) [mean, sd] 68 (13) 74 (10) 
Weight (kg) [mean, sd] 82 (19) 80 (16) 
Height (cm)[mean, sd] 169 (10) 169 (10) 
BMI [mean, sd] 29 (6) 28 (5) 
Indications [n, %] 
Atrial Fibrillation 
Pulmonary Embolism 
Deep Vein Thrombosis 
Mitral Heart Valve Prosthetic 
Cerebrovascular accident & transient 
Ischemic diseas 
Others 
 
302 (66.2) 
76 (16.7) 
42 (9.2) 
1 (0.2) 
27 (5.9) 
 
8 (1.8) 
 
197 (75.2) 
22 (8.4) 
26 (9.9) 
6 (2.3) 
10 (3.8) 
 
1 (0.4) 
Concomitant Disease [n, %] 
Cardiovascular 
Respiratory disease 
Hepatic disease 
GI disease 
Renal Disease 
Neurological Disorder 
 
366 (80.3) 
162 (35.5) 
15 (3.3) 
166 (36.4) 
44 (9.6%) 
86 (18.9) 
 
189 (72.1) 
33 (12.6) 
0 
5 (1.9) 
50 (19.1) 
25 (9.0%) 
Amiodarone Use [n, %] 34 (7.5%) 14 (5.3) 
Warfarin dose (mg/day) 
Median [ IQR] 
Mean [sd] 
 
4.0 (0.38) 
4.2 (2.04) 
 
4.0 (1.9) 
4.12 (0.5) 
Smoker [n, %] 63 (13.8) 14 (5.3) 
Alcohol intake (at least 2 or  3 times 
per week) [n, %] 
152 (33.3) 162 (61.8) 
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The genotype frequencies of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 for 
both, the derivation and validation cohorts are summarized in Table 2-3.  The genotype 
frequencies for all 3 SNPs conformed to Hardy-Weinberg equilibrium.  When the two 
cohorts were combined, the minor allele frequencies (MAF) for CYP2C9*2, 
CYP2C9*3 and VKORC1 -1639 were 0.13, 0.06 and 0.37, respectively, and the MAFs 
are comparable to previous studies conducted in British populations (Stubbins et al. 
1996, Aithal et al. 1999, Sconce et al. 2005). 
 
Table 2-3.  Genotype frequencies of CYP2C9*2, CYP2C9*3 and VKORC1-1639 
polymorphisms in patients from our derivation and validation cohorts. 
Genotypes Derivation cohort (n= 456 ) 
n, (%) 
Validation cohort (n=262) 
n, (%) 
CYP2C9*2  
Wild-type  (CC) 
Heterozygous mutant  (CT) 
Homozygous mutant  (TT) 
Hardy-Weinberg  p-value 
 
351 (77.0) 
101 (22.1) 
4 (0.9) 
0.9 
 
189 (72.1) 
68 (26.0) 
5 (1.9) 
0.9 
CYP2C9*3  
Wild-type  (AA) 
Heterozygous mutant (AC) 
Homozygous mutant  (CC) 
Hardy-Weinberg  p-value 
 
402 (88.2) 
51 (11.2) 
3 (0.7) 
0.5 
 
233 (88.9) 
29 (11.1) 
0 
0.9 
VKORC1 -1639 
Wild-type  (CC) 
Heterozygous mutant (CT) 
Homozygous mutant  (TT) 
Hardy-Weinberg  p-value 
 
183 (40.1) 
210 (46.1) 
63 (13.8) 
0.9 
 
100 (38.2) 
123 (46.9) 
39 (14.9) 
0.9 
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2.3.2 Association of clinical and genetic factors with stable warfarin dose 
Clinical and genetic factors which showed significant univariate associations 
(p<0.05) in our derivation cohort are listed in Table 2-4.  An increase in age was 
associated with decreased warfarin stable dose while increase in weight, height, BMI 
and BSA were associated with elevated warfarin stable dose requirements.  When 
compared to female patients, male patients required higher doses of warfarin to 
achieve stability.  Patients who took amiodarone as a concomitant medication showed 
a significant reduction in warfarin dose requirement. 
Table 2-4.  Significant variables found in univariate analysis. 
Variables Univariate p-value Effect on warfarin stable dose R2 
Age 1.1 x 10-10 ↓ 0.09 
Weight 7.0 x 10-13 ↑ 0.11 
Height 4.7 x 10-6 ↑ 0.04 
BMI 2.3 x 10-7 ↑ 0.06 
BSA 2.7 x 10-13 ↑ 0.11 
Sex 5.1 x 10-5 ↑, Male 0.03 
Amiodarone use 0.018 ↓ 0.008 
CYP2C9*2 2.2 x10-5 ↓ 0.04 
CYP2C9*3 1.15 x10-6 ↓ 0.04 
VKORC1 -1639 3.6 x10-27 ↓ 0.21 
 
Given that weight, height and the derived BMI and BSA indices were all highly 
inter-correlated (p<0.001), BSA which gave the lowest univariate p value was selected 
to be included in our multiple linear regression analysis. 
Figure 2-9 illustrates the distribution of stable dose in our derivation cohort of 
patients stratified for the CYP2C9*2, CYP2C9*3 and VKORC1 -1639 genetic 
polymorphisms.  Carriers of the minor alleles for CYP2C9*2, CYP2C9*3 and 
VKORC1 -1639 exhibited a significantly reduced warfarin dose requirement when 
compared to carriers of the major allele. 
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(A) 
 
 
(B) 
 
 
 
(C) 
 
Figure 2-9.  Box and whisker plots showing the distribution of daily warfarin doses based 
on (A) CYP2C9*2 (B) CYP2C9*3 and, (C) VKORC1 -1639 genotypes.  Boxes represent 25th-
75th percentile (interquartile range) of warfarin dose, whiskers represent 5th-95th 
percentile, solid lines represent median dose.  Open dots denote outliers (a value between 
1.5 and 3 times the interquartile range away from the 25th or 75th percentile) and asterisks 
denote extreme outliers (a value more than 3 times the interquartile range away from the 
25th or 75th percentile). 
n:   351             101               4 
Pc=6.6 x 10-5 
n:   183              210             63 
n:   402             51               3 
Pc=1.1 x 10-26 
Pc=3.4 x 10-6 
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2.3.3 Deriving a pharmacogenetic algorithm for warfarin stable dose 
To identify the main clinical and genetic factors affecting warfarin stable dose, 
multiple linear regression analysis was performed.  After stepwise selection, only the 
predictors age, BSA, amiodarone use, CYP2C9*2, CYP2C9*3 and VKORC1 -1639 
remained significant and were included in our model.  Using the coefficients of the 
regression estimates, the algorithm for predicting daily warfarin stable dose was 
calculated:  
Predicted daily warfarin stable dose (mg/day) = [2.135 -0.313(VKORC1 
-1639) + 0.417(BSA) – 0.009(Age) – 0.309 (CYP2C9*3) – 0.186 
(CYP2C9*2) – 0.199 amiodarone] 2 
where BSA is in m2; age in years; amiodarone use was coded 0 if not prescribed and 
1 if prescribed. Our pharmacogenetic model explained 46% of warfarin dose variance 
and gave a mean (median) absolute error of 1.04 (0.78) (Table 2-5). 
 
Table 2-5.  Performance and accuracy comparison of our pharmacogenetic model in the 
derivation and validation cohorts. 
Prediction assessment Derivation cohort Validation cohort 
Dose variability explained by R2: 
Genetic and clinical factors 
 
 Clinical factors: (BSA, Age and 
amiodarone use) 
 Genetic factors:  (CYP2C9*2, 
CYP2C9*3 and VKORC1) 
 
46% 
 
31% 
 
15% 
 
 
43% 
 
29% 
 
16% 
 
Mean absolute error (mg/day) 
 (95% Confidence Interval, CI) 
 
Median absolute error (mg/day) 
1.04  
(0.94-1.15) 
 
0.78 
1.08  
(0.95-1.20) 
 
0.88 
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2.3.4  Validating the pharmacogenetic algorithm for warfarin stable dose 
The performance of our pharmacogenetic algorithm in our validation cohort is 
shown in Table 2-5.  Our algorithm explained 43% of warfarin dose variance in the 
validation cohort consisting of 262 individuals, and gave a mean (median) absolute 
error of 1.08 (0.88) mg/day.   
To assess the clinical accuracy of our pharmacogenetic algorithm, we 
calculated the percentage of patients in the validation cohort whose predicted dose was 
within 20% of the actual therapeutic stable dose.  49.6% of the dose prediction fell 
within 20% of the actual dose.  As shown in Figure 2-10a, our pharmacogenetic 
algorithm provided accurate dose estimates for the majority of patients requiring more 
than 2 mg and less than 6mg of warfarin per day.  61.8% of dose predictions for this 
group of patients fell within the ideal dose range, 15.7% of dose predictions were 
underestimated, and 22.5% of dose predictions were overestimated (Table 2-6).  Our 
pharmacogenetic algorithm however, did not perform as well for patients who required 
≤ 2mg/day or ≥ 6 mg/day, giving absolute dose differences of ≥ 2 mg/day in the 
majority of the patients (Figure 2-10b).  For patients requiring 2 mg or less of warfarin 
per day, our pharmacogenetic algorithm correctly predicted 26.7% of patients while 
the remaining 73.3% of dose predictions were overestimated.  For patients requiring 6 
mg or more of warfarin per day, our pharmacogenetic algorithm accurately predicted 
9.7% of patients while the remaining 90.3% of dose estimates were underpredicted. 
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(A)                                                              (B) 
        
Figure 2-10.  Evaluation of pharmacogenetic algorithm-predicted doses versus observed 
therapeutic doses in the validation cohort (n=262).  (A) Scatter plot comparing the 
observed and predicted warfarin stable doses in our validation cohort.  Each black circle 
represents the predicted versus observed dose for each subject.  The solid line represents 
perfect prediction (y=x).   (B) Scatter plot comparing the absolute dose difference versus 
observed dose in our validation cohort.   Each green circle represents the absolute dose 
difference versus observed dose for each subject.  The red dotted line represents mean 
absolute error and the two blue dotted lines encompass individuals with observed warfarin 
dose 2-6 mg/day. 
 
 
Table 2-6.  Accuracy of our pharmacogenetic algorithm based on percentage dose 
estimates within 20% of observed dose in the validation cohort. 
Warfarin dose Patients 
[n] 
Ideal dose 
[n (%)] 
Underestimation 
[n (%)] 
Overestimation  
[n (%)] 
Validation cohort 
≤ 2 mg/day 
>2 to <6 mg/day 
≥ 6 mg/day 
Total 
 
30 
191 
41 
262 
 
8 (26.7) 
118 (61.8) 
4 (9.7) 
130 (49.6) 
 
0 (0) 
30 (15.7) 
37 (90.3) 
67 (25.6) 
 
22 (73.3) 
43 (22.5) 
0 (0) 
65 (24.8) 
Ideal dose: Predicted dose was within 20% of the actual stable therapeutic dose. 
Underestimation: Predicted dose was below 20% of the actual stable therapeutic dose. 
Overestimation: Predicted dose was more than 20% of the actual stable therapeutic dose. 
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2.4 Discussion 
To date, this is the first study which derived a pharmacogenetic algorithm using 
one large prospective cohort of British Caucasian patients initiated onto warfarin 
therapy.  Utilising data from 456 prospectively recruited patients, we developed a 
pharmacogenetic algorithm which incorporated BSA, age, amiodarone use, and the 
alleles CYP2C9*2, CYP2C9*3 and VKORC1.  Using an external cohort of 262 patients 
recruited retrospectively as a validation cohort, our pharmacogenetic algorithm 
predicted 43% of warfarin dose variability. 
In line with previous studies (Kaminsky et al. 1993, Aithal et al. 1999, Bodin 
et al. 2005, D'Andrea et al. 2005, Herman et al. 2005, Sconce et al. 2005, Aquilante 
et al. 2006, Carlquist et al. 2006, Kosaki et al. 2006, Schalekamp et al. 2006, Borgiani 
et al. 2007, Cho et al. 2007, Limdi et al. 2008a, Huang et al. 2009), our results replicate 
the associations of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 with warfarin stable 
dose, where patients carrying the CYP2C9*2, CYP2C9*3 and VKORC1-1639 minor 
allele resulted in lower dose requirements relative to the wild-type carriers.  
In agreement with Gage et al, (2008), our results showed that VKORC1 -1693 
is the most important predictor (R2=21%).  This polymorphism alters a VKORC1 
transcription factor binding site (Yuan et al. 2005) and a VKORC1 haplotype 
containing the VKORC1-1639 A allele was reported to result in lower mRNA 
expression in human liver (Rieder et al. 2005).  This change in gene expression may 
lower the steady-state tissue concentration of vitamin K epoxide reductase, the rate 
limiting enzyme in vitamin K cycle (Wajih et al. 2005).  As a result individuals with 
this allele are most susceptible to inhibition by warfarin.   
In the present study, we developed and validated a pharmacogenetic-algorithm 
incorporating clinical and genetic data for predicting warfarin dose.  Our 
pharmacogenetic algorithm explained less warfarin stable dose variability compared 
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to the pharmacogenetic algorithm developed by Sconce et al. which was validated in 
a very small cohort of patients (Sconce et al. 2005, Hatch et al. 2008).  The largest 
prospective warfarin cohort study predicting warfarin dose at initiation of therapy was 
carried out in Swedish population (Wadelius et al. 2009). They derived the 
pharmacogenetic algorithm which included CYP2C9*2, CYP2C9*3, VKORC1, age, 
sex and number of interacting drugs that potentially increase INR (Appendix A) in 
1,496 patients and validated in 181 patients.  The pharmacogenetic algorithm 
explained 52.8% of warfarin stable dose variability which is better compared to our 
pharmacogenetic algorithm, but the clinical accuracy of the algorithm was not 
evaluated, thus we cannot establish that their algorithm is better in predicting warfarin 
stable dose.  
For that reason, we calculated the mean and median absolute error of our 
algorithm.  Our mean (median) absolute error is comparable to the study by Gage et 
al. (2008) who used CYP2C9*2, CYP2C9*3, VKORC1-1639, target INR, concomitant 
drug-amiodarone use, smoker, race and indication of warfarin given mean absolute 
error of 1.0 (1.3) mg/day but better compared to the seminal study by IWPC (Klein et 
al. 2009), where they derived (n=4,043) and validated (n=1,009) pharmacogenetic 
algorithm from multiple sites worldwide (including patients from our derivation 
cohort) using CYP2C9*2, CYP2C9*3, VKORC1, age, height, weight, race, 
concomitants drug – enzyme inducer (carbamazepine, phenytoin, rifampin and 
rifampicin), concomitant drug – amiodarone given mean absolute error of 1.2mg/day.  
We evaluated the potential clinical value of our pharmacogenetic algorithm by 
calculating the percentage of patients whose predicted dose of warfarin was within 
20% of actual dose.  In a study by IWPC (Klein et al. 2009), their pharmacogenetic 
algorithm predicted only 35% of patients within 20% of the actual dose.  Another 
retrospective study by Finkelman et al. (2011) in 1,378 patients using the 
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pharmacogenetic algorithm developed by Gage et al. (2008) predicted 52% of patients 
within 20% of the actual dose.  Our algorithm has a similar predictability as Gage et.al 
(2008) but the advantage of our pharmacogenetic algorithm eless complicated.  Our 
algorithm only requires VKORC1 and CYP2C9 genotypes, height and weight to 
calculate BSA and amiodarone use status.  While in Gage et al’s algorithm, another 5 
information need to be collected .  In addition, it is difficult to assess accurately for 
smoking status (Lewis et al. 2003, Martı́nez et al. 2004) and race (Foster and Sharp 
2002). 
Observing the graphs presented in Figure 2-10(a) which compared the 
observed dose with predicted dose and (b) which compared observed dose with mean 
absolute error suggesting that our pharmacogenetic algorithm is of most benefit to the 
group of patients who required a warfarin stable dose range 2-6 mg/day with 62% of 
prediction within the ideal dose range.  Similar predictability accuracy was evidenced 
in the IWPC study for those patients who required a warfarin stable dose range 4-6 
mg/day.  Therefore, our pharmacogenetic algorithm benefits the larger group of 
Caucasian patients.   
Our algorithm only explains approximately 43% of warfarin stable dose 
variability and there still remains 57% to be explained.  There are other clinical factors 
which would contribute to warfarin stable dose which we did not include in our 
analysis such as vitamin K intake (Reaves et al. 2013), diabetes mellitus (Lenzini et 
al. 2010), and alternative medicine (Mousa 2010, Na et al. 2011). In addition, we did 
not include drugs other than amiodarone which have been shown in the literature to 
affect warfarin dose requirement (example as in Table 1-8, page 24).  Despite the 
available literature review linking warfarin dose/response and smoking and alcohol 
intake (Havrda et al. 2005, Nathisuwan et al. 2011, Bazan et al. 2013), these factors 
were not included in our analysis as they are challenging to assess accurately and 
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objectively.  It is also likely that other SNPs influence warfarin stable dose such as 
polymorphism in CYP4F2 (McDonald et al. 2009, Zhang et al. 2009), APOE (Kimmel 
et al. 2008), FII (D'Ambrosio et al. 2004) or some rare variants.  Recent publications 
have reported some rare variants associated with lower requirement of warfarin dose 
in patients with CYP2C9*12 (rs9332239) genotypes (O'Brien et al. 2013) and higher 
requirement of warfarin dose in patients with VKORC1 D36Y  (rs61742245 ) 
genotypes  (Kurnik et al. 2012).  The MAF for CYP2C9*12 and VKORC1 D36Y in 
Caucasians was reported as 0.006 and 0.04 (Kurnik et al. 2012, O'Brien et al. 2013) 
respectively.   
Whether our pharmacogenetic algorithm can be practiced in a clinical setting 
is still on open question.  Other clinical and genetic factors could be incorporated into 
a future pharmacogenetic algorithm to improve their accuracy.  However, prospective 
randomised control trials are required to determine whether initial warfarin dosing 
would improve the outcome of warfarin therapy.  At the moment, there are four 
randomised multicentre controlled trials currently underway with this aim. Three of 
them are in the United States; the clarification of Optimal Anticoagulation through 
Genetics trial (COAG), the Genetic Informatics Trial (GIFT) of Warfarin to Prevent 
Deep Venous Thrombosis and the Clinical and Economic Implication of Genetic 
Testing for Warfarin Management trial.  The other one is in Europe, the European 
Pharmacogenetic of Anticoagulant trial (EU-PACT).  Information about the studies 
can be view at www.clinicaltrials.gov.  If such trials show a benefit of using a 
pharmacogenetic algorithm, then successful implementation of the new algorithm 
would depend on the availability of a rapid and accurate genotyping method which 
allows easy genotyping in a clinical setting. 
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3.1 Introduction 
Atrial fibrillation (AF) is the most common heart arrhythmia, with a prevalence 
of approximately 1.2% in primary care in the UK (NHS Improvement 2009).  Stroke 
is the leading complication of AF and patients with AF have a five-fold higher stroke 
risk than those without AF (NICE 2006). 
There is much evidence that long-term treatment with an oral anticoagulant 
(OAC) such as warfarin, reduces the risk of stroke associated with AF (Hart et al. 
1999, Hart et al. 2007, Singer et al. 2009).  However, the main drawback to this 
approach is a high risk of bleeding (Budnitz et al. 2007, Shehab et al. 2010).  It is 
estimated that every year, 1-7% of patients on long-term treatment with OAC will 
suffer a major bleeding event which requires hospitalisation (Levine et al. 2004, Mant 
et al. 2007). 
As increasing numbers of patients with AF will be treated using this drug class, 
efforts to develop tools for the estimation of bleeding risk may be helpful in 
counselling patients and informing them of treatment decisions.  Recently, HAS-
BLED (acronym for Hypertension, Abnormal kidney/liver function, Stroke, Bleeding 
disposition, Labile INR, Elderly and Drug/alcohol use) has been recommended by the 
European Society of Cardiology guidelines (ESC) as a bleeding risk assessment tool 
to be used before starting anticoagulation treatment for the management of atrial 
fibrillation (Camm et al. 2012).   
HAS-BLED is a bleeding risk score to assess the one year risk of major 
bleeding in AF patients (Pisters et al. 2010). It was derived from a European AF cohort 
participating in the EuroHeart survey, a survey and registry which provide extensive 
data on the management of heart failure patients from 24 countries (Cleland et al. 2003, 
Komajda et al. 2003).  In the original study, the prediction ability of HAS-BLED was 
assessed using the c-statistic.  The c-statistic is the area under the curve (AUC) of the 
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receiver operating characteristic (ROC) graph and it is considered that this can  capture 
the ability of the model to discriminate between those who will develop the event and 
those who will not (Hanley and McNeil 1982).   
Hosmer and Lemeshow (2000) provide general rules to interpret AUCROC 
values: 0.5 means that discrimination is no better than by chance, 0.7 to 0.8 shows 
acceptable discrimination, 0.8 to 0.9 indicates excellent discrimination and  ≥ 0.9   
describes outstanding discrimination.  In brief, the ability of HAS-BLED to 
discriminate was acceptable (good) when tested in patients treated with warfarin (32% 
of the whole cohort).  The value of the c-statistic was better in groups of patients taking 
warfarin concomitantly with anti-platelet drugs, compared to those who were taking 
warfarin alone.  The c-statistic in the first group (n=239) was 0.78 (95% CI 0.65-0.91), 
and in the second group (n=1,722), it was 0.69 (95%CI 0.59-0.80). 
HAS-BLED has been first externally validated in a trial cohort of 7,329 
patients participating in the SPORTIF III and V clinical trials, a randomized controlled 
trial (RCT) comparing ximelagatran with warfarin for stroke prevention in atrial 
fibrillation. (Lip et al. 2011b).  In this validation study, HAS-BLED predictability was 
compared with the predictability of other contemporary scores as proposed by 
Shireman et al. (2004), Gage et al. (2006), Beth et al. (1998), and Kuijer et al. (1999).  
A description of HAS-BLED and the four comparative schemes is presented in Table 
3-1.  The HAS-BLED scheme showed a marginally better c-statistic value than the 
other four schemes evaluated (Table 3-2), but there was overlap of the 95% confidence 
intervals in all cases.   
Later, HAS-BLED score has been compared and shown better performance 
compared to other bleeding scores that have been derived and validated in patients 
with AF (eg HEMORR2HAGES (Gage et al. 2006) and ATRIA (Fang et al. 2011)) 
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but none of the studies reached statistical significance (Olesen et al. 2011b, 
Apostolakis et al. 2012). 
Table 3-1.  Bleeding Risk Stratification Schemes tested by Lip et al., 2011b. 
Schemes Study design Calculation of bleeding risk score 
Pisters et 
al. (2010) 
The score was derived from bleeding risk 
factors identified from 3,381 atrial 
fibrillation patients from Euro Heart Survey 
cohort (12 months retrospective follow-up) 
together with consistent risk factor for 
major bleeding identified in systemic 
review.  The score was compared with 
HEMORR2HAGES scheme (without genetic 
data) in similar cohort and was found  
better in prediction 
Acronyms:  HAS-BLED 
Hypertension (1 point), Abnormal 
Renal/Liver Function (1 point 
each), Stroke, Bleeding History or 
Predisposition(1 point) , Labile 
INR(1 point) , Elderly Drugs/ 
Alcohol concomitantly (1 point 
each) 
Shireman  
et al. 
(2006) 
Retrospective chart review of the National 
Registry of Atrial Fibrillation (NRAF) cohort 
and Medicare data of atrial fibrillation 
patients with 3 months follow-up (n= 
26,386) 
 
Derivation cohort: 19,875 patients  
Validation cohort: 6,511 patients  
(0.49 x age >70 years)+(0.32 x 
female) + (0.58 x remote bleed) 
+(0.62 x recent bleed) + (0.71 x 
alcohol/drug abuse) + (0.27 x 
diabetes) + (0.86 x anaemia) + 
(0.32 x antiplatelet drug use) with 1 
point for presence of each, and 0 if 
absent 
Gage et 
al. (2006) 
Derivation: The score was derived from 
systematic review} and PubMed search. 
 
Validation cohort: Retrospective analysis of 
3,791 patients’ data from the National 
Registry of Atrial Fibrillation (NRAF).  1604 
were discharged on warfarin (113 of whom 
also received aspirin), 660 were discharged 
on aspirin alone and 1,527 were discharged 
without any anti-thrombotics.  However, 
CYP2C9 genotype was unavailable for the 
study and was omitted in validation. 
Acronyms:  HEMORR2HAGES 
Liver/renal disease, Ethanol abuse, 
malignancy, age>75 years, low 
platelet count or function, re-
bleeding risk, uncontrolled 
hypertension, anaemia, genetic 
factors (CYP2C9), risk of fall or 
stroke, with 1 point for each factor 
present with 2 points for previous 
bleed.   
Kuijer et 
al. 
(1999)l 
Use database of Columbus Investigators 
(prospective cohort). 1021 VTE patients 
randomly allocated to receive an initial 
subcutaneous Low Molecular Weight 
Heparin or continuous fractioned heparin. 
Derivation cohort: 241 patients, 3 months 
follow-up. 
Validation cohort: 780 patients, 3 months 
follow-up. 
(1.6 x age) +(1.3xsex) +(2.2 x 
cancer) with 1 point for age≥60 
years, female or malignancy, and 0 
if none. 
Beyth et 
al. (1998) 
Derivation cohort: 556 patients who 
started warfarin,  4 years retrospective  
follow-up. 
Validation cohort: inception cohort of 264 
who started warfarin, 4 years prospectively 
follow-up. 
Age≥65 years, GI bleed in the past 
2 weeks, previous stroke, 
comorbidities (recent MI, Hct˂30%, 
diabetes, creatinine>1.5 ml/l) with 
1 point for presence of each 
condition and 0 if absent. 
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Table 3-2.  Comparing performance of published bleeding schemes by Lip et al. (2011b). 
Bleeding Risk Score  Warfarin 
Patients (n = 3,665) 
(c-statistic (95% CI) 
Patients taking warfarin and 
aspirin (n = 722) 
(c-statistic (95% CI) 
HAS-BLED  0.66 (0.61–0.70) 0.60 (0.53–0.68) 
Shireman et al., 2006 0.63 (0.58–0.67) 0.58 (0.31–0.66) 
HEMORR2HAGES, 2006 0.61 (0.56–0.65) 0.58 (0.51–0.66) 
Kuijer et al. ,1999 0.52 (0.48–0.56) 0.49 (0.45–0.55) 
Beyth et al., 1998 0.56 (0.51–0.60) 0.52 (0.46–0.57) 
 
Recently, researchers have suggested calculating IDI (Integrated 
Discrimination Improvement) and NRI (Net Reclassification Improvement) as 
statistical method for assessing the performance of newer biomarkers (Pencina et al. 
2008b).  IDI and NRI measure the new model’s ability to improve categorization 
amongst those who do and do not develop the events.  Both serve the same purpose, 
but the NRI method requires patients to be classified into two or more outcome 
categories based on a model’s prediction output.  As shown in Table 3-3, IDI and NRI 
analyses by Lip et al., (Lip et al. 2011a) significantly demonstrated that HAS-BLED 
predicted major bleeding episodes more accurately than the other risk scores, except 
for the scheme for NRI by Shireman et al.(2006).   
 
Table 3-3.  NRI and IDI analysis comparing HAS-BLED with other bleeding schemes (Lip et 
al, 2011a). 
HAS-BLED versus NRI  IDI  
Shireman et al, 2006 0.089  (p value 0.25) 0.668  (p value <0.0001) 
HEMORR2HAGES, 2006 0.152 (p value 0.05) 0.416 (p value 0.0021) 
Kuijer et al., 1999 0.306  (p value <0.0001) 0.883  (p value <0.0001) 
Beyth et al., 1998 0.262  (p value <0.0001) 0.828  (p value <0.0001) 
P value is a statistical test provided by Pencina et al (2008) to test for null hypothesis of IDI 
and IDI=0 (refer  section 3.2.4). 
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To date, the usefulness of genetic polymorphisms as biomarkers in predicting 
bleeding risk score have not been evaluated.  HEMORR2HAGES (Gage et al. 2006), 
a bleeding risk score developed based on literature review, included a polymorphism 
in the CYP2C9 gene, but the contribution of this polymorphism has never been 
evaluated in the original study or in any validation cohort (Friberg et al. 2012, Poli et 
al. 2013, Seet et al. 2013).  In recent meta-analyses studies, CYP2C9*2, CYP2C9*3 
have been found significantly associated with major bleeding risk in patients treated 
with warfarin (Jorgensen et al. 2012, Yang et al. 2013).  Even though VKORC1 
polymorphisms have not been associated with major bleeding they have been 
associated with over-anticoagulation risk (Yang et al. 2013).   
On this basis, we decided to further investigate whether the addition of genetic 
factors could improve the predictive performance of a bleeding risk score. Specifically, 
our objectives were (i) to identify predictors of bleeding in a cohort of patients during 
the first 6 months of warfarin treatment, (ii) to investigate the performance of HAS-
BLED in this cohort and (iii) to evaluate whether the addition of genetic factors to 
HAS-BLED schemes could improve the prediction of major bleeding. 
  
  CHAPTER 3 
82 
 
3.2 Method 
3.2.1 Patient Recruitment and Genotyping 
The same cohort of patients as used for analysis in Chapter 2 was used in the 
current analysis.  This cohort of patients was originally recruited as part of a large, 
prospective study of warfarin pharmacogenetics (Jorgensen et al. 2009)  Patient 
recruitment and genotyping methods are described in Chapter 2.   
Inclusion criteria: Only atrial fibrillation patients with 6 months’ completed 
follow-up were included in the analysis. The risk of bleeding on anticoagulant therapy 
is highest during the early phase of treatment (Landefeld and Goldman 1989, Fihn et 
al. 1993, Douketis et al. 2000, Linkins et al. 2003, Hylek et al. 2007) and so we 
believed that assessing the performance of HAS-BLED on patients during only the 
initial six months of warfarin therapy would provide important information in decision 
making during warfarin therapy 
3.2.2 Definition of Major Bleeding 
Bleeding events were categorised according to classification provided by Fihn 
et al. (1996).  The study established three categories to define anticoagulant–related 
bleeding: (i) minor bleeding (reported but not requiring a further test, referral or visit), 
(ii) major bleeding (requiring treatment, medical evaluation or ≥ 2 units of blood) and 
(iii) life-threatening bleeding (leads to cardiac arrest, surgical/angiographic 
intervention or an irreversible sequel).  For each bleeding event, the relationship 
between warfarin use and the bleeding was recorded as ‘unrelated’, ‘unlikely’, 
‘possible’, ‘probable’ and ‘almost certain’.  The relationship was determined by the 
clinical physician.  For the purpose of our analyses, patients experiencing either a life 
threatening bleeding event or a major bleeding event were classified as cases, provided 
that the event was considered as being ‘possible’, ‘probable’ or ‘almost certain’ in 
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terms of its relationship with warfarin use. All other patients were classified as 
controls.  
3.2.3 Statistical Analysis 
All data analyses were performed with SPSS, version 19.  Patients 
demographics including age, BMI, medical history and genotype polymorphisms were 
compared across patients who experienced or did not experience bleeding, using 
percentages to look for any differences between groups.  For our analysis, HAS-BLED 
definitions as described in Table 3-4 were used.  Each factor is given a 1 point score if 
present.  
Table 3-4.  Definition of HAS-BLED used in our study. 
HAS-BLED Score  
(Acronyms) 
Definition in current study 
Hypertension 
(H) 
Combination therapy with at least two of the following classes 
of antihypertensive drugs: Adrenergic α-antagonist, non-loop 
diuretics, vasodilators, beta blockers, calcium channel 
blockers, and renin angiotensin system inhibitors 
Abnormal Kidney 
Function (A)-  
presence of chronic dialysis, renal transplant, or serum 
creatinine ≥ 200 µmol/L. 
Abnormal Liver Function 
(A) 
The presence of chronic hepatic disease (e.g. cirrhosis) or 
biochemical evidence of significant hepatic derangement (at 
least positive in 2 liver function tests) 
Stroke (S) Previous history of stroke 
Bleeding history or 
predisposition 
(anaemia) (B) 
Haemoglobin<13g/dL for men and ˂12g/dL in women 
Labile INR (L) Labile INR described as <60% time in the therapeutic range, 
calculated using the Rosendaal method (Rosendaal et al. 
1993). 
Elderly (E) Age >65 years old 
Drug (D) 
 
Antiplatelet agent or non-steroidal inflammatory drugs 
conconmitantly  prescribed with warfarin  during follow-up 
Excessive alcohol use (D) AUDIT questionnaire question 3 with an answer of 3 or 4. 
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We use the same definition of HAS-BLED as in the original study by Pister et 
al (2010), a part from the following:  
(a) Uncontrolled hypertension: The original definition is a blood pressure 
measurement of >160mmHg systolic. Since data of blood pressure were not 
available in our study, we defined uncontrolled hypertension as combination 
therapy with at least two of the following classes of antihypertensive drugs: 
Adrenergic α-antagonist, non-loop diuretics, vasodilators, beta blockers, calcium 
channel blockers, and renin angiotensin system inhibitors.  This definition has 
been used by Olesen et al. (2011b) in their study comparing HAS-BLED Score 
and HEMORR2HAGES Score.  This definition has previously been validated in 
75,538 atrial fibrillation patients (Olesen et al. 2011a). 
(b) Bleeding history or prediposition: In the original definition predisposition of 
bleeding  was defined as anemia.  We refine the definition as haemoglobin <13 
g/dL for men and ˂12g/dL in women for easiness of diagnosis. We did not 
include any bleeding history because no record was available. 
(c) Alcohol use:  There is no specific definition in the original study so we used 
AUDIT questionnaires (Figure 3.1) as a tool to assess excessive use of alcohol 
in our study.  AUDIT is the acronym for the Alcohol Use Disorders 
Identification Test (Babor et al. 1989).  It was developed by the World Health 
Organization (WHO) as a simple method of screening for excessive drinking and 
to assist in brief assessment.  The purpose of question number 3 in the 
questionnaire is to evaluate the frequency of heavy drinking. We took an answer 
of (3) or (4) to represent excessive alcohol drinking. Sensitive analysis was 
performed to examine excessive use of alcohol using a total AUDIT score >7 
(indicators of hazardous and harmful alcohol use) and a total AUDIT score >16 
(representing a high level of alcohol problems). 
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Figure 3-1.  The AUDIT questionnaire. 
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3.2.3.1 Identifying predictors of bleeding risk in our study 
The following baseline clinical and genetic factors which had previously been 
associated with bleeding risk or with warfarin dose variability were each univariately 
tested for association with major bleeding.     
Clinical Factors: height (Sconce et al. 2005), weight (De Jaegere et al. 1992), 
age (De Jaegere et al. 1992), body surface area (Gage et al. 2004), body mass index, 
abnormal kidney function (Pisters et al. 2010), abnormal liver function (Pisters et al. 
2010), stroke (Pisters et al. 2010), bleeding predisposition (Pisters et al. 2010), labile 
INR (Pisters et al. 2010), age (Pisters et al. 2010, Lip et al. 2011b), alcohol abuse 
(Pisters et al. 2010), gender (Hillman et al. 2004) and concomitant drug use (aspirin, 
clopidogrel, dipyridamole, selective serotonin reuptake inhibitors (SSRI), amiodarone, 
paracetamol 1gm and non-steroidal anti-inflammatory drugs (NSAID) (Hauta-Aho et 
al. 2009, Pisters et al. 2010). 
Genetic Factors: CYP2C9*2, CYP2C9*3 and VKORC1 associated with major 
bleeding or over-anticoagulation in recent meta-analysis were included in the analysis.  
In the analysis, wild-type homozygotes were coded ‘0’, heterozygous patients were 
coded as ‘1’ and mutant homozygotes were coded as ‘2’  Prior to analyses of 
association with these genetic factors, an assessment of conformity with Hardy 
Weinberg Equilibrium (HWE) for each SNP was performed using Haploview software 
(version 4.2).  A p value of < 0.001 was assumed to indicate deviation from HWE. 
Each of these factors were compared between the group of patients who 
experienced a major bleed (cases), and those that did not (controls). The Fisher exact 
test or chi-square test (if > 2 categories) was used for categorical factors and the 
independent sample t-test, was used for continuous factors. 
Finally, all factors identified from the univariate analysis as having p value 
≤0.10 were included together in a logistic regression model.   
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3.2.3.2 To assess performance of HAS-BLED in our cohort 
Prediction performance of HAS-BLED was tested both in the whole cohort and 
in sub groups of patients, i.e. those who were taking warfarin without antiplatelet drugs 
and those who were taking warfarin with antiplatelet drugs.  All tests were performed 
2-tailed, with a p value ≤ 0.05 considered as statistically significant.  To test the 
performance of the bleeding score the following analyses were performed:   
ROC and c-statistical analysis : Logistic regression analysis including HAS-
BLED covariates (uncontrolled hypertension, abnormal kidney function, abnormal 
liver function, history of stroke, bleeding predisposition, labile INR, age > 65 years 
old, drug used and alcohol consumed) was undertaken, with discrimination tested on 
the ROC curve and area under the curve (c-statistic) (Zou et al. 2007).  For the c-
statistic value, we used the Hosmer and Lemeshow rules to interpret the discriminative 
ability of the model (Hosmer and Lemeshow 2000).   
3.2.3.3 To assess improvement made by incorporating genetic variables in HAS-
BLED score 
To evaluate the improved performance of HAS-BLED when incorporating 
genetic covariates, (referred to as HAS-BLEDG), the following analyses were 
performed: 
ROC and c-statistical analysis:  ROC and c-statistical analysis was performed 
on both HAS-BLED and HAS-BLEDG as described in 3.2.3.2. Logistic regression 
analysis was undertaken in the same way as HAS-BLED for HAS-BLEDG, except it 
also included genotype identified as significant in our univariate analyses..  The ROC 
curve with the highest rise was the model generally considered to have the best 
predictive qualities. The log likelihood ratio c-statistic was also calculated to assess 
the improvement in model fit.  
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IDI analysis: As we did not assign any risk categories for the outcomes based 
on HAS-BLED or HAS-BLEDG scores (eg: for low, moderate or high risk of 
bleeding), only IDI was used to assess the discrimination improvement made by the 
addition of genetic variables to HAS-BLED.  The formula to estimate IDI is illustrated 
below (Pencina et al. 2008b): 
Absolute IDI = (Pnew,events –Pnew, nonevents) – (Pold,events – Pold,nonevents) 
Where Pnew,events  is the mean of the HAS-BLEDG score predicted probabilities of an 
event for those who develop events; Pold,events is the corresponding quantity, based on 
the HAS-BLED model; Pnew,nonevents is the mean of the HAS-BLEDG predicted 
probabilities of an event for those who do not develop events and Pold,nonevents is the 
corresponding quantity based on the HAS-BLED.  
Therefore, (Pnew,events –Pnew, nonevents) is equivalent to the difference in the mean 
of predicted probabilities for events and non-events by HAS-BLEDG, or the 
discrimination slope by HAS-BLEDG.  Similarly, (Pold,events – Pold,nonevents) is equivalent 
to the difference in the mean of predicted probabilities for events and non-events by 
HAS-BLED, or the discrimination slope by HAS-BLED.  Thus, IDI is equal to the 
difference between the discrimination slopes of HAS-BLEDG and HAS-BLED. 
Pencina et al. (2008) also provide the following test statistic which tests the 
null hypothesis of IDI =0: 
zIDI =     ______Absolute IDI________             
                    √ (SEevents)2 + (SEnonevents)2 
 
In the equation, SEevents is the standard error of paired differences of new (HAS-
BLEDG) and old model (HAS-BLED) predicted probabilities across all event subjects, 
while SEnonevents is the standard error of the paired differences of new (HAS-
BLEDG) and old model (HAS-BLED) predicted probabilities across all non-event 
subjects.   
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The magnitude of IDI is hard to interpret and so we looked at relative IDI 
(rIDI).  rIDI is described as ratio of differences between means of model-based 
probabilities for events and non-events for model with and without new biomarker 
minus 1.(Pencina et al. 2008a).  rIDI represents the percentage relative improvement 
of the model after this modification.   
Rates of major haemorrhage stratified by bleeding score in both HAS-BLED 
and HAS-BLEDG were also calculated to observe the distribution of percentage 
patients experiencing bleeding events stratified by score.  HAS-BLED was calculated 
using points given as shown in Table 3-5 .  Briefly, score of zero indicated  low risk, 
2-3 moderate risk and ≥3 high risk (Lip et al. 2011b).  Previous studies have shown, 
patients with score of ≥5 have triple time higher risk compared to patients with score 
3 (Apostolakis et al. 2012, Roldán et al. 2013).  For HAS-BLEDG the score was 
calculated in the same way as HAS-BLED, except that the score was adjusted with 
genotypes identified as significance in univariate analysis, where wild-types, 
heterozygotes and mutant homozygotes were given scores of 0, 1 and 2 points 
respectively. 
Table 3-5.  HAS-BLED calculation 
Accronym Clinical characteristics Point awarded 
H Hypertension 1 
A Abnormal liver of kidney function ( 1 point each) 1 or 2 
S Stroke 1 
B Bleeding 1 
L Labile INR 1 
E Elderly 1 
D Drug or alcohol (1 point each) 1 or 2 
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3.3 Results 
Out of 657 AF patients (white European), 526 had complete 6 months follow-
up.  Of these, 44 patients did not have complete genotyping because of inadequate 
DNA; therefore a total of 482 patients were included in the analysis. Baseline 
characteristics of the patients are summarized in Table 3-6.   
Table 3-6.  Patient demographics 
Characteristic Bleeding event 
(n=15) 
No Bleed (n=467) P values 
Age, years, mean (SD) 
Age >65 (%) 
Weight, kg , mean (SD) 
BMI, mean (SD) 
Height, cm, mean (SD) 
Gender, male (%) 
 
Medical History 
Cardiovascular disease, n (%) 
Respiratory disease, n (%) 
Hepatic disease, n (%) 
Renal disease, n (%) 
Gastrointestinal disease, n (%) 
 
Polymorphism 
CYP2C9*2, n (%) 
Wild-type (CC)  
Heterozygous variant (CT) 
Homozygous variant (TT) 
 
CYP2C9*3, n (%) 
Wild-type (AA) 
Heterozygous variant (AC) 
Homozygous variant (CC) 
 
VKORC1, n (%) 
Wild-type (CC) 
Heterozygous variant (CT) 
Homozygous variant (TT) 
71.60 (6.74) 
13( 86.7) 
77.47 (20.22) 
27.76 (6.16) 
166.73 (10.27) 
9 (60) 
 
 
15 (100%) 
6 (40%) 
1(6.7%) 
2(13.3%) 
4(26.7) 
 
 
 
12 (80) 
3 (20) 
0 
 
 
12 (80) 
2 (13.3) 
1 (6.7) 
 
 
5 (33.3) 
9 (60) 
1 (6.7) 
71.53(10.07) 
353(75.6) 
81.02 (18.78) 
28.24 (5.81) 
169.15 (10.55) 
275 (58.9) 
 
 
430 (92.1) 
149 (31.9) 
17 (3.6) 
49 (10.2) 
165 (35.3) 
 
 
 
365 (78.2) 
99 (21.2) 
3 (6) 
 
 
412 (88.2) 
52 (11.1) 
3 (0.7) 
 
 
198 (42.4) 
206 (44.1) 
63 (13.5) 
0.980* 
0.258** 
0.512* 
0.768* 
0.383* 
0.999** 
 
 
0.619** 
0.516** 
0.440** 
0.905** 
0.591** 
 
 
 
0.945** 
 
 
 
 
0.038** 
 
 
 
 
0.446** 
*independent sample t-test p value 
** fischer exact test p value 
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During their first 6 months of follow-up, 3.1% (95%CI 1.55-4.65) patients 
(n=15) presented with a major bleeding event. The percentage of bleeding events in 
the sub group of patients taking warfarin alone (n=405), patients concomitantly taking 
aspirin (n=55), clopidogrel (n=18) and aspirin together with clopidogrel (n=4) were 
2.5% (95%CI 0.98-4.02), 3.6% (95%CI 0-8.52), 5.9% (95%CI 0-17.1) and 50% 
(95%CI 1-99) respectively.   
3.3.1 Identification of Risk Factors for Major Bleeding in Our Cohort 
Results of the univariate analyses of association are given in Table 3-7. Factors 
significantly associated with major bleeding (p≤0.1) were concurrent amiodarone use 
(p<0.05), labile INR (p<0.01), concurrent clopidogrel use (p<0.1), bleeding 
predisposition (p<0.1), aspirin (p 0.1), CYP2C9*3 (additive mode inheritance) p<0.05.   
Multivariate analyses of risk factors predictive of major bleeding are shown in 
Table 3-8.  Inclusion of all factors found significant univariately in a multiple 
regression model, resulted in a c-statistic of 0.86 (95%CI 0.787-0.944). 
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Table 3-7.  Risk factors for major bleeding by univariate analysis using our cohort (n=482). 
Bleeding risk factor P value 
Clinical covariates:  
Amiodarone use 0.002 
Labile INR 0.007 
Clopidogrel 0.023 
Bleeding predisposition 0.070 
Aspirin use 0.098 
Height 0.383 
Weight 0.512 
Body surface area 0.393 
Age >65 years old 0.258 
Body mass index 0.768 
Abnormal kidney function 0.999 
Abnormal liver function 0.999 
Stroke 0.249 
#Alcohol use (AUDIT question 3) 0.484 
Dypiridamole use 0.939 
Selective serotonin re-uptake inhibitors use 0.999 
Paracetamo 1000 mg use 0.397 
Non-steroidal anti-inflammatory drugs use 0.999 
Hypertension 0.309 
  
Genetic covariates:  
Analysis with no underlying assumption  
CYP2C9 *2 0.827 
CYP2C9*3 0.130 
VKORC1-1693  0.901 
  
Analysis assuming an additive mode of inheritance  
CYP2C9 *2 0.945 
CYP2C9*3 0.038 
VKORC1-1693 0.446 
  
# In Sensitivity analysis using a total AUDIT score >7  and a total AUDIT score >16 , the p-
values were both 0.9  and hence conclusion remain the same. 
 
Table 3-8.  Multivariate analyses of bleeding risk using our cohort (n=482). 
Bleeding risk factor Coefficients (B) of the final regression model 
Constant -6.090 
Amiodarone 2.051 
Labile INR 2.079 
Clopidogrel 1.706 
Bleeding predisposition 0.34 
CYP2C9*3 (additive) 0.699 
Aspirin 0.767 
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3.3.2 Assessing performance of HAS-BLED in our cohort  
HAS-BLED performed well in predicting major bleeding in our whole cohort 
with a c-statistic 0.80 95%CI (0.707-0.899) (Table 3-9).  In the subgroup analyses of 
patients taking antiplatelet drugs and those who did not, four patients were excluded 
because they were prescribed both aspirin and clopidogrel concomitantly. The c-
statistic in the group of patients concomitantly taking anti-platelet drugs was 0.82 
(95% CI: 0.660-0.978) and in the group of patients not on anti-platelet drugs was 0.79 
(95% CI: 0.657-0.914).The difference was not statistically significant.  
3.3.3 Assessing improvement made by adding genetic variables to HAS-
BLED score  
There was no evidence of statistically significant improvement in prediction of 
HAS-BLEDG compared to HAS-BLED either in our c-statistic analysis (Table 3-9), 
ROC analysis (Figure 3.2) or IDI analysis (Table 3-10).  Further, the addition of 
genetic covariates into the HAS-BLED score only made a small improvement of the 
prediction as showed by relative IDI of 10% (95%C:7-12) in all patients but decrease 
by 4% (95%CI: 2-4) in patients not on antiplatelet drugs. The relative IDI for patients 
on antiplatelet drugs was 58% (95%CI: 47-69) although this result needs to be treated 
with caution since the number of patients in this group is small (n=73).  
 
Table 3-9.  Comparison of c-statistic (95%CI) for HASBLED and HAS-BLED G in whole study 
cohort and subgroup of patients those who were  taking warfarin without antiplatelet 
drugs and those taking warfarin concomitantly with antiplatelet drugs. 
Bleeding risk 
score 
c-statistic (95% CI) 
Whole cohort 
(n=482) 
Patients without 
antiplatelet (n=406) 
Patients with anti-
platelet (n=72) 
HAS-BLED 0.80 (0.707-0.899) 0.79 (0.657-0.914) 0.82 (0.660-0.978) 
HAS-BLEDG 0.81 (0.717-0.912        
 
0.785 (0.664-0.907) 0.805 (0.627-0.982)       
P value c-
statistic 
0.2 0.7 0.4 
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(A)                                                             (B)   
   
(C) 
 
Figure 3-2.  ROC curves for the model with and without genetic factors in analyses of 
three sub groups.  (A) Whole cohort (n=482) (B) patients without antiplatelet drugs (n= 
406) and (C) patients on antiplatelet drugs (n=72).  The blue line represents mean predicted 
probability with HAS-BLED, the green line represents mean predicted probability with 
HASBLEDG and the red line represents the reference line where prediction is no better than 
by chance.  Sensitivity is the probability of an individual with the bleeding being predicted 
as having it, while specificity is the probability of an individual not bleeding and being 
predicted as not having it. 
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Table 3-10.  IDI analysis to quantify improvement in the performance of HAS-BLEDG (new 
model) compared to HAS-BLED (old model). 
HAS-BLEDG vs. 
HAS-BLED 
Whole cohort 
(n=482) 
Patients without 
antiplatelet 
(n=405) 
Patients with 
antiplatelet 
(n=73) 
*Slope for HAS-BLEDG 0.0513 0.0321 0.1158 
ϮSlope for HAS-BLED 0.0465 0.0335 0.0731 
IDI 0.0048 (-)0.0013 0.0427 
rIDI  
(95%CI) 
0.10 
(0.07-0.12) 
(-)0.04 
(0.02-0.06) 
0.58 
(0.47-0.69) 
SE events 0.0068 0.0014 0.0029 
SE non-events 0.0006 0.0002 0.0560 
z-score 0.7 -0.9 0.8 
**P value for IDI(2 tail) 0.5 0.9 0.4 
*Discrimination slope for new model (HAS-BLEDG)= Pnew,events –Pnew, nonevents 
ϮDiscrimination slope for  old model (HAS-BLED)= Pold,events – Pold,nonevents 
rIDI = (Slope for HAS-BLEDG/slope for HAS-BLED) -1 
SE events = standard error of paired differences of HAS-BLEDG and HAS-BLED predicted 
probabilities across all event subjects. 
SE non-events= standard error of paired differences of HAS-BLEDG and HAS-BLED predicted 
probabilities across all non-event subjects. 
**P value is a statistical test provided by Pencina et al (2008) to test for null hypothesis of 
IDI and IDI=0 (refer  section 3.2.4). 
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The rate of major bleeding stratified by HAS-BLED score and HAS-BLEDG 
are presented in Table 3-11 and Figure 3-3.  The median HAS-BLED score was 3 
(interquartile range 1).  The median HAS-BLEDG score was also 3 (interquartile range 
2).  Approximately only 4 % of patients who were identified by HAS-BLED and HAS-
BLEDG as having a score of ≥3 experienced major bleeding events.  Even though the 
figure shows no difference in rates of haemorrhage between HAS-BLED and HAS-
BLEDG score, but interestingly, one patient in bleeding group with HAS-BLED score 
of 3 and was scored 5 by HAS-BLEDG. 
Table 3-11.  Rates of major bleeding stratified by HAS-BLED and HAS-BLEDG Score. 
Bleeding 
risk score 
HAS-BLED HAS-BLED G 
n Rates of major bleeding  
[n, (%; 95%CI)] 
(n) Rates of major bleeding 
[n, (%, 95%CI)] 
0 12 0 (0%) 11 0 (0%)  
1 84 1 (1.2%; 0 - 3.5 ) 77 1 (1.3%; 0- 3.8) 
2 142 4 (2.8%; 0.1 - 5.5) 137 4 (2.9%; 0.1 - 5.7) 
3 143 4 (2.8%;  0.1 - 5.5) 133 3 (2.2%; 0-10.2) 
4 75 4 (5.3%; 0.2 - 10.4) 85 4 (4.7%; 0.2- 9.2) 
≥5 26 2 (7.7%; 0 - 17.9) 39 4(10.2%; 0 - 19.8) 
 
 
 
Figure 3-3.  Rate of bleeding (%/6-months) of major bleeding events according to the 
HAS-BLED and HAS-BLEDG scores. 
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3.4 Discussion 
We have validated the HAS-BLED score as a successful predictor of major 
bleeding, as assessed by the c-statistic, in agreement with previous reports (Pisters et 
al. 2010, Lip et al. 2011b, Olesen et al. 2011b, Apostolakis et al. 2012).  Therefore, it 
appears that HAS-BLED score can be seen to be a useful tool for predicting major 
bleeding during initial treatment with warfarin. 
When using our own dataset to identify predictors of major bleeding, we 
identified the CYP2C9*3 (additive mode inheritance), amiodarone, labile INR, 
concomitant use with clopidogrel, concomitant use with aspirin, and bleeding 
disposition as significant predictors. The only HAS-BLED covariates which were 
significant were labile INR, concomitant use of clopidogrel, concomitant use of aspirin 
and bleeding disposition.  This study also replicates the contribution of CYP2C9*3 
(number of variant alleles) to bleeding risk in patients taking warfarin (Jorgensen et 
al. 2012, Yang et al. 2013). Multivariate analysis of the predictive risk factors found 
significant in our cohort gave a c-statistic of 0.86 (95%CI 0.787-0.944).  However, this 
needs an external validation in order to compare it with HAS-BLED or other bleeding 
scores.   
In this present study, we also examined whether addition of genetic covariates 
(HAS-BLEDG) would improve the discriminative capability of HASBLED.  
CYP2C9*3 was found to be a significant predictor of bleeding risk, so was 
incorporated with HAS-BLED score.  Adding these covariates to HAS-BLED score, 
did not significantly improve HAS-BLED prediction in all analyses.   
In addition to the list of drugs included as risk factors for bleeding in previous 
studies, we found that amiodarone was also a significant contributor to major bleeding 
in the univariate analysis.  The interaction of warfarin and amiodarone has been widely 
reported. Amiodarone reduces the clearance of R- and S- warfarin by inhibition of 
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CYP2C9 and CYP1A2 (O'Reilly et al. 1987, Heimark et al. 1992, Kumar et al. 2006), 
the enzymes responsible for metabolising warfarin in the liver. The interaction that 
always occurs between these two drugs necessitates a 25-40% warfarin dose reduction 
(Kerin et al. 1988, Sanoski and Bauman 2002).  However, the study by Olesen et al. 
(2011b) in a larger cohort of atrial fibrillation patients (n=44,771 patients treated with 
vitamin K antagonists) did not produce an association between amiodarone use and 
major bleeding (p=0.71).  The number of patients taking amiodarone in that cohort 
was 86 (4.3%) compared with 50 (10.4%) in our study.  The smaller percentages of 
patients on amiodarone in the Olesen et al. (2011b) study possibly influenced the 
significance of the association.  In our view, concomitant use of amiodarone should be 
considered as one of the more important risk factors for major bleeding in a patient 
treated with warfarin. 
Based on the c-statistic value,  performance of HAS-BLED in patients taking 
warfarin, the current study found that the model prediction was stronger (c-statistic 
0.80), when compared to a previous studies with one year follow-up by Pister et al. 
(2010), Lip et al (2011b) and recently by Apostolakis et al (2012) where the c-statistic 
was all 0.65.  In the study by Olesen et al. (2011b), data for labile INR were not 
included because the information was unavailable, but they showed similar 
performance (c-statistic 0.79) to our findings.   
The original definition of uncontrolled hypertension used for the HAS-BLED 
score was a systolic blood pressure >160 mmHg.  This definition is problematic 
because there are many contributing factors to uncontrolled blood pressure, including 
treatment compliance, disease and lifestyle.  The time that blood pressure is taken also 
influences measurement.  Systematic reviews suggest that poorly controlled blood 
pressure is an independent risk factor for bleeding (Hughes and Lip 2007).  In our 
definition, as suggested by many guidelines, patients were considered as showing 
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uncontrolled hypertension if they were not responding to initial antihypertensive 
treatment (Huntzinger 2008, Cheung and Cheung 2012, Schäfer et al. 2012).  
Thus, since both our analyses and that of Olesen et al.(2011b) used similar 
definitions of uncontrolled hypertension and produced better values of c-statistic, we 
suggest that the definition we used to define uncontrolled hypertension is used in future 
applications of the score.   
Limitations in our study includes inability to compare our newly developed 
regression model with HAS-BLED or HAS-BLEDG since we only had one dataset.  
We cannot use our retrospective cohort used in previous chapter because it will 
introduce bias in selection of patients as some patients are eliminated because of 
bleeding.  In addition too few people had CYP2C9*3, therefore we may require a larger 
sample size to show that adding genetics to HAS-BLED improved prediction.  
Furthermore, we did not investigate the contribution of rs6018 in the clotting factor V 
gene, which was significantly associated with major bleeding events in our interim 
analysis of our prospective cohort (Jorgensen et al. 2012).   
We only included patients who was classified as ‘possible’,’probable’ or 
almost certain’ related to bleeding due to warfarin as cases.  Some patients who are 
bleeding but classified as ‘unrelated’, ‘unlikely’ are referred to as control.  Thererefore, 
some true cases might be eliminated and contaminating the control group with some 
cases and lessening the chances of finding real exposure differences between cases and 
controls. 
The prospective study design that we chose may reduce the potential for 
incomplete recording of data whilst enhancing completeness and robustness of the 
statistical analysis.  Moreover, prospective design allowed us to avoid any selection 
bias due to some patients being excluded because of bleeding during therapy. 
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None of the prospective studies so far extended the clinical use of 
pharmacogenetics beyond initial stable warfarin dose prediction (Gage et al. 2008, 
Wadelius et al. 2009).  Therefore, this study added new knowledge of using 
pharmacogenetics in predicting the adverse effect of warfarin during initiating the 
dose.  This study is of practical importance because the most dangerous side-effect of 
warfarin treatment is major bleeding, which occurs most commonly during the early 
months of therapy (Landefeld and Goldman 1989, Fihn et al. 1993, Douketis et al. 
2000, Linkins et al. 2003, Hylek et al. 2007). 
The primary advantage of the HAS-BLED score is that it is simple and easy to 
remember, yet offers good prediction of major bleeding risk.  It supports physicians in 
making an informed decision when giving warfarin therapy, rather than guessing.  For 
example, if the patient’s bleeding score is sufficiently high, caution should be 
exercised by ensuring more regular reviews for that patient.  Additionally, the bleeding 
risk score can be modified, by stopping aspirin or by counselling on alcohol intake.  
Therefore the HAS-BLED score not only gives the option to stop warfarin therapy if 
the score is sufficiently high, but it also provides alternative management strategies for 
those patients who would really benefit from warfarin therapy. 
Genotyping for CYP2C9 and VKORC1 may possibly improve the predictive 
capability of HAS-BLED, but we were unable to demonstrate this in our study cohort.  
For example, one patient in bleeding group with HAS-BLED score of 3 and having 
homozygous CYP2C9*3 was scored as 5 by HAS-BLEDG.  HAS-BLEDG score 
indicated that patient has higher risk of major bleeding compared by HAS-BLED.  
Therefore, caution should be taken when prescribing warfarin to this patient, or newer 
oral anticoagulant such as dabigatran, a direct thrombin inhibitor should be prescribed 
to this patient.  (Apostolakis et al. 2012, Roldán et al. 2013). However, it would be 
worthwhile investigating this further in a larger cohort of patients.  Of course, if the 
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genotype of an individual patient is already known, there is no harm in using HAS-
BLEDG rather than HAS-BLED.  Although genotypes are not available for most 
patients at present, this may change in the future through patients obtaining their own 
genome-wide SNP data (eg by sending samples to 23anMe ), or as the cost of 
genotyping/sequencing falls. 
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4.1 Introduction 
The incidence of venous and arterial thrombosis is rare in children, although 
recent studies have revealed that the incidence has been increasing over the last decade, 
specifically for venous thromboembolism (VTE) (Vu et al. 2008, Raffini et al. 2009, 
Setty et al. 2012).  As an example, a study in the Children’s Hospital of Philadelphia 
has shown that the annual rates of VTE increased by 70% during the 7-year study 
period from 2001 (Raffini et al. 2009).  The increasing incidence of VTE in this 
population is due to the medical progress in the treatment of critically ill patients.  This 
can be explained by the increasing use of central catheters and innovative 
interventional procedures in the treatment of premature infants, neonates and older 
children who are critically ill, suffering from complex cardiac defects, and from 
malignant diseases. 
Warfarin is the most frequently prescribed oral anticoagulant for both the 
treatment and prevention of thromboembolic disease, and has been used in paediatrics 
since the 1970s (Carpentieri et al. 1976).  The American College of Chest Physicians’ 
Guidelines has recommended warfarin as thromboprophylaxis in many diseases 
including in patients with a prosthetic heart valves, after deep vein thrombosis and 
after Fontan palliation for congenital heart disease (Monagle et al. 2012).   
As with adults, warfarin is a difficult drug to prescribe because of unpredictable 
responses and has a narrow therapeutic range.  Similar to adults, age, disease, drugs 
and dietary factors can interfere with the response to warfarin.  Dosing algorithms have 
been published for paediatric populations, but none of them include pharmacogenetic 
information (Andrew et al. 1998, Paediatric Stroke Working et al. 2004, Roach et al. 
2008, Monagle et al. 2012). These warfarin dosing algorithms are extrapolated from 
adult algorithms, using the patient’s age, weight and serial INR, to dictate initial 
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warfarin dose and dose adjustment to therapeutic levels.  While these algorithms are 
relatively effective in clinical practice, they do not take into consideration differences 
between adult and paediatric haemostatic systems, which affect the pathophysiology 
of thrombosis and response to anticoagulation.  In an American survey using an on-
line questionnaire, paediatric haematologists identified a need for a better warfarin 
dosing algorithms and expressed an interest in updated algorithms that potentially 
included genetic factors (Thornburg et al. 2010). 
Polymorphisms in CYP2C9 and VKORC1 have consistently been associated 
with warfarin dose requirements in adult populations around the world; however the 
impact of pharmacogenetics (e.g., CYP2C9 and VKORC1) on paediatric therapy 
outcomes has not been fully explained.  A literature search on warfarin 
pharmacogenetics in Caucasian children led to three small cohort studies evaluating 
the influence of CYP2C9 and VKORC1 polymorphisms on warfarin response (Table 
4-1).  The studies showed conflicting results, with two studies (Biss et al. 2012, 
Moreau et al. 2012) suggesting CYP2C9 and VKORC1 explain approximately 40% of 
warfarin dose variation and one study (Nowak-Göttl et al. 2010) showing only a small 
contribution from these polymorphisms (~4%).  A further outcome being studied that 
relates to the efficacy of warfarin therapy is the time spent within INR range (Moreau 
et al. 2012) and time to therapeutic range (Nowak-Göttl et al. 2010); however neither 
of these were associated with CYP2C9 and VKORC1 polymorphisms. 
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The aims of this study were firstly to examine the association between genetic 
(VKORC1, CYP2C9) and non-genetic factors and the response to warfarin in children 
at the onset of therapy and during stable maintenance dosing.  Secondly, the study aims 
to quantify the proportion of variability explained by the factors mentioned above.  The 
response to warfarin was measured as the proportion of time in which INR 
measurement fell within the target range (PTTR), INR exceeding the target range 
within the first week of treatment, warfarin stable dose and bleeding complications. 
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Table 4-1  Results of literature search of warfarin pharmacogenetics in children . 
Author Study design Sample size and study 
characteristics 
Definition  of stable 
dose 
Statistical methodology Multivariate analysis 
association with the outcomes  
(R2) 
Moreau 
et al., 
(2012) 
 Inclusion criteria 
- VKA therapy for 
at least the past 
2 months 
-Age: 3 months to 
18 years  
- Targeted INR  1.5-
4 
 Retrospective 
cohort 
 
 83 patients received 
warfarin, 35 patients  
received flunidione 
 Mean age: 8.4 years  
(warfarin) 
 32% patients with 
indication for Fontan 
procedure and 39% 
with indication for 
mitral/aortic valve 
replacement 
 >90% Caucasian 
Mean dose required 
to achieve INRs within 
the therapeutic range 
for 3 consecutive INR 
determinations at 2-
week intervals 
 Univariate analysis: 
-- 2-sample Wilcoxon test or 
nonparametric ANOVA 
(Kruskal-Wallis test) for 
qualitative variables  
-The Spearman rank 
correlation coefficient for 
quantitative variables 
 Multivariate analysis 
-including covariated with 
p<0.2 in univariate analysis 
-Backward  selection method 
-Retain covariates with p 
<0.05 
Maintenance dose: 
 height (48.1%) 
 number of variant alleles of 
VKORC1 -1693 (18.2%) 
 target INR (4.4%) 
 number of variant allele 
CYP2C9*2/CYP2C9*3(20%) 
Time spent within INR range 
 Target INR group (the only 
factors that associated in 
univariate analysis 
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Author Study design Sample size and study 
characteristics 
Definition  of stable 
dose 
Statistical methodology Multivariate analysis 
association with the outcomes  
(R2) 
Biss et 
al., 
(2012) 
 
 
 
 
 
 
 
 Inclusion criteria 
- VKA therapy for 
at least the past 3 
months 
- Age: 3 months to 
18 years  
- Targeted INR 2-
3.5 
 Cross sectional 
cohort 
 All received warfarin 
(n=120) 
 Median age is 11 
years 
 Majority of patients 
were prescribed 
warfarin for Fontan 
(53%) 
 75.8% Caucasians 
no change of dose for 
at least the previous 3 
consecutive INR 
measurements over a 
minimum period of 4 
weeks 
 
 Univariate analysis: 
-Pearson correlation test for 
continuous  variables  
-Student t-test or ANOVA for 
categorical variables 
 Multivariate analysis 
- did not mention univariate p 
value included covariates  
-retain covariates with p<0.05 
Maintenance dose: 
 height (29.8%) 
 indication (3.2%) 
 Number of variant allele of 
VKORC1-1693 (26.6%) 
 Number of variant alleles for 
CYP2C9*2 and CYP2C9*3 
(12.8%) 
Nowak-
Göttl et 
al. 
(2010) 
 Inclusion criteria 
- VKA therapy for 
at least the past 3 
months 
-Age: 3 months to 
18 years  
- Targeted INR   2-3 
 Prospective cohort 
 
 43 patients received 
warfarin, 26 received 
phenprocoumon 
 Mean age: 2.3 years  
(both group) 
 Indication warfarin for 
the target INR 2-3 
with majority are 
deep vein thrombosis 
(33%) and pulmonary 
embolism (32%) 
 100% Caucasians 
median of 3 
consecutive dosages 
when the patient had 
achieved stable 
anticoagulation where 
stable anticoagulation 
was defined by VKA 
requirement 
remaining constant for 
3 consecutive days 
after achieving the 
target INR 
 Univariate analysis: 
-Did not mention types of 
test performed 
- VKORC1 genotype was 
categorized into 3 groups 
(AA, GA, and GG) and CYP2C9 
genotype into 2 groups for 
(any mutation 1.2, 1.3 or 2.2, 
and wild-type 1.1). 
 Multivariate analysis 
-including covariates with 
p<0.2 in a univariate analysis 
 
Maintenance dose 
 age (28.3%) 
 VKORC1 -1693(2.8%) 
 Variant CYP2C9*2 or 
CYP2C9*3  (0.5%) 
Time to therapeutic range 
None 
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Author Study design Sample size and study 
characteristics 
Definition  of stable 
dose 
Statistical methodology Multivariate analysis 
association with the outcomes  
(R2) 
Biss et 
al 
(2013) 
 Inclusion criteria 
 - VKA therapy for 
at least the past 3 
months 
 -Age: 3 months to 
18 years  
 - Targeted INR   2-
3.5 
 Cross sectional 
cohort 
 Same cohort as 
Biss et al,. 2012 
 All received warfarin 
(n=51) 
 Median age is 4 years 
 Majority of patients 
were prescribed 
warfarin for Fontan 
(54%) 
 
NA  The association between 
the CYP2C9 genotype and 
peak INR was examined 
using the t-test and 
between the VKORC1 
genotype and peak INR 
using linear regression 
analysis 
 The association between 
the incidence of supra-
therapeutic INR during the 
first month of warfarin 
therapy and CYP2C9 
genotype was evaluated 
using a Mann–Whitney test 
and the VKORC1 genotype 
using regression analysis. 
Over-anticoagulation during 
initiation therapy         
*In univariate analysis (p<0.05): 
 Children with a variant 
CYP2C9 allele (*2 or *3) had 
a higher mean peak INR 
during week 1 than those 
with wild-type 
 Children with the VKORC1 
AA genotype had a higher 
mean peak INR (5.1 ± 2.1) 
than those with the GA (3.5 
± 1.4) or GG (3.0 ± 1.3) 
 Children with a variant 
CYP2C9 allele had a greater 
proportion of INR values 
above the target therapeutic 
range during month 1 of 
warfarin therapy than those 
with wild-type CYP2C9; 
19.3% vs. 15.9%, 
respectively 
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4.2 Method 
4.2.1 Study design and setting 
We conducted a retrospective cohort study in Alder Hey Children’s Hospital, 
Liverpool, between November 2009 and January 2011.  Alder Hey Children’s Hospital 
is one of Europe’s biggest and busiest children’s hospitals, providing care for over 
200,000 children and young people each year.  The majority of patients on warfarin 
are cared for in the community using point of care therapy (POCT).  In POCT, 
equipment and training for INR monitoring are provided to patients or their 
families/carers. Patients and families inform the cardiac liaison nurse team after INRs 
and dose adjustment is carried out accordingly.  All INR data is provided and dose 
adjustments are recorded by the cardiac liaison nurse team.   
Patients were identified by the cardiac liaison nurse team or the relevant 
clinical team within the hospital and approached about participating in the study. This 
study received full ethical approval from North West 3 Research Ethics Committee. 
4.2.2 Patient eligibility 
Inclusion criteria were: warfarin prescribed for ≥ 3 months, age ≤18 years and 
therapeutic drug monitoring of INR performed by Alder Hey Children’s Hospital.  
Written informed consent was sought from children and young people (each child was 
assessed on a case by case basis for level of understanding).  The written informed 
consent was signed by a parent/guardian for patients aged <16 years and by the patient 
if aged ≥ 16 years old.  Prior to the consent/assent process, information was provided 
to the parents/guardians and the participants about the nature of the study and the 
information it was expected to produce.  Refusal to give assent was an exclusion 
criterion. 
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4.2.3 Data collection 
Age, gender, height, weight, BMI, albumin, target INR group and indication 
for treatment were collected from medical notes or information on the Alder Hey 
children’s hospital computerised results system (Meditech).  The data were collected 
from date of initiation of warfarin therapy to the date of recruitment.  Any evidence of 
bleeding (either verbally reported by parents or recorded in medical notes) was also 
recorded and graded as mild/severe/life threatening/fatal as classified Fihn et al.(1996) 
and Streif et al.(1999). 
Following the data collection, the coded samples were completely anonymized 
and could not be traced to any individual.  All variables were checked for completeness 
and accuracy.  Where missing data were noted, an attempt was made to retrieve the 
data. To check data accuracy, range and consistency checks were undertaken. 
4.2.4 DNA collection and extraction 
Saliva samples were collected using the Oragene® DNA kit (information is 
available at www.dnagenotek.com).  Patients were required to spit 1-2ml of saliva into 
an Oragene® DNA vial.  When the lid was closed, the saliva was automatically mixed 
with Oragene® DNA preserving solution.  If the child was unable to produce a saliva 
sample, then a buccal swab was used to collect the saliva.  The resulting sample 
solutions were stored at -20°C and then thawed at room temperature before processing.  
Samples were then incubated at 50°C, to maximize DNA yield and to ensure that 
nucleases were permanently inactivated.   
Purification was conducted using the Oragene DNA purification protocol.  In 
this protocol, Oragene DNA Purifier was added to each sample in the ratio of 1:25 
(e.g. 80 µl of purifier was added to 2 ml of sample).  To increase the effectiveness of 
impurity removal, the mixture was then incubated on ice for 10 minutes.  The mixture 
was then centrifuged at 4600 x g and the supernatant transferred to a fresh tube.  An 
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equal volume of 95% ethanol (at room temperature) was added to the clear supernatant 
to precipitate DNA.  The mixture was then centrifuged again at 4600 x g and the 
supernatant was removed as completely as possible.  Subsequently 1 ml of 70% 
ethanol was added, without disturbing the smear or the pellet.  After gentle swirling, 
the ethanol was discarded from the tube.  This process ensured that any residual 
inhibitors were removed.  The DNA pellet was rehydrated in TE buffer and stored in 
a cold room for a week, before quantification using Nanodrop.  
4.2.5 Genotyping 
Genotyping of CYP2C9*2 (rs 1799853), CYP2C9*3 (rs 1057910) and 
VKORC1-1693 (rs 9923231) was performed on an ABI 7900HT Real time PCR using 
Taqman chemistry. These SNPs have been replicated in many studies associated with 
warfarin dose in the adult population.  PCR was carried out using Taqman Drug 
metabolism Genotyping Assays C-30403261_20, C-25625805_10 and C-
30403261_20).  A reaction volume of 10 µl contained 10 ng DNA, 1X Taqman 
Universal PCR Master Mix (without AmpErase) and 1X TaqmanDrug Metabolising 
Genotyping Assays.  The genotyping procedure is discussed in detail in Chapter 2.2.4. 
4.2.6 Study outcomes 
Study outcomes were specified in the protocol, as follows: 
a) Primary outcome measure: The proportion of time in which INR 
measurements fell within the target range (PTTR) within the first six months.  The 
method of linear interpolation (Rosendaal et al. 1993) was used to estimate the 
proportion of time patients spent in therapeutic range (PTTR) between two test days.  
The PTTR is used to interpret the relative efficacy and safety of anticoagulant control 
in children (Streif et al. 1999, Bradbury et al. 2008, Bhat et al. 2010).  We chose this 
as a primary outcome because the value explained the proportion of time patients were 
adequately protected against thromboembolism without a risk of bleeding.  The target 
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range was defined as recommended by the British Society of Haematology Guidelines 
(Keeling et al. 2011). 
b) Secondary outcome measures: Five secondary outcomes were evaluated:  
i. INR exceeding the target range within the first week of treatment.  This outcome 
was chosen because over-anticoagulation could result to bleeding and the bleeding 
risk is greatest during the first week of therapy (Fihn et al. 1993, Landefeld and 
Beyth 1993, Douketis et al. 2000). 
ii. Stable dose (mg/day), defined as the mean daily dose required to achieve three 
consecutive INR measurements within the individual’s target range, over a 
minimum period of four weeks, at the same daily dose.  If several periods of stable 
dose were observed, the stable dose at the earliest date was taken.   
iii. Bleeding complications, classified according to both Fihn et al. (1996) and Streif 
et al. (1999).  A summary of bleeding definitions used for this study is provided 
in Table 4-2. 
Table 4-2  Definition of Bleeding Complications 
Bleeding grade Definition 
Minor Bleeding events not meeting the criteria for a major bleed. 
Major Clinically overt bleeding causing admission to hospital, OR a 
decrease of >20 g/L in haemoglobin in 24 hours OR need for 
transfusion of red blood cells, OR any CNS or retroperitoneal bleed. 
Life Threatening Leading to cardiopulmonary arrest; surgical or angiographic 
intervention, or irreversible sequelae, such as myocardial 
infarction, neurologic deficit consequent to intracerebral 
haemorrhage, or massive haemothorax. 
Fatal Leading directly to the death of the patient 
 
 
The time taken to achieve therapeutic INR and a stable warfarin dose were 
included as secondary outcome measures in the study protocol; however, there was 
insufficient follow-up data of patient demographics such as weight, height at the time 
the outcomes were reached  to allow accurate assessment of these outcomes. 
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4.3 Statistical Analysis  
All analyses were performed in R version 2.13 by a statistician, Laura Sutton.  
R is a free software environment for statistical computing and graphics (R Core Team 
2011). The conformity of each SNPs with Hardy Weinberg Equilibrium (HWE) was 
tested (p<0.01 indicated deviation).  
4.3.1 Non-genetic variables 
Non genetic variables including age, gender, height, weight, BMI, albumin, 
target INR group and indication for treatment, were recognised as being potentially 
important variables which may influence warfarin response.   
Age, height and target INR group was associated with warfarin response in a 
previous study in a paediatric population (see Table 4-1).  Weight, BMI and gender 
are also very interesting variables to explore, as studies have found them to be 
associated with warfarin response in adults (as discussed in section 1.2.4).   
Warfarin is highly bound to plasma albumin, with only 0.7% free circulating 
in the blood (Johnson et al. 2006).  Many children who take warfarin commence on 
the drug at a time when they may be hypoalbuminaemic (e.g. after cardiac surgery or 
nephritic syndrome) and therefore the effect of plasma albumin levels needs to be 
considered.  
The indication for warfarin therapy also affects warfarin response.  Evidence 
has shown children who are anticoagulated for prevention of thromboembolic events 
following a Fontan procedure, have a lower warfarin dose requirement than those who 
are anticoagulated for other indications (Streif et al. 1999, Biss et al. 2012).  The likely 
explanations are associated with right-sided cardiac failure, which causes liver 
dysfunction.  As a result, warfarin metabolism is reduced and warfarin sensitivity is 
increased.   
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For the variable ‘INR group’, patients were grouped according to the lower 
limit of their referral therapeutic range.  They were classified as either 1.5, 2.0, 2.5 or 
3.0.  For example if a patient’s target INR was 1.5-2.0, they were grouped to an INR 
target group as 1.5, but if a patient’s INR was 2.0-3.0, they were grouped as 2.0. 
For the variable ‘treatment indication’, patients were divided into non-Fontan 
and Fontan groups. A second classification was also used and tested in a sensitivity 
analysis, where patients were divided into non-Fontan cardiac, Fontan cardiac and 
non-cardiac groups. 
Considerable volumes of data for the non-genetic variables were missing 
(Table 4-3).  In order to increase power and reduce bias , multiple imputation using 
chain equations (van Buuren and Groothuis-Oudshoorn 2011), specifically the 
predictive mean matching method, was used to impute data which had <30% missing 
observations.  With a rate of missingness of 30%, the efficiency of estimates based on 
3 imputations is approximately 91% (Rubin 2008).  Multiple imputation was not used 
for variables which had ≥30% missingness.  Instead, these variables were excluded 
from the list of potential covariates.   
4.3.2 Genetic variables 
The SNPs CYP2C9*2 (rs 1799853), CYP2C9*3 (rs 1057910) and VKORC1-1693 (rs 
9923231) were selected for the analysis as these have been shown to affect warfarin 
response in adult and children populations using warfarin (Biss et al. 2012, Moreau 
et al. 2012, Yang et al. 2013). 
4.3.3 Association of non-genetic variables with the outcomes 
First, the non-genetic variables were each individually tested for association 
with each outcome.  Variables giving a p-value <0.10 were adjusted for, when testing 
for association with individual SNPs.  If a pair of variables was found to be collinear, 
only the variable with the lowest p-value was adjusted for in the analysis. 
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For the outcome of proportion of time in which INR measurements fell within 
the target range (PTTR) within the first six months and INR that exceeded the target 
range during the first week, the value of non-genetic variables at the start of warfarin 
treatment were used.  For the outcome of stable dose, values of non-genetic variables 
at the time stable dose was achieved were used.  For the outcome of bleeding 
complications, no tests for association with non-genetic variables were undertaken, as 
it was not possible to determine which time point should be referred to for obtaining 
the value of these variables in those not experiencing the complication.   
4.3.4 Analysis of association with each SNPs 
We tested for associations with each individual SNP.  Two regression models 
were fitted for each SNP.  The first (the ‘baseline model’) included all non-genetic 
factors giving a p value <0.10 univariately and second (the ‘genetic model’) was the 
same as the first but also included covariates to represent the SNP of interest.  The 
likelihood ratio test was used to compare both models.  Two analyses were carried out 
for each SNP; one with no underlying assumptions regarding the mode of inheritance 
and another assuming an additive mode of inheritance.  In the analysis with no 
underlying assumption, two variables were used to represent the SNP which is one 
representing heterozygotes and one representing mutant homozygotes.  In the analysis 
assuming an additive mode of inheritance, a single variable to represent the SNP was 
used.  Wild-type homozygotes were coded ‘0’, heterozygous patients were coded as 
‘1’ and mutant homozygotes were coded as ‘2’.  The false discovery rate (FDR) was 
calculated for each SNP association tested (Benjamini and Hochberg 1995).   
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4.3.5 Multiple regression analysis 
Finally, we investigated the total variation explained by all significant non-
genetic and genetic factors.  A multiple regression model was fitted for each outcome 
which included covariates with a p value <0.10 in the univariate analysis and all SNPs 
that were significant under FDR control.  For continuous outcomes, multiple linear 
regression models were fitted and for binary outcomes, logistic regression models were 
fitted. 
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4.4 Results 
4.4.1 DNA yield and quality 
The estimated amount of total DNA extracted from 2 mL saliva samples varied 
between 0.05 and 619.5 μg with a mean of 85.2 μg.  The mean values of the 260/280 
and 260/230 nm ratios were 1.7 (range 1.4-2.78) and 0.9 (range 0-4.9), respectively.  
DNA which did not meet the 260/280 in the range of 1.7-2 was purified by centrifuging 
and pippette out the cloudy portion.   If the 260/280 was still out of target range, EZ-
DNA extraction column kit was used to purify the DNA.   
4.4.2 Patient Characteristics 
A total of 100 patients were recruited (male=55, female=45).  Ninety-seven 
were Caucasian while the others were black (n=1), Indian (n=1) and Afghan (n=1).  
The three non-Caucasians were excluded from the analysis to minimise the effect of 
ethnic differences in warfarin response (see chapter 1.9). 
Patient characteristics are shown in Table 4-3.  The majority of our patients 
were very young during the start of warfarin therapy: 75.3 % were below 5 years old 
at the time of start of therapy. Out of 85 patients who reached stable dose, 53% were 
below 5 years of age.   
Of the 97 children, 85 were anticoagulated following surgery for congenital 
heart disease and 12 were non-cardiac (Table 4-4).  The primary indication for warfarin 
was the Fontan procedure.  Genotype distribution for all four SNPs met Hardy-
Weinberg equilibrium (p>0.60) (Table 4-5).  Allele frequencies for CYP2C9*2 (0.11), 
CYP2C9*3 (0.09) and VKORC1-1693 (0.36) were similar to those previously reported 
in adult populations (Stubbins et al. 1996, Aithal et al. 1999, Sconce et al. 2005). 
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Table 4-3.   Summary of participant characteristic at the start of warfarin therapy and at 
the time stable dose was achieved. 
12 patients did not achieve stable dose during follow-up 
 
Table 4-4.  Indication for warfarin treatment. 
Indication for warfarin treatment Number of 
patients (%) 
Surgery for  congenital heart 
disease 
Fontan procedure 61 (62.9%) 
Other cardiac procedures:  
(e.g. Mitral valve replacement, post 
shunt, modified Norwood procedure) 
24 (24.7%) 
Non-cardiac patients Pulmonary embolism  3 (3.1%) 
Deep Vein Thrombosis 2 (2.1%) 
Prophylaxis of line/catheter clotting or 
post-surgery 
6 (6.2%) 
Factor V Leiden Syndrome 1 (1.0%) 
 
Table 4-5  Genotype frequencies for the four SNPs. 
Genotype Homozygous wild type Heterozygote Homozygous 
mutant 
CYP2C9*2 76 (78.4%) 19 (19.6%) 2 (2.1%) 
CYP2C9*3 79 (81.4%) 18 (18.6%) 0 (0%) 
VKORC1-1693 40 (41.2%) 45 (46.4%) 12 (12.4%) 
 
 
 
 
 
 
 
 
 
Variable Start of therapy (n=97) Time of stable dose (n=85)* 
Mean SD Missing 
(n (%)) 
Mean SD Missing   
(n (%))  
Age (decimal yrs.) 3.9 3.9 0 6.9 4.5 0 
Height (m) 0.94 0.28 26 (26%) 1.06 0.28 40 (47%) 
Weight (kg) 15.7 14.5 12 (12%) 20.6 15.7 35 (43%) 
BMI (kg.m-2)† 16.1 3.1 26 (26%) 16.5 2.5 40 (47%) 
Albumin (g.L-1) 38.3 5.3 30 (30%) 39.2 6.2 62 (64%) 
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4.4.3 Summary of the outcomes 
The mean proportion of time spent within the target INR range in the first six 
months of treatment was 49% (SD 27%) and the mean stable warfarin dose was 2.70 
mg/day (SD 1.65) (Table 4-6).  40.2% patients experienced an INR above range in the 
first week and 50.5% did not.  The remainder (9.3%, n=9) were not categorized 
because insufficient data was available.  There were no reported major or severe 
bleeding events (e.g. life threatening or fatal).  Sixty-nine patients experienced a minor 
(as per Fihn classification) or mild (as Streif classification) bleed.  The remaining 28 
patients did not experience any bleeding complications. 
 
Table 4-6  Summary of outcome variables. 
Variable Mean Median SD Min Max NAs 
Proportion of time in INR 
range (first 6 months) 
0.50 0.51 0.27 0.00 1.00 7 
Stable dose (mg) 2.7 2.4 1.8 0.0 10.0 8 
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4.4.4 Association of non- genetic variables with outcomes 
Table 4-7 shows the association between the non-genetic factors and the 
outcome variables.  It was not possible to test for association between height, weight, 
BMI or albumin and stable dose due to a significant amount of missing observations 
(>30%) for these variables at the time stable dose was achieved.   
a) For the outcomes of the proportion of time in the INR range (PTTR) during six 
months follow-up, target INR group and indication for treatment (2 groups) were 
both associated (p<0.10) with this outcome.  The distribution of PTTR stratified 
by INR group and indication for treatment are shown in Figure 4-1 (a) and (b) 
b) For the outcome of INR exceeding target range during the first week, none of 
the variables were associated. 
c) For the outcome of stable dose, age and target INR group were significantly 
associated (p<0.10) with this outcome.  The scatter plot in  
d) Figure 4-2 shows the relationship between warfarin daily dose and age and Box 
plot in Figure 4-3 shows the distribution of daily warfarin dose stratified by 
target INR group. 
Table 4-7  P-values from tests of association of non-genetic variables with the outcome. 
Variables 
 
Proportion of time INR 
within target range in 
1st 6 months (n=90) 
INR exceeding target 
range in week 1 (Y/N) 
(n=88) 
Stable dose 
(mg/day) 
(n=85) 
P value n* P value n* P value n* 
Age  0.144 0 0.584 0 <0.001* 0 
Height 0.105 26 0.802 26 NA 0 
Weight 0.336 12 0.619 12 NA 0 
BMI 0.334 26 0.215 26 NA 0 
Albumin 0.982 30 0.897 30 NA 0 
Gender 0.468 0 0.173 0 0.351 0 
INR group* 0.004* 0 0.657 0 0.015* 0 
##Indication ** 0.050* 0 0.543 0 0.379 0 
* INR group: Patients were group into the lower limit of their referral range: i.e 1.5, 2.0, 2.5 or 3.0 
**Indication (2 groups):  Patients were divided into non-Fontan and Fontan group 
## In Sensitivity analysis where patients were split to 3 indication groups:-non-Fontan cardiac, 
Fontan cardiac and non-cardiac, the p-values were 0.144, 0.77 and 0.575 respectively and hence 
conclusion remain the same 
n*number of sample imputated 
NA Due to abundant data missing (>30%), the variables was excluded in the analysis  
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(A) 
 
(B) 
 
Figure 4-1.  Box and whisker plot showing the distribution of PTTR based on (A) target INR 
group and (B) indication treatment group. Boxes represent 25th-75th percentile 
(interquartile range) of PTTR, whiskers represent 5th-95th percentile, solid lines represent 
median dose.  Open dots denote outliers (a value between 1.5 and 3 times the interquartile 
range away from the 25th or 75th percentile). 
 
P 0.004 
P 0.050 
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Figure 4-2.  Relationship between warfarin daily stable dose and age. 
 
 
Figure 4-3.  Box and whisker plot showing the distribution of PTTR stratified by INR target 
group. Boxes represent 25th-75th percentile (interquartile range) of PTTR, whiskers 
represent 5th-95th percentile, solid lines represent median dose.  Open dots denote 
outliers (a value between 1.5 and 3 times the interquartile range away from the 25th or 75th 
percentile). 
 
R2=0.22 
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4.4.5 Analysis of association with each SNP 
Table 4-8 presents the results from undertaking likelihood-ratio tests and 
comparing the baseline model to the genetic model for each outcome and SNP in turn.  
VKORC1-1693 was significantly associated with PTTR and stable dose when 
assuming an additive mode of inheritance and with bleeding complications when 
making no assumption regarding mode of inheritance.  The distribution of PTTR and 
stable dose stratified by VKORC1-1693 genotypes is illustrated in Figure 4-4 and 
Figure 4-5(b) respectively.  CYP2C9*2 was significantly associated with INR above 
range in the first week of treatment and warfarin stable dose when assuming an 
additive mode of inheritance.  The distribution of warfarin stable dose stratified by 
CYP2C9*2 genotypes showed in Figure 4-5 (a). 
Table 4-8  Individual SNP association analyses 
Outcome SNP (assumption) p-value 
from LRT 
Significant following 
FDR adjustment 
Proportion of time in 
INR range (PTTR)* 
CYP2C9*2 (none) 0.58 No 
CYP2C9*2 (additive) 0.53 No 
CYP2C9*3 (NA†) 0.95 No 
VKORC1*2 (none) 0.03 No 
VKORC1*2 (additive) 0.001 Yes 
INR above range in 
week 1 
CYP2C9*2 (none) 0.04 No 
CYP2C9*2 (additive) 0.004, Yes 
CYP2C9*3 (NA†) 0.80 No 
VKORC1*2 (none) 0.23 No 
VKORC1*2 (additive) 0.020 No 
Stable dose** CYP2C9*2 (none) 0.09 No 
CYP2C9*2 (additive) 0.008 Yes 
CYP2C9*3 (NA†) 0.049 No 
VKORC1*2 (none) 0.35 No 
VKORC1*2 (additive) 0.003 Yes 
Bleeding complications CYP2C9*2 (none) 0.819 No 
CYP2C9*2 (additive) 0.423 No 
CYP2C9*3 (NA†) 0.482 No 
VKORC1*2 (none) 0.006 Yes 
VKORC1*2 (Additive) 0.288 No 
FDR = false discovery rate; LRT = likelihood ratio test. 
* Analyses adjusted for indication for treatment and target INR group. 
** Analyses adjusted for age and target INR group. 
† No mutant homozygotes so assumption regarding mode of inheritance irrelevant.  
For non-additive assumption p-value from LRT is for heterozygous and homozygous each SNP. 
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Figure 4-4.  Box and whisker plot showing the distribution of PTTR stratified by VKORC1 
genotypes.  Boxes represent 25th-75th percentile (interquartile range) of PTTR, whiskers 
represent 5th-95th percentile, solid lines represent median dose.  Open dots denote 
outliers (a value between 1.5 and 3 times the interquartile range away from the 25th or 75th 
percentile). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P 0.001 
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(A)  
 
(B)  
 
Figure 4-5.  Box and whisker plot showing the distribution of warfarin stable daily dose 
stratified by (A) CYP2C9*2 and (B) VKORC1-1693 genotypes. Boxes represent 25th-75th 
percentile (interquartile range) of PTTR, whiskers represent 5th-95th percentile, solid lines 
represent median dose.  Open dots denote outliers (a value between 1.5 and 3 times the 
interquartile range away from the 25th or 75th percentile) and and asterisks denote extreme 
outliers (a value more than 3 times the interquartile range away from the 25th or 75th 
percentile). 
P 0.008 
P 0.003 
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4.4.6 Final multiple regression models 
Using the non-genetic variables with p<0.10 and genetic variables that were 
significant after FDR correction, the multiple regression models were built for each 
outcome.  The R2 values for the models are provided in Table 4-9. 
Taken together, the indication for treatment and target INR groupings 
accounted for approximately 11% of variability in the proportion of the first six 
months’ treatment time spent within target INR range. The presence of variant alleles 
in VKORC1-1693 was associated with a greater time spent within range, with each 
additional variant allele associated with approximately 13% (95% CI 5% to 21%) more 
time spent within the target INR range in the first six months. VKORC1-1693 
combined with the aforementioned non-genetic factors explained almost 21% 
variability in proportion of the first six months’ treatment time spent within the target 
INR range.   
The variant allele CYP2C9*2 was associated with an increased likelihood in 
the INR values exceeding the target range in the first week of therapy. Odds ratio for 
heterozygotes versus wild-type homozygotes was 4.10 (95% CI: 1.42, 12.34).  
Overall, the patient’s age, target INR range, CYP2C9*2 and VKORC1-1693 
genotypes accounted for approximately 41% of the variability in the warfarin dose 
required to stabilise INR. The presence of variants in CYP2C9*2 and VKORC1-1693 
were both associated with a lower dosage required to stabilise INR.  The CYP2C9*2 
variant allele was associated with an approximate decrease in dose of 0.82 mg/day and 
the VKORC1-1693 variant allele was associated with an approximate decrease of 0.66 
mg/day. Based on the change in adjusted R2 values with the addition of the genetic 
variables, variability in VKORC1-1693 accounted for approximately 7% and 
variability in CYP2C9*2 approximately 5% of the overall variance in stable dose. 
The presence of one variant allele at VKORC1-1693 was associated with an 
increased likelihood of bleeding complications, with the odds ratio for heterozygotes 
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versus wild-type homozygotes being 4.53 (95% CI: 1.59-12.93).  No significant 
association was found between having two copies of the variant allele and bleeding 
complications; however bleeding events were both rare, as were patients who were 
homozygous for variant alleles, and therefore there may be insufficient power to detect 
a significant association with mutant homozygotes. 
Table 4-9  Final multiple regression models. 
Outcome Variables 
included 
Coefficient (95% CI)† Adjusted/pseudo R2 
Non 
genetic 
variables 
Genetic 
variables 
All 
variables 
Proportion of 
time INR 
within target 
range (PTTR) 
Indication for 
treatment * 
 
INR group** 
 
 
 
VKORC1-
1693 
(additive) 
0.09 (-0.04, 0.22) 
 
 
1: -0.33 (-0.54, -0.12) 
2: -0.00 (-0.17, 0.17) 
3: 0.20 (-0.08, 0.49) 
 
0.13 (0.05, 0.21) 
11.3% 9.5% 20.8% 
INR exceeding 
target range 
in week 1 
CYP2C9*2 
(additive) 
4.18 (1.42, 12.34) - 6.8% 6.8% 
Stable dose Age 
 
INR group ** 
 
 
 
CYP2C9*2 
(additive) 
 
VKORC1 -
1693 
(additive) 
0.19 (0.12, 0.25) 
 
1: -1.05 (-2.36, 0.26) 
2: 0.93 (0.14, 1.73) 
3: -0.27 (-2.81, 2.27) 
 
-0.82 (-1.39, -0.25) 
 
 
-0.66 (-1.08, -0.25) 
29.2% 11.9% 41.4% 
Bleeding 
complications 
VKORC1-
1693 (none) 
Het: 4.53 (1.59, 12.93)  
 
Homo: 1.13 (0.20, 6.51) 
- 8.7% 8.7% 
†Regression coefficient for multiple regression models; odds ratio for logistic regression models; CI = 
confidence interval; INR group: 1 for 1.5, 2 for 2.0, 3 for 2.5; Het=heterozygous; Homo= homozygous. 
*Indication for treatment: Patients were divided into non-Fontan and Fontan group (2 group) 
**INR group: Patients were group into the lower limit of their referral range i.e 1.5, 2.0,2.5 or 3.0 
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4.5 Discussion 
In this prospective cohort study of 97 Caucasian children treated with warfarin, 
we have demonstrated that the target INR, indication for treatment and VKORC1-1693 
were significantly associated with the proportion of time spent in INR range (PTTR) 
explaining approximately 21% of the variation. To date, this is the first study that has 
demonstrated a significant association between a genetic polymorphism in VKORC1-
1693 and this outcome.  We also replicated the previously reported association 
between CYP2C9*2 and VKORC1-1693 polymorphisms and warfarin dose in a 
paediatric population, together with age and target INR group (which in total explained 
41.4% dose variation).  This study is also the first to show an association between 
CYP2C9*2 and INR exceeding target range during the first week of therapy, and the 
association between VKORC1-1693 and minor bleeding events in children treated with 
warfarin.   
The INR is used to monitor warfarin response.  It is essential to maintain the 
INR value within the targeted range to minimize the risk of either thromboembolism 
(caused by under-dosing) or haemorrhage (caused by over-dosing).  It has been 
suggested (Biss et al. 2011) that anticoagulation control in children receiving warfarin 
should be reported as the proportion (or percentage) of time in which INR 
measurement fell within the target range (PTTR).  Based on a PTTR of 0.49, we 
reported poor anticoagulation control among children in our cohort compared to 
control data observed in previous studies (Biss et al. 2012, Moreau et al. 2012). 
Our study corresponds with that of Moreau et al. (2012) with regard to the 
significant association between target INR and PTTR.  In their study, three pre-
specified INR ranges were used: 2.2 (for INR range 1.5-3.3), 2.5 (for INR range 1.8-
3.2) and 3.3 (for INR range 2.5-4).  Unlike Moreau et al. (2012) however, our study 
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showed that PTTR was also significantly associated with indication of warfarin 
treatment and VKORC1-1693 polymorphisms.  
Interestingly, the presence of mutant alleles in VKORC1-1693 was associated 
with a greater time spent in the target INR range (PTTR), with each additional variant 
allele associated with approximately 13% (95%CI 5% to 21%) more time spent in 
range in the first six months.  This finding conflicts with a previous study in children 
(Biss et al. 2013) and adults (Schwarz et al. 2008).  Schwarz et al. (2008) have shown 
that those who are homozygous for VKORC1-1693 variant alleles spent significantly 
more treatment time above their INR therapeutic range. A similar finding was 
observed in study by Biss et al (2013) in children (n=51) given warfarin during the 
first month of therapy but the findings were not significant.  However, Biss et al., 
(2013) found no association between the CYP2C9 (*2 and *3) and VKORC1-1693 
genotypes and the proportion of INR values above the target range beyond the first 
month of therapy.  This suggests that the adjustment of warfarin doses based on INR 
after the first month of therapy had counteracted the influence of the CYP2C9 (*2 and 
*3) and VKORC1-1693 genotypes.  A possible explanation of what was observed in 
our analysis is that as carriers of allele A (VKORC1-1693 variant allele) are more 
sensitive to warfarin and they reach the target INR in a shorter time, even though they 
possibly undergo over anti-coagulation, their INR was more frequently monitored by 
POCT thus leading to greater time spent in the target INR range. 
The current recommended dosing regimens for warfarin initiation in children 
are based solely on patients’ weight (Monagle et al. 2012).  Unfortunately, we had to 
exclude weight from our analysis because of the high volume of missing data.  
However, age and height were found to be highly correlated with weight and therefore 
we believe that omitting weight from our analysis will not unduly affect the quality of 
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our findings. The relationship of age, height and weight at stable dose in our cohort 
are illustrated in Figure 4-6. 
 
(A) 
 
(B) 
 
Figure 4-6.  Cohort relationship between (A) age and height and (B) age and weight at 
warfarin stable dose was achieved. 
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CYP2C9*2, CYP2C9*3 and VKORC1-1693 have been shown as important 
factors in predicting warfarin dose in previous studies (Biss et al. 2012, Moreau et al. 
2012).  As described in Table 4-1, the contribution of SNPs in these genes is similar 
to that explained in the adult population, approximately 38% (except for study by 
Nowak et al, the findings was not replicated due to small sample size) (Cooper et al. 
2008, Gage et al. 2008, Takeuchi et al. 2009).  However, this was not reflected in our 
analysis where these SNPs only explained 11.9% of variation in warfarin dose 
requirements.  One possible reason for this could be that when compared to the other 
two study groups, our cohort consisted of children of a much younger age.  54% of our 
study cohort was less than 6 years old when stable dose was reached compared to 23% 
in the cohort studied by Biss et al. (2012). Similarly, in the study by Moreau et al. 
(2012), the mean age was 8.4 years (± 5.6) while in this study, it  was 6.9 (± 4.5) years.   
There are two possible reasons for the proportion of  variability in dose 
requirements explained by CYP2C9*2 and VKORC1-1693 polymorphisms being 
lower in younger patients.  First, the accuracy of dosing taken by patients is 
questionable.  Children aged less than 6 years have difficulty in swallowing warfarin 
in tablet form, and thus warfarin is given by crushing the tablet or extemporaneously 
prepared by the pharmacist.  There is paucity of data to support the use of 
extemporaneously prepared suspensions of warfarin (Jackson and Lowey 2010); for 
example stability issues, uniformity of suspension which is critical for warfarin due to 
its narrow therapeutic range and interaction with packaging material.  In addition, the 
bitter taste of warfarin possibly caused young patients to spit or vomit the medicine, 
or refuse to take the medicine.  Second, the large variability in CYP2C9 protein 
expression (approximately 35=fold) in younger children, especially in children below 
the age of 1 year (Koukouritaki et al. 2004, Hines 2007) probably explains the low 
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contribution of these SNPs in our cohort, where 46% of children were below 1 year 
old.   
In our analysis, we found an association of CYP2C9*2 with INR above range 
within the first week therapy and an association between VKORC1-1693 and bleeding 
complication.  This was supported by recent studies by Biss et al. (Biss et al. 2013) as 
they found CYP2C9*2 and CYP2C9*3 allele carriers had higher mean INR during the 
first week of therapy compared to wild-type.  These findings provide the possibility to 
improve warfarin therapy in children because the most dangerous side-effect of 
warfarin is bleeding, and over-coagulation may lead to severe bleeding.  This finding 
could assist a physician in identifying patients who need extra-care when initiated on 
warfarin.  However, the findings need replication in a large external cohort. 
This is a retrospective cohort study.  Thus, even though all the data were 
recorded systematically from a single site, missing data cannot be avoided.  We 
intended to analyse the association as a longitudinal study, so that we could observe 
the contribution made by variables at different ages, but since we had insufficient data 
on these variables measured over time, this allowed us only to perform a cross sectional 
analysis.  
As studies have shown large variability in CYP2C9 protein expression in 
younger children, including patients from newborn to 18 years old as a single studied 
cohort is not an ideal study design to explore the CYP2C9 polymorphisms contribution 
to warfarin dose.  In addition, due to the limitations of our sample size, it was not 
possible to undertake the association analyses stratified by age. Medication adherence 
of the patients was also not assessed and was also beyond the control of the study team, 
firstly because medication was administered by family members as these patients are 
treated as out-patients and secondly because the data was collected retrospectively.  
This may explain a significant part of the unexplained variability, although the cohort 
  CHAPTER 4 
134 
 
was closely monitored through the POC testing system and regular education of the 
patients and their family was undertaken. 
We limited our cohort to Caucasian European children in the inclusion criteria, 
to minimise variability in effect caused by ethnic differences.  Consequently, our 
results may not equally apply to non-white and non-European populations.  Further, 
as a result of our small study samples, we did not identify any children with 
homozygous CYP2C9*3 and therefore the effect of homozygous CYP2C9*3 could not 
be evaluated in our analysis.  
In this chapter, we have replicated the association between VKORC1-1693 and 
CYP2C9*2 polymorphisms and paediatric warfarin dose requirements as seen in 
previous studies (Nowak-Göttl et al. 2010, Biss et al. 2012, Moreau et al. 2012).  Our 
study also provides new information on the contribution of these SNPs to variations in 
the proportion of time spent within therapeutic range, INR above range within 1 week 
of initial warfarin treatment and bleeding complications.  This evidence suggests that 
genetic knowledge could improve the management of warfarin in paediatric 
populations, but, further work is needed to replicate the study in a larger sample set, in 
particular with a view to stratify the analyses by age.  An alternative approach to 
achieving a larger sample size would be to organise an individual patient data (IPD) 
meta-analysis of ours and other similar datasets, and we will be investigating this 
possibility further. 
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5.1 Introduction 
In addition to VKORC1 and CYP2C9, other genetic factors have been 
previously reported to have influential effects on warfarin response in adults as 
discussed in Chapter 1 (section 1.9 and 1.10). These include genes involved in the 
pharmacokinetics and pharmacodynamics of warfarin such as CYP4F2, GGCX, Factor 
II, Factor VII, Factor X, EPHX1, CALU, and ABCB1 (Kristensen 2002, D'Ambrosio 
et al. 2004, Shikata et al. 2004, van der Heijden et al. 2004, Kohnke et al. 2005, 
Loebstein et al. 2005, Wadelius et al. 2005, Aquilante et al. 2006, Kimura et al. 2007, 
Loebstein et al. 2007, Caldwell et al. 2008, Kimmel et al. 2008, Borgiani et al. 2009, 
Takeuchi et al. 2009). 
In chapter 4, a candidate gene approach was used to investigate the response to 
warfarin treatment in children, focussing on genetic variants in two genes CYP2C9 
and VKORC1. For the outcome ‘proportion of time spent in INR range (PTTR)’, target 
INR together with warfarin indication and VKORC1 -1693 explained only ~21% 
variability. For warfarin stable dose, ~41.4% of dose variation was explained by age, 
target INR group, and SNPs in CYP2C9 and VKORC1. A large proportion of missing 
heritability remains to be accounted for, suggesting that other genetic factors might be 
involved in warfarin’s pharmacological effects in children.  Knowledge of additional 
polymorphisms with large effect sizes would be extremely valuable in improving the 
safety and efficacy of warfarin therapy specifically in this vulnerable population. 
Genome-wide association studies (GWASs) offer a powerful approach to gene 
function discovery and in understanding the genetic basis of drug response. To date, 
no GWAS has been reported in any paediatric population on warfarin treatment. 
Therefore, the aim of this chapter were to perform a GWAS in our cohort of children 
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prescribed warfarin, and investigate the association of genetic variation across the 
whole human genome with response to warfarin. 
5.2 Methods 
5.2.1 Patients and clinical outcomes 
The study design, patient recruitment and clinical outcome measures have 
previously been described in sections 4.2.1, 4.2.2, 4.2.3 and 4.2.6. 
5.2.2 Genome-wide genotyping 
Of the 100 paediatric patients recruited retrospectively, 1.5-2 µg (quantified by 
picogreen) DNA samples from 87 patients were shipped to ARK-Genomics (The 
Roslin Institute, University of Edinburgh) for genome-wide genotyping on the 
Illumina Human OmniExpressExome-8 v1.0 chip using the Infinium HD Super assay 
(Illumina, Inc.).  
Figure 5-1 summarises the principles and chemistry of genome-wide 
genotyping on the Illumina platform. In this system, whole-genome amplification is 
used to increase the amount of DNA up to 1000-fold.  The DNA is fragmented and 
captured on a BeadChip by hybridisation to immobilised SNP-specific primers, 
stopping one base before the locus of interest.  Marker specificity is conferred by 
enzymatic single-base extension where a fluorescently-labelled nucleotide is 
incorporated.  Subsequent dual-colour florescent staining allows the labelled 
nucleotide to be detected by Illumina’s iScan imaging system, which identifies both 
colour and signal intensity. 
Finally, 951,117 SNPs were mapped to NCBI Build 37 (hg19) using Illumina 
manifest file Human OmniExpressExome-8v1.0_B.bpm. Bead intensity data were 
processed and normalized for each sample in GenomeStudio Data Analysis Software 
(Illumina, Inc.). 
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Figure 5-1.  Outline of the Infinium HD assay chemistry for whole-genome genotyping. 
Five modular steps are involved. (i) DNA Amplification:  After denaturation and 
neutralisation, the DNA is isothermally amplified whereby whole-genome amplification 
uniformly increases the amount of DNA by several thousand-fold without introducing large 
amounts of amplification bias.  (ii) Fragmentation and precipitation: The amplified product 
is fragmented by a controlled enzymatic end-point fragmentation process to avoid over-
fragmenting the sample. Following isopropanol precipitation, the fragmented DNA is 
resuspended in hybridisation buffer. (iii) Hybridisation to BeadChip: The BeadChip is 
prepared for hybridization in a capillary flow-through chamber. During hybridisation, the 
amplified and fragmented DNA samples selectively anneal to locus-specific 50-mer probes, 
stopping one base before the interrogated marker. Unhybridised and non-specifically 
hybridised DNA is washed away.  (iv) Single base extension (SBE) and staining:  If there is a 
perfect match, extension occurs. Extension of the primer incorporates a biotin nucleotide 
or a dinitrophenyl-labelled nucleotide. C and G nucleotides are biotin-labelled (green); A 
and T nucleotides are dinitrophenyl labelled (red). Signal amplification of the incorporated 
label further improves the overall signal-to-noise ratio of the assay. (v) Array scanning and 
genotype calling:  The Illumina iScan scans the BeadChip by using a laser to excite the 
fluorophore of the single-base extension product on the beads, recording high-resolution 
images of light emitted from the fluorophores. The iScan Control Software then determines 
the intensity values for each bead type and creates data files for each SNP. 
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5.2.3 Data quality control 
 Quality control measures were undertaken using the open-source genome-wide 
analysis toolset PLINK, v1.07 (Purcell et al. 2007). 
Sample quality control: 
Subjects with genotyping success rate ≤ 95% (n = 3) were excluded from the 
dataset. Samples that showed gender inconsistencies (n = 2) were also removed. 
Cryptic relatedness was assessed by calculating identity by descent (IBD) and no 
kinship was detected. The ethnic origin of our samples was confirmed by principal-
component analysis (PCA) using the SNPRelate (Zheng et al. 2012) package in R. 
HumanOmniExpressExome-8 v1.0 chip data were merged with genotype information 
from four HapMap 2 populations (CEU, YRI, JPT, and CHB), and samples were 
identified as ethnic outliers on the basis of their projection onto the four principal 
components of genetic variation (Figure 5-2). Samples of non-European ancestry were 
removed (n = 4). In total, 78 subjects passed quality control. 
SNP quality control: 
 SNPs were excluded from downstream analysis if they were monomorphic (n 
= 18), had a MAF < 0.01 (n = 286,940), a HWE P-value < 0.0001 (n = 10,656) or a 
missing call rate ≥ 5% (n = 27,738). A total of 625, 765 SNPs passed quality control. 
 
5.2.4 Imputation 
 Prior to imputation using the reference genotype data from the 1000 Genomes 
project (Phase I integrated variant set release v3, NCBI build 37 (hg19))(Altshuler et 
al. 2010), SNP alignment was undertaken. All SNPs with mismatched alleles (n = 
125), those not present in the 1000 Genomes project (n = 1,475) and those that gave 
A>T or G>C or vice versa (n = 5,715) were excluded from the dataset. Haplotype 
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inference was then carried out by phasing our genotype data (n = 618,450) using the 
software SHAPEIT v2.r644 (Delaneau et al. 2013). Imputation of additional SNPs on 
chromosomes 1 to 22 throughout the whole genome was performed using the freely 
available program IMPUTE v2.3.0 (Howie et al. 2009). A total of 38,042,669 SNPs 
were imputed. Using a command line utility program, QCTOOL, imputed variants 
with low imputation quality (r2 < 0.8), MAF < 1% and HWE P-value < 0.0001 were 
excluded and 7,775,788 SNPs remained for analysis.  All the imputation processes 
were undertaken by Dr Eunice Zhang, a post-doctoral research associate in our 
research team. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2.  Principal-component analysis of subjects in our study. CEU = HapMap 
Caucasians (n=90); CHB = HapMap Han Chinese (n=45); JPT = Hapmap Japanese (n=45); YRI 
= HapMap Yoruban (n=90); WAP = Retrospectively recruited children on current or previous 
warfarin therapy (n = 87). Blue circles enclosed in purple triangles represent ethnic outliers 
(n = 4). 
 
 
Ethnic outliers 
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5.2.5 Statistical analysis 
Statistical analyses were conducted in SPSS v21 or in PLINK, v1.07. Clinical 
variables with P-value < 0.05 were included as covariates in the regression models. 
Using an additive model, the linear regression was employed to test for SNP 
associations with continuous outcomes (proportion of time in which INR 
measurements fell within the target range within the first six months, and stable dose) 
while the logistic regression was utilised for binary outcomes (INR exceeding the 
target range within first week of treatment, and haemorrhagic complications). SNP 
showing a P-value < 5 x 10-8 was regarded as genome-wide significant. A threshold 
P-value < 1 × 10−5 was suggestive of genome-wide significance. Manhattan plots were 
generated using the freely available high-performance visualization tool Integrative 
Genomics Viewer (IGV) (Robinson et al. 2011, Thorvaldsdóttir et al. 2013). The open-
source web-based plotting tool, LocusZoom, was used for regional visualisation of 
genome-wide results (Pruim et al. 2010).  The statistical analyses (in PLINK), 
manhattan and regional plots were performed and generated by Dr Eunice Zhang. 
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5.3 Results 
5.3.1 Patient characteristics 
Of the 78 patients who remained after genome-wide genotyping quality 
control, insufficient clinical data was available for one patient and was therefore 
excluded from further analysis. The demographics of the remaining 77 paediatrics are 
summarised in Table 5-1 and Table 5-2.  All patients were Caucasians with Fontan 
procedure being the most common indication for warfarin therapy. Out of the 77 
patients included in the analysis, 66 (86%) achieved stable dose during the course of 
follow-up and 53 (68.8%) experienced a haemorrhagic complication. Complete data 
on proportion of time in which INR measurements fell within the target range (PTTR) 
within the first six months were available for 72 patients (93.5%). INR measurements 
during the first week of warfarin therapy were unavailable for 8 patients.  Hence of the 
remaining 71 patients, 31 (40.3%) had INR values exceeding the target range within 
first week of treatment. 
Table 5-1.  Indication of warfarin treatment 
Indication of warfarin treatment Number of 
patients (%) 
Surgery for  
congenital 
heart disease 
Fontan procedure 51 (66.2) 
Other cardiac procedures: (e.g. Mitral valve 
replacement, post shunt, modified Norwood procedure) 
19 (24.7) 
Non-cardiac 
patients 
Pulmonary embolism  1(1.3) 
Prophylaxis of line/catheter clotting or post-surgery 5 (6.5) 
Factor V Leiden Syndrome 1 (1.3) 
 
Table 5-2.  Patients’ characteristics at the start of warfarin therapy and at the time stable 
11 patients did not achieve stable dose during follow-up 
Variable Start of therapy (n=77) Time of stable dose (n=66)* 
Mean SD Missing Mean SD Missing 
Age (years) 4.16 4.21 0 7.54 4.70 0 
Height (m) 0.96 0.29 20 1.09 0.29 31 
Weight (kg) 16.86 16.24 10 22.43 17.05 27 
Albumin (g.L-1) 38.38 5.72 27 39.67 6.44 48 
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5.3.2 Univariate analysis of association between clinical variables and 
outcomes 
Table 5-3 summarises the tests of association results from the univariate 
analyses of clinical variables with each outcome. For PTTR within the first six months, 
INR group was the only clinical variable that gave a p-value < 0.05 and was included 
as a covariate in subsequent regression analysis. For the outcome warfarin stable dose, 
age at time of dose stability showed a significant association (p = 2.7 x 10-5) and was 
accounted for in the GWAS regression analysis. No clinical variables were found 
significant for outcome INR values exceeding the target range within first week of 
treatment. 
 
Table 5-3.  p-values from tests of association of non-genetic variables with outcome 
measures 
Variables p-value 
Proportion of time INR 
within target range in 1st 6 
months 
Stable 
dose¥ 
(mg/day) 
INR exceeding 
target range in week 
1 
Age 0.257 2.7 x 10-
5* 
0.376 
Height 0.329 - 0.517 
Weight 0.451 - 0.580 
Albumin 0.665 - 0.919 
Gender 0.120 0.547 0.476 
INR group 0.010* 0.26 0.744 
Indication (2 groups)** 0.121 0.288 0.912 
Indication (3 
groups)*** 
0.235 0.571 0.493 
*Included as covariate in GWAS regression analysis. 
**Indication (2 groups):  Patients were divided into non-Fontan and Fontan group. 
***Indication (3 groups): Patients were divided into non-Fontan cardiac, Fontan cardiac and 
non-cardiac group. 
¥ log10 stable dose transformation. 
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5.3.3 Genome-wide association analysis 
Proportion of time in which INR measurements fell within the target range (PTTR) 
within the first six months 
GWAS for the outcome PTTR within the first six months identified two 
genome-wide significant variants in chromosome 5q31.1 (Figure 5.3). One was an 
imputed SNP rs13167496 and the other a genotyped SNP rs6882472 (Figure 5.4A; p 
= 1.12 x 10-8). These two SNPs are 985bp away from each other and are in complete 
LD (r2=1, D’=1). rs13167496 and rs6882472 are located in an intergenic region ~34kb 
upstream of the gene which encodes for TRAF-Interacting Protein With Forkhead-
Associated Domain, Family Member B (TIFAB). Carriers of the mutant allele for 
rs13167496 or rs6882472 were significantly associated with decreased time spent 
within target INR range (PTTR: homozygous wild-type = 0.58 ± 0.23, heterozygous = 
0.05 ± 0.16). Since rs13167496 tags for rs6882472, their association results were 
exactly the same. Therefore, only results for rs13167496 were reported in Figure 5.5A. 
SNPs with p < 10−5 were observed in several other regions. These included a 
region on chromosome 8q11.23 as well as a region on chromosome 9q33.3. The most 
significant SNP on chromosome 8q11.23 was rs4873646 (p=5.3 × 10−7; Figure 5.4B) 
located ~6.7kb from the 5’ end of the transcription factor Suppression of 
tumorigenicity 18 (ST18). Carriers of the minor A-allele for rs4873646 showed 
increased time spent within therapeutic INR (PTTR: TT = 0.32 ± 0.20, AT = 0.51 ± 
0.25, AA = 0.7 ± 0.21; Figure 5.5B). On chromosome 9q33.3, rs4838313 was the most 
significant genetic variant (P=1.6 × 10−6; Figure 5.4C) and is located 63kb from the 3’ 
end of Pre-B-Cell Leukemia Homeobox 3 (PBX3). In contrast to rs4873646 on 
chromosome 8q11.23, carriers of the minor A-allele for rs4838313 exhibited 
decreased time spent within therapeutic INR (PTTR: GG = 0.66 ± 0.19, AG = 0.43 ± 
0.27, AA = 0.05 ± 0.24; Figure 5.5C). 
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Warfarin stable dose 
For warfarin stable dose, although no SNPs attained genome-wide 
significance, a cluster of 4 SNPs on chromosome 10p14 had p < 10−5 (Figure 5.6). 
However, within this cluster, all 4 SNPs were imputed (rs71483712; P=3.4×10−7, 
rs80049351; P=4.4×10−7, rs116905303; P=5.7 × 10−7, rs78428882; P=9.9 × 10−6) and 
none of these SNPs are located in any genes (Figure 5.7). Interestingly for all these 4 
SNPs, heterozygote patients carrying the minor allele required lower warfarin stable 
doses compared to patients homozygous for the major allele. Given that the association 
results for these 4 SNPs were very similar, only results for rs71483712 (the most 
significant SNP on chromosomal region 10p14) were reported in Figure 5.8. Subjects 
homozygous for the rs71483712 major T-allele required ~1.7mg more of warfarin per 
day than heterozygous carriers (mg/week: TT = 2.71 ± 1.55, CT = 1 ± 0.54; Figure 
5.8). In addition, rs71483712 was found to account for ~21% of warfarin dose 
variability after adjusting for stable age (the only significant covariate observed during 
univariate analysis) in our multiple regression model.  
 
INR values exceeding the target range within first week of treatment and 
Haemorrhagic complications 
None of the SNPs achieved p<10−5 for outcomes INR values exceeding the 
target range within first week of treatment and haemorrhagic complications. 
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Figure 5-3.  Genome-wide Manhattan plot showing the proportion of time in which INR measurements fell within the target range (PTTR) within the first six 
months in our cohort of warfarin-treated children. INR group was included as a covariate. Individual –log10 P values are plotted against their genomic position by 
chromosome. The red solid line at 5x10−8 marks the genome-wide significance threshold and the dotted line at 10−5 marks the threshold for promising SNPs. 
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Figure 5-4.  Regional association plots and recombination rates for the proportion of time in 
which INR measurements fell within the target range within the first six months in our 
cohort of warfarin-treated children. (A) Chromosome 5q31.1. (B) Chromosome 8q11.23. (C) 
Chromosome 9q33.3. Each coloured circle represents a SNP P value, with the colour scale 
reflecting the extent of LD (r2) with the target SNP (purple diamond). Genetic recombination 
rates (cM/Mb), estimated using HapMap CEU samples, are shown with a light blue line. 
Physical positions are based on build 37 (NCBI) of the human genome. Also shown are the 
relative positions of genes mapping to the region of association. 
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Figure 5-5.  Box and whisker plots showing the proportion of time in which INR 
measurements fell within the target range within the first six months (PTTR) based on 
genotype groups in (A) rs13167496, (B) rs4873646 and (C) rs4838313. Boxes represent 25th-
75th percentiles of PTTR, whiskers represent 5th-95th percentiles, solid lines represent median 
PTTR in each group, and open dots represent outliers. 
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Figure 5-6.  Genome-wide Manhattan plot showing warfarin stable dose in our cohort of warfarin-treated children.  Age at stable dose was included as a 
covariate. Individual –log10 P values are plotted against their genomic position by chromosome. The dotted line at 10−5 marks the threshold for promising SNPs. 
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Figure 5-7.  Regional association plots and recombination rates on chromosome 10p14 for 
warfarin stable dose in our cohort of warfarin-treated children. Each coloured circle 
represents a SNP P value, with the colour scale reflecting the extent of LD (r2) with the 
target SNP (purple diamond). Genetic recombination rates (cM/Mb), estimated using 
HapMap CEU samples, are shown with a light blue line. Physical positions are based on 
build 37 (NCBI) of the human genome. Also shown are the relative positions of genes 
mapping to the region of association. 
 
 
 
 
 
 
 
 
 
Figure 5-8.  Box and whisker plots showing the distribution of stable warfarin daily doses 
based on genotype groups in rs71483712.  Boxes represent 25th-75th percentiles of PTTR, 
whiskers represent 5th-95th percentiles, solid lines represent median stable warfarin dose in 
each group, and open dots represent outliers. 
 
 
 
 
 
n:               69                                        6    
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5.4 Discussion 
To date, we are the first to report a GWAS in a paediatric population on 
warfarin treatment. Two genetic variants on chromosomal region 5q31.1, rs13167496 
and rs6882472, reached genome-wide significance and were associated with ~50% 
reduction in PTTR during the first six months of warfarin therapy. These two SNPs 
are in complete LD with each other and are located ~34kb 5’ of TIFAB. TIFAB is a 
protein-coding gene which associates with TRAF-Interacting protein with Forkhead-
Associated domain (TIFA) and inhibits TIFA-mediated activation of the transcription 
factor, NF-κB (Matsumura et al. 2004). Studies have shown that NF-κB mediates the 
expression of tissue factor (TF) and factor VIII (Mackman et al. 1991, Figueiredo and 
Brownlee 1995), which activate the extrinsic and intrinsic coagulation pathways, 
leading to thrombin generation and coagulation (Song et al. 2009). Thrombin produced 
during coagulation activates NF-κB–dependent genes, forming a positive feedback 
loop that further amplifies coagulation (Anrather et al. 1997). NF-κB has also been 
reported to mediate type 1 plasminogen-activator inhibitor (PAI-1) expression, where 
an increased level of PAI-1 impairs fibrinolysis, promoting coagulation (Hou et al. 
2004). Therefore, the suppression of NF-κB by TIFAB may lead to reduced 
coagulation, resulting in decreased proportion of time where patients were adequately 
protected against thromboembolism or bleeding complications. 
We have also identified two other SNPs, rs4873646 and rs4838313, which 
showed association with PTTR during the first six months of warfarin therapy at 
significance levels of P < 10−5. rs4873646 was associated with increased PTTR and is 
located ~6.7kb upstream of ST18 on chromosomal region 8q11.23. ST18 has been 
reported to play an important role in regulating the mRNA levels of proapoptotic and 
proinflammatory genes (e.g. TNF-α, IL-1α, IL-6) and when overexpressed, ST18 
significantly enhances apoptosis (Yang et al. 2008) but its relation to the coagulation 
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pathway is unknown. Conversely, rs4838313 on chromosome 9q33.3 (~63kb 
downstream of PBX3) was associated with decreased PTTR. PBX3 is one member of 
a group of PBX transcription factors belonging to the TALE (3 amino acid loop 
extension) homeobox gene family. They seem to play important developmental roles 
in cancers, particularly of hematolymphoid origin (Ho et al. 2013, Li et al. 2013), but 
its role in coagulation is not known. 
Although no SNPs attained genome-wide significance with warfarin stable 
dose, results from our preliminary multiple regression model showed that the most 
significant SNP located on chromosome 10p14 (rs71483712) explained ~21% of 
warfarin dose variability. Given that rs71483712 is an imputed SNP, genotyping will 
need to be performed to ensure that this association result was not an imputation 
artefact. 
Albeit none of the usual suspects CYP2C9*2, CYP2C9*3 and VKORC1-1639 
showed genome-wide significance for any of the clinical outcomes tested, but 
statistically significant associations between warfarin stable dose and CYP2C9*2 (P = 
0.0026) and VKORC1-1639 (P = 7.9 x 10-5) were observed (confirms results reported 
in Chapter 4). Our small sample size may be underpowered to detect genome-wide 
significant differences for the numerous polymorphisms tested. 
Despite our small sample size, our findings implicate that other genetic factors 
may possibly be involved in warfarin clinical outcomes. However, this must be 
interpreted with caution, and these results need to be validated in a replication cohort.  
In addition, to gain further insight into the biologic networks underlying the 
different warfarin outcomes in children, genes and pathway analyses will need to be 
performed as potential combined effects of SNPs contributing to warfarin clinical 
outcomes may be missed through conventional single marker association. 
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6.1 Introduction 
In response to the accumulating evidence of the importance of genotyping in 
guiding warfarin dosing, the FDA has updated the warfarin label stating that genetic 
information may improve estimation of warfarin dosing (Thompson 2007).  Recently 
a survey conducted by the Clinical Pharmacogenetics Implementation Consortium 
(CPIC) among members of the American Society for Clinical Pharmacology and 
Therapeutics has shown that two of the highest ranked gene drug/pairs, based on the 
perceived importance of the data linking the drug to the gene variation, are 
CYP2C9/warfarin and VKORC1/warfarin (Relling and Klein 2011).  Despite a CPIC 
rating of level A (strong evidence) for a recommendation of warfarin dosing based on 
patients’ genotypes (Johnson et al. 2011), the genetic dosing of warfarin has not yet 
been implemented.  In contrast, the American College of Chest Physicians 
recommends against routine pharmacogenetic testing (grade 1B) because of the lack 
of randomized evidence that it improves clinical end points or that it is cost effective 
(Holbrook et al. 2012).   
The translation of warfarin pharmacogenetics into clinical practice has been 
slow because no large randomized controlled trial has been published that has 
evaluated clinical outcomes of warfarin dosing based on pharmacogenetic testing.  As 
a result, several clinical trials are currently in progress, including the European 
Pharmacogenetic of Anticoagulant Therapy (EU-PACT) trial.  The EU-PACT trial is 
a prospective randomised controlled trial to assess the safety and clinical utility of 
genotyped-guided dosing of the three main coumarins used in Europe: acenocoumarol, 
phenprocoumon and warfarin (Van Schie et al. 2009).  This trial aimed to include 3000 
patients with atrial fibrillation or venous thromboembolism recruited across 7 
European countries: UK, Sweden, the Netherlands, Spain, Greece, Germany and 
  CHAPTER 6 
158 
 
Australia.  Patients were randomised to either genotyping-guided dosing (intervention 
arm) or to standard dosing (control arm).  Patients in the intervention arm were 
genotyped for CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057919) and VKORC1-1693 
(rs9923231) prior to initiation of treatment.  They were given a three day loading dose 
based on the IWPC pharmacogenetic maintenance dose algorithm (Klein et al. 2009) 
and the predicted elimination half-life of warfarin for each CYP2C9 genotype 
(Hamberg et al. 2010).  After the first three days of therapy, patients were dosed 
according to a modified version of a pharmacogenetic warfarin dose algorithm 
(Lenzini et al. 2010).   
The other important barrier to implementing testing is the non-availability of a 
rapid genotyping platform with properties such as accuracy, testing at point of care 
and a good turn-around time so that patients’ dosing can be based on the genotyping 
results.  A range of genotyping assays for detecting CYP2C9 and VKORC1 
polymorphisms related to warfarin response have been published previously, including 
PCR-restriction fragment length polymorphism (RFLP) analysis (Sconce et al. 2005), 
pyrosequencing (King et al. 2008), Invader assays (Burmester et al. 2011) and several 
fluorescence based real time PCR methods (Verstuyft et al. 2003, Hatch et al. 2006, 
Lefferts et al. 2010).  At the time of writing of this thesis, seven platforms for 
CYP2C9/VKORC1 genotyping have been approved by the FDA as described in Table 
6.1.  In general, studies comparing the validity of the various methods have shown 
very high levels of accuracy and good agreement across platforms (King et al. 2008, 
Joshi et al. 2009, Lefferts et al. 2010).  However, all the available technologies require 
initial DNA extraction from blood and the process takes more than two hours to obtain 
genotype results. 
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Table 6.1.  Platform for CYP2C9/VKORC1 genotyping approved by FDA. 
Test Name/ Manufacturer Properties 
Test name:  eSensor Warfarin 
Sensitivity Saliva Test 
Manufacturer: GenMark 
Diagnostics 
 Requires DNA extraction using ethanol 
precipitation 
 HOT approximately 40 minutes (product flyers) 
 TAT approximately 3.5 hours (product flyers) 
Test name:  eQ-PCR LC Warfarin 
Genotyping kit (requires Roche 
LightCycler) 
Manufacturer: TrimGen 
Corporation 
 
 Requires DNA extraction  
 Test time approximately 2 hours including DNA 
extraction (product flyer)  
Test name:  eSensor Warfarin 
Sensitivity Test and XT-8 
Instrument 
Manufacturer: Osmetech 
Molecular Diagnostics 
 Requires DNA extraction 
 HOT approximately 14 minutes per sample 
(Maurice et al. 2010) 
 TAT approximately  3-4 hours per sample (Joshi 
et al. 2009, Maurice et al. 2010) 
 A simple, touch-screen user interface, easy-to-
interpret, customizable reports, and no routine 
maintenance or instrument calibration required 
Test name:  INFINITI 2C9 & 
VKORC1 Multiplex Assay for 
Warfarin (requires Autogenomic 
INFINITY Analyzer) 
Manufacturer: AutoGenomics, Inc. 
 
 Requires DNA extraction 
 TAT approximately 6-8 hours (King et al. 2008, 
Joshi et al. 2009) 
 
Test name:  Gentris Rapid 
Genotyping Assay - CYP2C9 & 
VKORCI (requires Cepheid Smart 
Cycler Dx) 
Manufacturer: ParagonDx, LLC 
 
 Requires DNA extraction 
 TAT approximately 4 hours (Babic et al. 2009) 
 Technically complex method compared to 
eSensor Warfarin Sensitivity Test and XT-8 
Instrument or INFINITI 2C9 & VKORC1 Multiplex 
Assay for Warfarin (Babic et al. 2009) 
Test name:  Verigene Warfarin 
Metabolism Nucleic Acid Test and 
Verigene System 
Manufacturer:  Nanosphere, Inc. 
 Requires DNA extraction and high DNA 
concentration 
 HOT approximately 2 minutes per sample 
(Maurice et al. 2010) 
 TAT approximately 1.7 hours per sample 
(Maurice et al. 2010) 
Turn-around time (TAT) was calculated as the time from computer data entry to final 
results. 
Hands on time (HOT) = manual steps involved, i.e. computer data entry, reagent and 
sample preparation, pipetting and plate handling. 
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Genotyping using HyBeacon® probes on the prototype Genie I PCR 
instrument is a new rapid point of care test (POCT) for determining CYP2C9*2 
(rs1799853), CYP2C9*3 (rs1057910) and VKORC1 -1639G>A (rs9923231) 
genotypes in the EU-PACT trial.  The Genie 1 PCR instrument and the HyBeacon® 
assays were developed by the British company LGC (Teddington, Middlesex).  It 
provides genotype results for the three SNPs within 1.5 hours to enable initial warfarin 
dosing based on individual genetic make-up.  In addition, the procedure is simple 
because genotyping is performed directly from whole blood. 
Therefore, the aim of this study was to validate the performance of this novel 
HyBeacon® POCT on the Genie I PCR instrument and to compare the accuracy of 
CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057919) and VKORC1-1693 (rs9923231) 
genotypes to data obtained using TaqMan® allelic discrimination assays on an ABI 
7900HT Real-Time PCR system (Applied Biosystems).  
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6.2 Method  
6.2.1 Sample recruitment 
A total of 278 patients were recruited from the Royal Liverpool University 
Hospital NHS Trust (RLUHT) and the St Helens and Knowsley Teaching Hospital 
NHS Trust (SKTHT) for the EU-PACT study. The latter NHS Trust covers two sites, 
which were both used for the study: Whiston Hospital and St Helens Hospital. A 
minimum of 9mL EDTA-blood was collected from all patients.  Patient recruitment 
started in 2010 and ended in February 2013.  Out of the total recruitment, 135 patients 
(95 patients from the RLUHT and 40 patients from SKTHT) were randomized into the 
genotype-guided dosing arm.  Genotyping for CYP2C9*2, CYP2C9*3 and VKORC1-
1693 was performed using the Genie 1 PCR instrument prior to initiating warfarin 
dosing.  Genie genotyping was carried out by a laboratory research staffs at the 
University of Liverpool or by nurses at the St Helens & Knowsley Teaching Hospital 
NHS Trust. 
 
 
 
 
 
 
 
 
 
 
  CHAPTER 6 
162 
 
6.2.2 Genotyping CYP2C9*2, CYP2C9*3 and VKORC1 SNPs by 
HyBeacon® POCT on the Genie 1 instrument. 
For patients who were randomized to the genotype-guided arm, genotyping 
was performed on the Genie 1 PCR platform immediately after whole blood samples 
were received.  Details of primers used are listed in Table 6.2.   
Table 6.2.  Primers for point of care genotyping. 
Assay Primer Name Primer sequence 5’  3’ 
CYP2C9*2 
 
C9*2CF3 CCTCCTAGTTTCGTTTCTCTTCCTGTTAGGAATT 
C9*2CR4 GTAGAGAAGATAGTAGTCCAGTAAGGTCAGTGATATG 
CYP2C9*3 
 
C9*3F2 TGCATGCAAGACAGGAGCCACAT 
C9*3R2 GGAGAAACAAACTTACCTTGGXAATGAGA 
X = Inosine 
VKORC1 
For blood only 
VKOF2 GGAGCCAGCAGGAGAGGGAAATA 
VKOR3 CGGCCTCCCAAAATGCTAGGATT 
VKORC1 
For DNA only 
VKOF3 CAG AAG GGT AGG TGC AAC AGT AAG GGA TCC 
VKOR4 CTG ACC TCA AGT GAT CCA CCC ACC TCG 
(Adapted from Howard et al., 2011) 
A novel HyBeacon® probe technology was used to detect and identify 
CYP2C9*2, CYP2C9*3 and VKORC1-1639 (Howard et al. 2011).  HyBeacon® probes 
comprise of fluorescent dye labels (fluorophore) attached to the internal position of the 
oligonucleotide and a 3’phosphate (PCR blocker) to prevent PCR extension from 
probes (French et al. 2001).  The probes emit greater amounts of fluorescence when 
bound to complementary target DNA sequences than when the probes are single 
stranded (Figure 6-1).  The quantity change in fluorescence emission occurs as a direct 
result of target hybridization and therefore permits the detection and discrimination of 
sequences by melting curve analysis on the Genie 1 PCR instrument.  Details of probes 
used are provided in Table 6.3. 
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Figure 6-1.  Structure of HyBeacon® probe and the method of target detection. HyBeacon 
probes are single-stranded fluorescence labeled probes complementary to the target DNA 
sequences.  In unhybridised condition, the fluorophore on the HyBeacon probe cannot 
emit fluorescence.  When bound to complementary target DNA sequences, excitation and 
fluouresence emission occurs, allowing the detection of target sequences. 
 
Table 6.3.  Probes for point of care genotyping. 
Assay Probe Name Probe sequence 5’ 3’ 
CYP2C9*2 C9*2C2 2GCATFGAGGACCGFGTTCAAG3 
CYP2C9*3 2C9*3C5 2TCCAGAGATACCTFGACCTFCTCCC3 
VKORC1 VKORC1 2CATFGGCCAGGFGCGGT3 
F = FLUOROSCEIN dT   2= Trimethoxystilbene   3 = PHOSPHATE 
 
All genotyping assays, PCR reagents and lysis buffer were supplied by LGC 
(Teddington, UK).  The PCR mastermix was pre-prepared in strips of 8 low profile 0.2 
ml tubes, where each assays was prepared in 17 µl reaction containing 0.7 µl 
HemoKlen Taq in 1 X HemoKlen buffer (New England Biolabs), 0.2 mM dNTP (New 
England Biolabs), 0.1 µM forward primer, 10 µM reverse primer and 0.2 µM 
HyBeacon® probe. The first three tubes (tubes 1 to 3) were the diagnostic PCR master 
mixes for CYP2C9*2, CYP2C9*3 and VKORC1-1693.  The next three tubes were 
control assays (tubes 4 to 6), which included 1.5 ng DNA from known heterozygote 
for each SNP, and the last two tubes (tubes 7 and 8) were template controls that did 
not contain any DNA.  Prior to use, the strips were stored at -20°C in the dark.  
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The genotyping process is illustrated in Figure 6-2.  To genotype an individual 
for CYP2C9*2, CYP2C9*3 and VKORC1 -1693, a mastermix strip was thawed.  5 µl 
of blood was mixed with 100 µl of lysis buffer A containing 0.32 M sucrose in 10 mM 
Tris-HCL pH 7.4 and 1% (v/v) Triton X-100 in a sterile microfuge tube. The mixture 
of blood and Buffer A was pipetted up and down to ensure a good mix and then left 
for 5 minutes at room temperature before use.  1 µl of the diluted blood was then 
transferred into each of the first three tubes (tubes 1 to 3) containing diagnostic PCR 
master mixes for CYP2C9*2, CYP2C9*3 and VKORC1-1693.  PCR amplification was 
performed in the Genie 1 PCR instrument (Optigene Ltd).  Thermocyling was carried 
out with an initial step of 95°C for 4 min followed by 50 cycles of 95°C for 3 s and 
64°C for 1 min, using a 5°C/s ramp rate.  Following amplification, results were 
obtained by performing melting curve analysis from 40°C to 75°C at a ramp rate of 
0.1°C/s and fluorescence changes were measured as the HyBeacon® probe dissociates 
from the amplified target DNA were measured.  Analysis of the fluorescence 
derivative profile was performed on a PC connected to the Genie 1 instrument using 
software developed for this purpose by Optigene Ltd.   
 
  CHAPTER 6 
165 
 
 
Figure 6-2.  Genotyping procedure on  the Genie I HyBeacon®. (A) First, 5 µl of blood was 
mixed with 100 µl of buffer A. Five minutes were allowed for the mixture to complete the 
lysis process. (B) Then 1 µl of diluted blood was added to the 3 diagnostic PCR tubes (1 to 
3).  Before placing the tubes into the machine, the tubes were gently flicked to ensure that 
all of the liquid fell to the bottom of the tubes. (C) PCR was performed on Genie 1 PCR 
instrument. (D)The analysis of the fluorescence derivative profile was performed on a PC 
connected to the Genie 1 instrument using software developed for this purpose by 
Optigene Ltd.  Concordances of melting peak profiles with result read out were checked.  A 
clear picture of melting peak profile was shown in figure 6.3. 
 
  CHAPTER 6 
166 
 
The typical melting temperature ranges for each assay are shown in Table 6.4.  
Homozygous samples generate single melt peaks, which are matched or mismatched 
depending on the identity of target sequences.  On the other hand, heterozygous 
samples produce melting traces possessing both matched and mismatched peaks.  The 
genotype results were considered valid if (i) the melting temperature peak fell within 
the specified  range for each assay, (ii) the melting peak profiles were concordant with 
that in the result read-out, (iii) positive controls showed heterozygous genotypes and 
(iv) no peaks in the negative controls were detected.  An example of a valid result is 
shown in Figure 6-3.   
 
Table 6.4.  The temperature ranges for each assay peak to determine genotype call. 
Assay Match (wild-
type) Tm (°C) 
MisMatch (variant) Tm 
(°C) 
Heterozygous Tm (°C) 
CYP2C9*2 58.9 - 60.4  50.9 - 52.2 50.9 - 52.2; 58.9 - 60.4 
CYP2C9*3 61.4 - 65.1 54.9 - 58.1 54.9 - 58.1 ;61.4 - 65.1 
VKORC1 48.5 - 50.2 57.0 - 59.7 48.5 - 50.2 ;57.0 - 59.7 
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Figure 6-3.  Example of a valid melting peak profile. Based on the melting peak profiles (A), 
the CYP2C9*2, CYP2C9*3 and VKORC1-1693 genotypes for the sample were *1*2 
(heterozygous); *1*1(homozygous wild-type) and AG (heterozygous), respectively.  All melt 
peaks were in the relevant range, the positive controls showed heterozygous genotypes 
and no peaks were detected in the negative controls.  The summary genotype result read-
out (B) confirms the detection of the peaks in all 8 tubes. 
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6.2.3  Genotype validation of CYP2C9*2, CYP2C9*3 and VKORC1-1693 
by Taqman® Allelic Discrimination 
To validate the performance reliability of HyBeacon® genotyping on the Genie 
I instrument, DNA from all 135 patients were extracted using the chemagic module 
(as described in section 2.2.3).  The DNA were genotyped via real-time Taqman® 
Allelic Discrimination (as described in section 2.2.4).  The genotypes results from the 
two different platforms were compared.  The Taqman® genotyping method was 
chosen because it has previously been validated with results from DNA sequencing 
(Carlquist et al. 2008, Joshi et al. 2009, Lefferts et al. 2010).   
6.2.4 Statistical analysis 
To test the reliability of the genotype results from the Genie I HyBeacon and 
ABI 7900HT Real-Time Taqman, the exact agreement and kappa (κ) statistics were 
calculated.  Kappa statistic is thought to be a more robust measure than simple percent 
agreement calculation since κ takes into account the agreement occurring by chance.  
Guidelines by Landis and Koch (1977) were used to evaluate simple and weighted 
kappa statistics: 0.00 to 0.20, poor agreement; 0.21 to 0.40, fair; 0.41 to 0.60, 
moderate; 0.61 to 0.80, good; and 0.81 to 1.00, almost perfect agreement. An example 
of the calculations is shown below:  
Example of result table: 
Genie ABI Taqman® Total 
Wild-Type Heterozygous Homozygous 
Wild-Type 65 3 2 70 
Heterozygous 4 10 6 20 
Homozygous 1 2 7 10 
Total 70 15 15 100 
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Example of calculation: 
1) Exact agreement (%) 
   =65 + 10 +7 =82 out of 100 rating (82%) 
2) Kappa (κ) 
   = proportion in agreement - proportion expected to agree by chance  
1- proportion expected to agree just by chance 
where:  
(a)Proportion in agreement= proportion of exact agreement= 82/100=0.82 
(b)Proportion expected to agree just by chance = 
= Probabilities* (genotype wild-type) + Probabilities* (genotype heterozygous) + 
Probabilities* (genotype homozygous variant)  
    = (70/100x70/100) + (20/100x15/100)+ (10/100x15/100) = 0.535 
*probabilities of both platform 
Therefore,  
kappa (κ)  = (0.82-0.535)/(1-0.535) = 0.61 
 
In addition, we evaluated the speed performance of the Genie I HyBeacon ® 
and ABI 7900HT Real-Time Taqman®  platforms by evaluating hands-on and turn-
around times.  The percentage of results which gave successful genotypes the first-
time were calculated because failure to produce perfect results in the first-time test will 
contribute to longer turn-around time.  Of the samples which gave successful 
genotypes during the first test, 50% (n=55) of samples were selected randomly and 
retested to investigate the reproducibility of the Genie I HyBeacon ® platform. 
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6.3 Results 
A total of 135 samples were genotyped for CYP2C9*2 (Table 6.5), CYP2C9*3 
(Table 6.6) and VKORC1-1693 (Table 6.7) by each method.  Kappa statistic showed 
strong agreement between Genie I HyBeacon® and ABI Taqman® platforms.  The 
lowest kappa value was obtained when testing the VKORC1-1693 genotype (κ=0.98), 
where two samples were discordantly genotyped by these platforms: “AG” was the 
genotype by ABI Taqman® and “AA” by Genie I HyBeacon®.  This is due to the low 
sensitivity of the VKORC1 HyBeacon® assay to detect the two heterozygous alleles 
in VKORC1-1693.  The peak for G allele (melting peak at~40-50 °C) is very small 
(Figure 6-4), therefore the heterozygosity of the VKORC1-1693 genotype was not 
detected by the software.  Furthermore, this small peak could not be spotted by eye 
due to the overlapping peaks from other assays (CYP2C9*2 and CYP2C9*3 assays). 
Table 6.5.  CYP2C9*2 genotype comparison between the Genie I HyBeacon® and ABI 
Taqman® genotyping methods. 
Genie ABI Taqman® Total 
Wild-Type Heterozygous Homozygous 
Wild-Type 98 0 0 98 
Heterozygous 0 35 0 35 
Homozygous 0 0 2 3 
Total 98 35 2 135 
Exact agreement: 100%          Kappa: 1 (95% CI 1-1) 
 
Table 6.6.  CYP2C9*3 genotype comparison between the Genie I HyBeacon® and ABI 
Taqman® genotyping methods. 
Genie ABI Taqman® Total 
Wild-Type Heterozygous Homozygous 
Wild-Type 124 0 0 124 
Heterozygous 0 11 0 11 
Homozygous 0 0 0 0 
Total 124 11 0 135 
Exact agreement: 100%          Kappa: 1 (95% CI 1-1) 
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Table 6.7.  VKORC1 genotype comparison between the Genie I HyBeacon® and ABI 
Taqman® genotyping methods. 
Genie ABI Taqman® Total 
Wild-Type Heterozygous Homozygous 
Wild-Type 47 0 0 47 
Heterozygous 0 62 0 62 
Homozygous 0 2 24 26 
Total 47 64 24 135 
Exact agreement: 98.5%          Kappa: 0.98 (95% CI 0.94-1.00) 
 
 
 
Figure 6-4.  VKORC1 genotyping discordance-results. Figures (A) and (B) show the melting 
peaks  of the two patients, where Genie I Hybeacon gave VKORC1 homozygous variant 
genotypes while ABI Taqman® gave heterozygous genotypes. The black circle shows a very 
small peak but below the intensity threshold limit.  The Genie I Hybeacon software could 
not detect this little peak, explaining why the result red outs were VKORC1 homozygous 
variant.  In figure (C), the peak for allele G could not be spotted by eye due to the overlapping 
peaks from other assays.  Figure (D) shows the melting peak of a valid result where a patient 
was successfully genotyped as VKORC1 heterozygous by Genie I Hybeacon.   
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Out of the 135 samples randomised to genotype-guided arm, 112 (83%) 
samples were succesfully genotyped on the Genie I HyBeacon®.  Of these, 77 were 
from RLUHT and 35 from the SKTHT.  The 55 which were successfully genotyped 
were randomly selected and tested for a second time on the Genie I HyBeacon® to test 
for reproducibility and 100% of these were concordant.   
The technical problems on the Genie I Hybeacon® are presented in Table 6.8.  
The total percentage failure for CYP2C9*2 and CYP2C9*3 and VKORC1-1693 were 
8.95%, 6.37% and 7.7% respectively.  Of which, 4.7%, 4.25% and 5.96% were not 
successfully genotyped for CYP2C9*2, CYP2C9*3 and VKORC1-1693 respectively.  
The failure rate for positive controls were 4.25%, 2.12%, 1.7% for CYP2C9*2, 
CYP2C9*3 and VKORC1-1693, respectively.   
It is surprising that peaks were observed in negative controls (4.2%) because 
the tubes were never been opened during genotyping.  Possibly the contamination 
source was from the supplier or during transportation (as the lids of the tubes were not 
really tight). 4.7% of summary genotype result read-out did not tally with the melting 
peaks profile. 
For the ABI Taqman® platform, 20 samples failed to genotype the first time 
(6 for CYP2C9*2, 9 for CYP2C9*3, 5 for VKORC1-1693) but were successfully 
genotyped on the second time.  The failure of genotyping was due to pipetting error 
(human error) during DNA transferred into a 384-well PCR plate. 
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Table 6.8.  Technical problems with Genie 
Description of technical problem RLUHT 
(n) 
SKTHT 
(n) 
Total 
failure 
rate (%) 
CYP2C9*2 Test:  Total number of tests performed 
Test sample not genotyped 
Positive controls not genotyped 
Total percentage failure 
176 
8 
10 
59 
3 
0 
 
4.7% 
4.25% 
8.95% 
CYP2C9*3 Test:  Total number of tests performed 
Test sample not genotyped 
Positive controls not genotype 
Total percentage failure 
176 
6 
5 
59 
4 
0 
 
4.25% 
2.12% 
6.37% 
VKORC1 Test:  Total number of tests performed 
Test sample not genotyped/ wrong genotype given 
Positive controls not genotype 
Total percentage failure 
176 
10 
4 
59 
4 
0 
 
5.96% 
1.7% 
7.7% 
Peak detected in negative control 
CYP2C9*2 negative control 
CYP2C9*3 negative control 
 
3 
7 
 
0 
0 
4.2% 
Result read-out  discordant with peaks observed 11 0 4.7% 
RULHT: Royal Liverpool University Hospital NHS Trust.    
SKTHT: St Helens & Knowsley Teaching Hospital NHS Trust. 
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A comparison of hands-on and total turn-around time for both platforms per 
experiment is shown in Table 6.9.  The total turn-around time per run on the Genie I 
HyBeacon® is 97.5 minutes while that on the ABI Taqman® is 247 minutes.  Only 
one sample can be genotyped for three SNPs by Genie I HyBeacon® and a maximum 
of 80 samples by ABI Taqman® in each run.  Therefore, with regards to hands-on and 
total turn-around time, our results suggest that the Genie I HyBeacon® is more 
practical to be use in a clinical setting because it can produce genotype results less in 
than 2 hours reducing patient waiting time.   
Table 6.9.  Comparison of hands-on and total turn-around time between Genie 1 
HyBeacon® and ABI Taqman®. 
Description Genie 1 HyBeacon® ABI Taqman® 
DNA extraction 0 55 min 
Sample preparation 6.5 min 90 min 
PCR/Run 90 min 100 min 
Result read 1 min 2 min 
Turn-around time per run 97.5 min (~1.6 hours) 247 min (~4 hours) 
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6.4 Discussion 
In this chapter we have genotyped 135 samples using the Genie 1 HyBeacon 
platform and validated the results by comparing genotypes using the ABI 7900HT 
Taqman® platform.  Genotyping by Genie HyBeacon® agreed strongly with the 
genotype results using ABI Taqman®.  With a turn-around time of 97.5 min per run, 
it was possible to obtain the genotypes for CYP2C9*2, CYP2C9*3 and VKORC1-1693 
before dosing with warfarin.  However, caution must be taken during genotype 
determination as 4.7% of the summary genotype result read-outs did not tally with 
observed melt peaks.  Checking the concordance of melting peak profiles with 
summary genotype read-outs is mandatory before the genotype results are used to dose 
the patients with warfarin. 
Despite there being a strong concordance in our study, two patients were 
discordantly genotyped for VKORC1-1693 by the platforms and we believe this is due 
to the low sensitivity of the HyBeacon® assay to detect the polymorphism.  For 
example, two patients who were carriers of the heterozygous VKORC1-1693 variant 
were detected as homozygous variants.  As demonstrated in Chapter 2.3.2 (Figure 2-9, 
page 64), a carrier of the heterozygous variant requires an approximately 40% higher 
dose compared with the homozygous variant.  Consequently, one of the patients was 
not given the therapeutic dose until the 5th visit and the other patients on the 6th visit.  
During the period of not having the therapeutic dose, the risk of thromboembolism was 
higher and could result in death.  In addition, the failure rate for all SNPs tested was 
over 7% and with the highest for VKORC1-1693 test (10.6%) (Table 6.8).  Because 
each assay strip contained assays to test 3 SNPs, repeating the genotyping procedure 
for any SNP which failed to genotype not only increased the time to dose the patients 
but it also resulted in the assays being wasted.   
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The low sensitivity of Genie 1 HyBeacon assay to detect VKORC1-1693 
allele has been observed in a previous study by Howard et al. (2011) as they did not 
produce a genotyping result for VKORC1-1693 in one of 28 blood samples (Howard 
et al. 2011).  Therefore, the success rate for Genie 1 HyBeacon compared with 
LightTyper HyBeacon was 96% with a 100% concordance.  Furthermore, they 
validated 128 blood samples by comparing results from various different genotyping 
platforms with a success rate of 100% complete concordance between methods.   
Several small studies have produced promising results regarding 
pharmacogenetic dosing to improve VKA management.  For example, one study 
showed that patients receiving a dose by pharmacogenetic algorithm required fewer 
and smaller dose adjustments and fewer INR determinations (Anderson et al. 2007).  
Other studies demonstrated that patients in a pharmacogenetic dosing group reached a 
stable dose faster (Huang et al. 2009) and spent more time within the therapeutic range 
(Caraco et al. 2008).  Ongoing Randomised Control Trials (RCT) such as EU-PACT 
should answer the question as to whether pharmacogenetic testing prior to dosing will 
significantly improve anti-cogulation with warfarin therapy.  If the findings are 
positive, we would recommend Genie HyBeacon® as a practical genotyping platform 
to be used in the hospital laboratory because the procedure is very easy, as 
demonstrated in this study where the genotyping for patients from the St Helens & 
Knowsley Teaching Hospital NHS Trust has been performed by nurses at the hospital 
sites.  However, there would need to be some improvement to the assays design to 
improve the reliability of VKORC1 genotyping assay. 
The limitation of our analysis is that we did not consider the cost of the 
instrument and reagents for the platform evaluated.  The Genie 1 instrument is 
predicted to cost in the region of 15,000 US dollars with each assay strip likely to cost 
under 50 US dollars (Howard et al. 2011).   
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As many studies have validated the usefulness of CYP2C9*2, CYP2C9*3 and 
VKORC1 in predicting warfarin responses, it is imperative to have a genotyping assay 
that is compatible with the clinical environment.  The Genie HyBeacon® genotyping 
platform is being validated in our study as it produces accurate results, the procedure 
is easy and has a very quick turn-around time.  In addition, a new formulation is 
currently being investigated by the LGC Company to improve total process time 
(Howard et al. 2011).  It is expected that by using a new high-performance blood-
tolerant enzyme technology, total analysis time will decrease at least 60 minutes.  All 
of these properties are very valuable when optimizing the accuracy of warfarin therapy 
based on a patient’s genetic make-up.   
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Final discussion 
 
  CHAPTER 7 
179 
 
7.1 Thesis summary 
Warfarin, although a difficult drug to dose due to its large inter-individual 
variability and narrow therapeutic window, is a very effective oral anticoagulant that 
has saved  millions of lives worldwide (Wysowski et al. 2007, Kim et al. 2009).  As 
quoted by Rose A.J (2013), “warfarin is a drug we all love to hate and wish to see 
replaced. But it is the drug that has been something of a puzzle, a puzzle that we may 
finally be starting to solve as we truly move towards optimising its management”.  I 
truly agree with him; from my experience in warfarin clinics, I have seen large 
variability in warfarin responses amongst patients.  However through medication 
counselling (one of the roles of a pharmacist in improving drug therapy), where drug 
adherence and factors influencing warfarin responses are discussed, we try to make 
warfarin a safe and more effective drug.  But given that patients still present with 
warfarin-related adverse events, this is probably not enough. 
Dabigatran, a direct thrombin inhibitor, has recently been shown to be either 
non-inferior (110mg bd) or superior (150mg bd) to warfarin in stroke prevention 
(Connolly et al. 2009). Its pharmacokinetic and pharmacodynamic characteristics have 
some advantages when compared with warfarin including more rapid onset of action, 
reduced food-drug and drug-drug interactions, and a predictable anticoagulant 
response (Yusuf 2002, Van Ryn et al. 2010, Baglin et al. 2012, Schulman and 
Crowther 2012).  However, dabigatran is much more expensive and the absence of a 
reliable reversal agent and the lack of a pharmacodynamic biomarker have limited the 
safe prescription of dabigatran (Liesenfeld et al. 2006, Van Ryn et al. 2010, Warkentin 
et al. 2012).  As such, warfarin may remain the mainstay of oral anticoagulant therapy 
for the foreseeable future. Thus, there remains a need to improve warfarin therapy. 
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The main aim of this thesis was to explore the use of pharmacogenetic data to 
guide personalised warfarin therapy. Prescribing the correct dose at the start of 
warfarin therapy is the most challenging.  As demonstrated by many studies, clinical 
factors together with genetic variables (CYP2C9*2, CYP2C9*3, VKORC1-1693) 
explain 50-60% of dose variability (Sconce et al. 2005, Gage et al. 2008, Hatch et al. 
2008, Perini et al. 2008).  Therefore, our study in Chapter 2 sought to answer how 
accurate a pharmacogenetic algorithm is in predicting warfarin stable dose.  Taking 
into account that our main concern when prescribing warfarin is major bleeding, our 
research question in Chapter 3 was whether genetic risk factors associated with major 
bleeding in patients treated with warfarin would be useful in distinguishing individuals 
with different risks of bleeding.  The paediatric population represents a unique 
pharmacogenetic challenge as children have the additional complexity of ontological 
phenotypes that impact on drug response. So our next research questions in Chapters 
4 and 5 address whether pharmacogenetics can predict the outcome of warfarin therapy 
in children population.  Chapter 6 focused on the application of warfarin 
pharmacogenetic testing in a clinical setting. This chapter focused on whether a 
currently available genotyping platform can be used in a clinical setting. 
7.1.1 Research Question 1: Can pharmacogenetic algorithm accurately 
predict warfarin dose? 
In Chapter 2, we developed a pharmacogenetic dosing algorithm to predict 
warfarin stable dose in a large population of prospectively recruited British Caucasians 
(n=456) initiated and maintained on warfarin therapy in a secondary care setting. Our 
algorithm was then validated in a cohort of retrospectively recruited patients from a 
primary care setting.  Similar to most published algorithms, we included age, BSA and 
amiodarone use together with CYP2C9*2, CYP2C9*3 and VKORC1 -1693 as 
covariates.   
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In order to properly assess the accuracy of our algorithm, we examined our 
algorithm in all aspects including (i) the R2 statistic to measure the variability of 
warfarin dosing explained by the prediction model, (ii) the mean absolute error to 
measure the predictive accuracy and (iii) the percentage of patients whose predicted 
warfarin dose was within 20% of the actual stable therapeutic dose to evaluate its 
potential clinical value.  The predictability of our algorithm was reproduced in our 
validation cohort giving a R2 value of 43% (mean absolute error of 1.08mg/day; 95% 
CI: 0.95-1.20) while the predicted dose of approximately 50% of patients fell within 
20% of the actual dose.  The performance of our pharmacogenetic algorithm was 
comparable to published algorithms, (Gage et al. 2008, Klein et al. 2009).  
Furthermore, our algorithm included fewer variables (6 vs. >8 variables), making it 
easier to use. There is therefore a possibility of implementing our secondary care 
setting-derived pharmacogenetic algorithm in a primary care setting.  However, it is 
unclear how this algorithm would compare to computerised dosing software programs 
which are now available in many primary and secondary care clinics.   
Our algorithm underestimated the dose for patients who required ≥ 6 mg/day and 
overestimated for patients who required ≤ 2 mg/day. The same observation has been 
reported in a seminal study conducted by the IWPC (Klein et al. 2009). As a 
pharmacist, my main concern would be when the dose is underestimated by the 
algorithm especially in patients suspected of having deep vein thrombosis and 
pulmonary embolism where immediate full anticoagulation is mandatory (Ansell et al. 
2008).  Therefore, further research in this group of patients should be undertaken to 
identify other non-genetic and genetic markers which lead to dose requirement in this 
group of patients, and develop dosing protocols which perform better in the extremes 
of the dosing range.   
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7.1.2 Research Question 2: Can pharmacogenetics provide guidance in 
predicting patients at high risk of major bleeding complications?  
In Chapter 3, we assessed the performance of HAS-BLED, a validated bleeding 
score developed to predict major bleeding.  We confirmed that HAS-BLED could be 
a useful tool for identifying atrial fibrillation patients at risk of major bleeding during 
warfarin therapy with a c-statistic of 0.80.  We also explored the contribution of 
CYP2C9*2, CYP2C9*3 and VKORC1 -1693 in predicting major bleeding, but in 
contrast to previous reports (Jorgensen et al. 2012, Yang et al. 2013), only CYP2C9*3 
was associated with major bleeding in our population (p≤0.05).  However, including 
this SNP into HAS-BLED did not improve its prediction. Taking into account the low 
MAF of CYP2C9*3 (6%), our study cohort was possibly underpowered to address our 
research question. Nevertheless, our findings indicate that HAS-BLED scores without 
the incorporation of genetic factors could be used to identify patients at high risk of 
major bleeding due to warfarin use.  In our analysis, some patients (3 out of 15) who 
experienced major bleeding during warfarin therapy were predicted at higher risk by 
HAS-BLEDG compared to HAS-BLED score.  Therefore, if genetic information was 
already available, there is no harm for it to be included in the HAS-BLED score.    
7.1.3 Research question 3: Can pharmacogenetics predict the outcome of 
warfarin therapy in children? 
In Chapter 4, we extended our research to a paediatric population as 
pharmacogenetic studies have the potential to improve the quality of warfarin therapy 
for this vulnerable population.  We evaluated the contribution of CYP2C9*2, 
CYP2C9*3 and VKORC1 -1693 to four clinical outcomes that could potentially lead 
to safer and more effective warfarin therapy.  The first outcome was proportion of time 
in which INR measurements fell within the target range within the first six months 
(PTTR).  This outcome would link pharmacogenetics to the quality of anticoagulation 
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control.  The second outcome was stable dose which would link to warfarin prediction 
dose. The third and fourth outcomes were INR exceeding target range in week one and 
bleeding complications, which provided an indication of bleeding risk. 
In the 97 retrospectively recruited Caucasian children treated with warfarin, we 
showed that the mean PTIR was 49%.  This finding highlights the poor stability of 
warfarin control that occurs in childhood during the first six 6 months of therapy, even 
when INR monitoring occurs frequently with the aid of a home monitoring device.  
Our work has demonstrated that VKORC1 -1693, indication for treatment (Fontan or 
non-Fontan group) and INR group (according to the lower limit of the referral 
therapeutic range) explained 20.8% of inter-individual variability in PTTR.  VKORC1-
1693 only contributed to a small proportion of PTIR variability (9.5%).  We observed 
that carriers of the VKORC1-1693 minor allele and frequent INR monitoring with a 
POCT device were associated with greater PTTR. Our results emphasize that by 
identifying and characterizing gene-environment interactions, we have more 
opportunities to effectively target intervention strategies. 
Polymorphisms in CYP2C9*2 and VKORC1-1693 together with age and INR 
target group explained 41% of warfarin stable dose variability.  In comparison to 
previous studies (Biss et al. 2012, Moreau et al. 2012), CYP2C9*2 and VKORC1 -
1693 accounted for much smaller warfarin dose variability (12% vs >30%). This could 
be explained by the younger ages of the children in our cohort.  For instance, only 
5.8% of children in the study by Biss et al., (2012) were ≤ three years of age compared 
to 27% in our study.  Children less than three years old have greater physiological 
differences compared to adults (Koukouritaki et al. 2004, Anderson and Lynn 2009).  
Our observations suggest that CYP2C9*2,and VKORC1 -1693 could be used to predict 
warfarin dose in children, but further work is needed to replicate our findings in a 
larger sample set, in particular with a view to stratifying the analyses by age.   
  CHAPTER 7 
184 
 
We showed that CYP2C9*2 was significantly associated with INR exceeding 
target range in the first week of warfarin treatment, explaining 6.8% of the variability. 
We also found that VKORC1 -1693 was significantly associated with bleeding 
complications and explained 8.7% of the variability.  Therefore information on 
VKORC1-1693 and CYP2C9*2 genotypes in paediatric patients could enable the 
identification of those at high risk of developing bleeding complications during the 
initiation of warfarin therapy and those who may benefit from pharmacogenetic-based 
personalised approach to warfarin dosing. 
Taken together, results from our candidate gene study show that a large 
proportion of genetic variance contributing to warfarin response in children remains 
unidentified and, hence we extended our investigations to using the genome wide 
association (GWA) approach in Chapter 5.  To our knowledge, this is the first GWAS 
investigating the influence of genetic factors on warfarin response in children.  Two 
novel SNPs on chromosome 5, rs13167496 and rs6882472, were found to be 
significantly associated with PTIR at genome-wide level.  These SNPs are located 
~34kb from the 5’ of TIFAB, a protein-coding gene which inhibits the activation of 
NF-κB, a transcription factor which has previously been reported to be involved in 
controlling coagulation (Mackman et al. 1991, Figueiredo and Brownlee 1995, 
Anrather et al. 1997, Hou et al. 2004, Song et al. 2009). . We did not identify any 
SNPs that attained genome-wide significance with warfarin stable dose, INR values 
exceeding the target range within the first week of treatment and bleeding 
complications.   
In adults, several GWA studies have shown that CYP2C9, VKORC1 and 
CYP4F2 were associated with warfarin stable dose in Caucasians at the genome-wide 
level (Takeuchi et al. 2009).  However, we cannot elucidate the contribution of these 
SNPs in children because our study was underpowered due to the small sample size.  
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An adequate sample size is very important to detect genome-wide significance 
(p<5×10−8) for polymorphisms that modestly alter warfarin response as shown by 
Takeuchi et al., (2009) when they failed to demonstrate the significance of CYP2C9, 
VKORC1 and CYP4F2 SNPs with warfarin dose in GWAS of 181 patients but then 
detected the significance in 1,053 patients (Cooper et al. 2008, Takeuchi et al. 2009). 
In this analysis, we focused on the association of single loci with target 
phenotypes.  Recently, a novel statistical approach has been adopted taking into 
account the correlations among SNPs in genes within a biological pathway (Luo et al. 
2010, Yaspan et al. 2011).  This analytical approach warrants further investigation.  A 
sample size with statistical power is very important in detecting the significance of 
SNPs with phenotype but recruiting children for a clinical study is difficult. An 
international multi-centre collaboration would be a good strategy to increase the 
sample size.  Such a collaboration would permit a more accurate representation of the 
distribution of genotypes amongst children of multiple ethnicities, and may help in 
determining the relative contributions of both non-genetic and genetic factors to 
warfarin response in children.   
7.1.4 Research question 4: Is the Genie point of care genotyping device 
usable in a clinical setting? 
Considering the large amount of evidence that has accrued which shows the 
usefulness of genotyping of CYP2C9*2, CYP2C9*3 and VKORC1-1693 
polymorphisms in improving warfarin therapy, there is a need to develop and test 
suitable genotyping platforms that could be used in clinical settings.  In order 
genotyping result to be used clinically, the test must be performed in a regulated 
clinical laboratory, have a quick turn-around time and be easy to perform.  An 
alternative to performing genotyping within a clinical laboratory, is to use a point-of-
care-test, which can be performed at the “bedside” in a clinical setting.  The aim in 
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chapter 6 was to evaluate such a platform, the Genie HyBeacon®, regarding its 
accuracy, turn-around time and complexity. 
We validated the genotyping performed on the point-of-care platform by 
comparing the results with Applied Biosystems Taqman® genotyping platform.  Very 
good agreement was observed overall, but further development is needed in the assay 
design for VKORC1 in particular to increase the reliability of genotyping.  Genie 
HyBeacon® was also performed by hospital staff in anticoagulant clinics.  With a turn-
around time of 97.5 min per run, it was possible to obtain the genotypes for CYP2C9*2, 
CYP2C9*3 and VKORC1-1693 before warfarin dosing.  Therefore, Genie Hybeacon® 
is suitable to use as point of care device to determine CYP2C9 and VKORC1 
genotypes before starting warfarin therapy.   
7.2 Pharmacogenetics-guided warfarin therapy: recommendations 
for future research 
From the findings in my thesis and those published in the literature, there is 
compelling evidence that genetic and clinical factors in combination determine the 
dose requirements for warfarin.  The effectiveness of this has recently been tested in 
the EU-PACT trial which showed that genotype guided dosing improved the time 
within range and some secondary outcome measures when compared with standard 
dosing (Pirmohamed et al. 2013). However, the US study (COAG) failed to show any 
advantage of genotype-guided dosing compared with the use of a clinical algorithm 
(Kimmel et al. 2013).  The reasons for the difference between the two studies are 
related to the design, in particular the algorithmic strategies used.  EU-PACT used a 
loading dose algorithm while COAG used a maintenance dose algorithm to initiate 
warfarin therapy.  Giving a loding dose, a largest dose on the first day of therapy to 
the patients so they get to a steady state early on might leading to shorter time to achive 
stable dose.  This highlights the importance of ensuring that the design of your clinical 
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study including randomised trials is as robust as possible.  The lessons from this need 
to be taken forward to further evaluate how the benefit-risk ratio of warfarin therapy 
can be improved.  Specific areas that could potentially be looked at include:   
 Refine dosing algorithms to improve accuracy in those at extremes of the 
dosing range.  This include using next-generation sequencing method to 
sequence individuals who denotes as extreme phenotype (figure 2.9). 
 Improve the identification of patients who at high risk of major bleeding 
complications during warfarin therapy through discovery of novel genetic 
factors.  This could then be incorporated into a revised bleeding score system. 
 To further evaluate the contribution(s) of genetic factors to warfarin outcomes 
in a larger prospective cohort of children undergoing initiation therapy 
allowing for analyses stratified by age. A multi-centre collaborative approach 
is needed to achieve adequate power.  
 To investigate the contribution of multiple variations in gene or collection of 
genes to phenotypic outcomes using pathway analysis of genome-wide data. 
 To replicate the association of rs13167496 and rs6882472 with PTTR  in 
children population.  
 To develop a decision analytic model to examine the cost-effectiveness of a 
genotype-based dosing strategy compared with standard induction of warfarin.  
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7.3 Conclusions 
This thesis has extended current knowledge on the role of genetic and clinical 
factors determining daily warfarin dose requirement and the potential for this to cause 
bleeding in both adults and children.  With the recent publication of two trials that have 
tested the utility of genotype guided dosing, it will be interesting to how this plays out 
in the research and clinical community.  The poor uptake of the new oral anticoagulants 
in clinical practice further adds to the uncertainty of what anticoagulants will be used 
and in what settings.  In summary, the research in this thesis shows that genetic factors 
are important in determining individual doses of warfarin.  Further work is required to 
develop strategies to choose the best anticoagulant for individual patients based on 
both their clinical characteristics and genetic background.   
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Wadelius, M., SöRlin, K., Wallerman, O., Karlsson, J., Yue, Q.Y., Magnusson, P.K.E., 
Wadelius, C., Melhus, H., 2004. Warfarin sensitivity related to cyp2c9, cyp3a5, 
abcb1 (mdr1) and other factors. Pharmacogenomics Journal 4 (1), 40-48. 
Wajih, N., Hutson, S.M., Owen, J., Wallin, R., 2005. Increased production of functional 
recombinant human clotting factor ix by baby hamster kidney cells engineered to 
   
212 
 
overexpress vkorc1, the vitamin k 2,3-epoxide-reducing enzyme of the vitamin k 
cycle. Journal of Biological Chemistry 280 (36), 31603-31607. 
Wajih, N., Sane, D.C., Hutson, S.M., Wallin, R., 2004. The inhibitory effect of calumenin on 
the vitamin k-dependent gamma-carboxylation system - characterization of the 
system in normal and warfarin-resistant rats. Journal of Biological Chemistry 279 
(24), 25276-25283. 
Wallentin, L., Yusuf, S., Ezekowitz, M.D., Alings, M., Flather, M., Franzosi, M.G., Pais, P., 
Dans, A., Eikelboom, J., Oldgren, J., Pogue, J., Reilly, P.A., Yang, S., Connolly, S.J., 
2010. Efficacy and safety of dabigatran compared with warfarin at different levels 
of international normalised ratio control for stroke prevention in atrial fibrillation: 
An analysis of the re-ly trial. The Lancet 376 (9745), 975-983. 
Wallin, R., Hutson, S., 1982. Vitamin k-dependent carboxylation - evidence that at least 2 
microsomal dehydrogenase reduce vitamin-k to support carboxylation. Journal of 
Biological Chemistry 257 (4), 1583-1586. 
Wallin, R., Hutson, S.M., Cain, D., Sweatt, A., Sane, D.C., 2001. A molecular mechanism for 
genetic warfarin resistance in the rat. Faseb Journal 15 (11), 2542-+. 
Wang, T.L., Li, H.L., Tjong, W.Y., Chen, Q.S., Wu, G.S., Zhu, H.T., Hou, Z.S., Xu, S., Ma, S.J., 
Wu, M., Tai, S., 2008. Genetic factors contribute to patient-specific warfarin dose 
for han chinese. Clin Chim Acta 396 (1-2), 76-9. 
Warkentin, T.E., Margetts, P., Connolly, S.J., Lamy, A., Ricci, C., Eikelboom, J.W., 2012. 
Recombinant factor viia (rfviia) and hemodialysis to manage massive dabigatran-
associated postcardiac surgery bleeding. Blood 119 (9), 2172-2174. 
Weathermon, R., Crabb, D.W., 1999. Alcohol and medication interactions. Alcohol Research 
and Health 23 (1), 40-54. 
Wells, P.S., Majeed, H., Kassem, S., Langlois, N., Gin, B., Clermont, J., Taljaard, M., 2010. A 
regression model to predict warfarin dose from clinical variables and 
polymorphisms in cyp2c9, cyp4f2, and vkorc1: Derivation in a sample with 
predominantly a history of venous thromboembolism. Thrombosis Research. 
West, B.D., Preis, S., Schroeder, C.H., Link, K.P., 1961. Studies on the 4-hydroxycoumarins. 
Xvii. The resolution and absolute configuration of warfarin. Journal of the American 
Chemical Society 83 (12), 2676-2679. 
White, H.D., Gruber, M., Feyzi, J., Kaatz, S., Tse, H.F., Husted, S., Albers, G.W., 2007. 
Comparison of outcomes among patients randomized to warfarin therapy 
according to anticoagulant control results from sportif iii and v. Archives of Internal 
Medicine 167 (3), 239-245. 
Williams, D.B., Karl, R.C., 1979. A simple technic for predicting daily maintenance dose of 
warfarin. The American Journal of Surgery 137 (4), 572-576. 
Winkelmann, B.R., Nauck, M., Hoffmann, M.M., März, W., 2003. Pharmacogenomics and 
complex cardiovascular disease – clinical studies in candidate genes. 
Pharmacogenomics. Wiley-VCH Verlag GmbH & Co. KGaA, pp. 251-266. 
Wittkowsky, A.K., 2003. Warfarin and other coumarin derivatives: Pharmacokinetics, 
pharmacodynamics, and drug interactions. Seminars in Vascular Medicine 3 (3), 
221-230. 
Woods, A., Vargas, J., Berri, G., Kreutzer, G., Meschengieser, S., Lazzari, M.A., 1986. 
Antithrombotic therapy in children and adolescents. Thrombosis Research 42 (3), 
289-301. 
World Health Organization, Global database on body mass index. 
http://apps.who.int/bmi/index.jsp?introPage=intro_3.html viewed in 8 July 2011. 
Wu, S.M., Mutucumarana, V.P., Stafford, D.W., 1997. Purification of γ-glutamyl carboxylase 
from bovine layer. pp. 346-357. 
Wynne, H., Cope, L., Kelly, P., Whittingham, T., Edwards, C., Kamali, F., 1995. The influence 
of age, liver size and enantiomer concentrations on warfarin requirements. British 
Journal of Clinical Pharmacology 40 (3), 203-207. 
   
213 
 
Yang, J., Chen, Y., Li, X., Wei, X., Chen, X., Zhang, L., Zhang, Y., Xu, Q., Wang, H., Li, Y., Lu, C., 
Chen, W., Zeng, C., Yin, T., 2013. Influence of cyp2c9 and vkorc1 genotypes on the 
risk of hemorrhagic complications in warfarin-treated patients: A systematic review 
and meta-analysis. International Journal of Cardiology. 
Yang, J., Siqueira, M.F., Behl, Y., Alikhani, M., Graves, D.T., 2008. The transcription factor 
st18 regulates proapoptotic and proinflammatory gene expression in fibroblasts. 
FASEB Journal 22 (11), 3956-3967. 
Yaspan, B.L., Bush, W.S., Torstenson, E.S., Ma, D., Pericak-Vance, M.A., Ritchie, M.D., 
Sutcliffe, J.S., Haines, J.L., 2011. Genetic analysis of biological pathway data through 
genomic randomization. Human Genetics 129 (5), 563-571. 
Yildirim, H., Tamer, L., Sucu, N., Atik, U., 2008. The role of cyp2c9 gene polymorphisms on 
anticoagulant therapy after heart valve replacement. Med Princ Pract 17 (6), 464-7. 
Yuan, H.Y., Chen, J.J., Lee, M.T., Wung, J.C., Chen, Y.F., Charng, M.J., Lu, M.J., Hung, C.R., 
Wei, C.Y., Chen, C.H., Wu, J.Y., Chen, Y.T., 2005. A novel functional vkorc1 promoter 
polymorphism is associated with inter-individual and inter-ethnic differences in 
warfarin sensitivity. Hum Mol Genet 14 (13), 1745-51. 
Yuping, C., S, F.S., Masahiko, N., A, G.J., 2004. Induction of human cyp2c9 by rifampicin, 
hyperforin, and phenobarbital is mediated by the pregnane x receptor. The Journal 
of Pharmacology and Experimental Therapeutics 308 (2), 495. 
Yusuf, S., 2002. Direct thrombin inhibitors in acute coronary syndromes: Principal results of 
a meta-analysis based on individual patients' data. Lancet 359 (9303), 294-302. 
Zambon, C.F., Pengo, V., Padrini, R., Basso, D., Schiavon, S., Fogar, P., Nisi, A., Frigo, A.C., 
Moz, S., Pelloso, M., Plebani, M., 2011. Vkorc1, cyp2c9 and cyp4f2 genetic-based 
algorithm for warfarin dosing: An italian retrospective study. Pharmacogenomics 12 
(1), 15-25. 
Zhang, J.E., Jorgensen, A.L., Alfirevic, A., Williamson, P.R., Toh, C.H., Park, B.K., 
Pirmohamed, M., 2009. Effects of cyp4f2 genetic polymorphisms and haplotypes on 
clinical outcomes in patients initiated on warfarin therapy. Pharmacogenetics and 
Genomics 19 (10), 781-789. 
Zhang, Z., Fasco, M.J., Huang, Z., Guengerich, F.P., Kaminsky, L.S., 1995. Human 
cytochromes p4501a1 and p4501a2: R-warfarin metabolism as a probe. Drug 
Metabolism and Disposition 23 (12), 1339-1346. 
Zheng, X., Levine, D., Shen, J., Gogarten, S.M., Laurie, C., Weir, B.S., 2012. A high-
performance computing toolset for relatedness and principal component analysis 
of snp data. Bioinformatics 28 (24), 3326-3328. 
Zou, K.H., O'malley, A.J., Mauri, L., 2007. Receiver-operating characteristic analysis for 
evaluating diagnostic tests and predictive models. Circulation 115 (5), 654-657. 
 
